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Abstract 
Gene therapy aims to act on the genetic cause of a pathology by gene inhibition or 
substitution. Gene delivery systems are necessary to deliver intact nucleic acids to the 
cells in order to achieve a therapeutic effect. Chitosan is a linear polysaccharide that 
displays properties such as biocompatibility and biodegradability. Despite the efforts to 
develop chitosan-based vectors, the therapeutic effectiveness of chitosan-base gene 
therapy still needs to be improved in order to achieve clinical significance.  
This work introduces a new chitosan-based polymer: N-(2-ethylamino)-6-O-glycol 
chitosan (EAGC). The new polymer aims to overcome the disadvantages of chitosan 
for gene delivery, such as poor solubility at physiological pH and low buffer capacity, in 
order to enhance its transfection efficiency while retaining its main benefits of low 
toxicity and biocompatibility.   
Three batches of EAGC were synthesized with different degrees of ethylamino 
substitution: EAGC17, EAGC21 and EAGC30. The EAGC synthesis and the degree of 
substitution of monomers with the new ethylamino group were confirmed by Nuclear 
Magnetic Resonance. The agarose gel retardation assay revealed that all polymers 
had the ability to condense with DNA/siRNA at different polymer, DNA/siRNA mass 
ratios. EAGC30 was able to condense both nucleic acids at smaller polymer, 
DNA/siRNA mass ratios due to its higher charge density. The nanoparticles formed 
between the different polymers and DNA/siRNA presented sizes between 100 and 
450nm with a positive charge of +40mV and spherical shape. The stability of the 
DNA/siRNA nanoparticles was tested in the presence of different biological challenges. 
All EAGC polymers were able to deliver the β-galactosidase plasmid to A431 cells in 
vitro. EAGC30 showed the best transfection capacity at lower polymer, DNA mass 
ratios. Differences in charge density of the polymers resulted in different gene activity. 
Nevertheless, all EAGC polymers were superior transfection agents to lipofectamine, 
particularly at high polymer, DNA mass ratios. In vitro down regulation of proteins was 
obtained for EAGC30, siRNA mass ratios 30 and 60.  
Delivery to the brain of a complex formed between siRNA and a chitosan derivative, 
with a nose to brain delivery method, will be presented for the first time. Fluorescent 
EAGC30, siRNA nanoparticles were visualized on the olfactory bulb tissue after nasal 
administration. The results of this study confirmed Ethylamino Glycol Chitosan as a 
good candidate for in vitro and in vivo gene delivery. 
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1. Introduction 
Gene therapy can be defined as the introduction of exogenous, therapeutic nucleic 
acids in target cells, enabling the treatment of diseases at a genetic level [1]. The 
concept was first shown by Mulligan et al. in 1979, when they introduced recombinant 
plasmid DNA using calcium phosphate transfection technology [2]. Transfection of cells 
was done later by liposomes (in 1980) [3], polylysine [4] and polyethyleneimine (in 
1990) [5]. Various diseases have been targeted for the treatment with gene therapy, 
such as haemophilia [6], muscular dystrophy [7], cystic fibrosis [8] and age-related 
macular degeneration [9]. Gene therapies have also been developed for cardiovascular 
[10], and neurological [11] diseases as well as cancer [12]. 
Gene therapy aims to act on the genetic cause of a pathology by gene inhibition or 
gene substitution. Gene substitution relies on the introduction, into the cell, of 
transcriptionally fully competent genes, to augment the production of a specific protein 
in order to restore its functional expression. Gene inhibition silences overexpressed 
genes, normally at the messenger RNA (mRNA) level, stopping the expression of 
proteins at the post-transcriptional level [13, 14]. Nucleic acid therapy can be based on 
DNA (including plasmids, oligonucleotides (antisense and antigene applications), DNA 
aptamers and DNAzymes) or RNA (including antisense RNA, ribozymes, RNA decoys, 
RNA aptamers, small interfering RNA (siRNA) and microRNA) [1]. 
Plasmid DNA (pDNA) is a high molecular weight, double-stranded DNA construct that 
encodes a specific gene sequence. Inside the cell it expresses a functional protein 
through transcription and translation in order to produce a therapeutic effect [1, 15]. 
pDNA requires access into the nucleus to be expressed by the host-cell transcription 
machinery [16]. It might be integrated into the host genome, causing long-term gene 
expression, or stay outside the chromosome with a transient effect [17]. 
Gene inhibition can be achieved by the RNA interference (RNAi) mechanism for down-
regulation of protein expression. RNA interference was discovered in 1998 by Mello et 
al. in the nematode Caenorhabditis elegans [18]. The RNAi pathway is fundamental in 
eukaryotic cells for post-transcriptional protein expression regulation [19, 20]. A double 
stranded RNA is introduced in the cell and cleaved by the enzyme Dicer (cytoplasmic 
ribonuclease III) into small fragments (21-23 nucleotides long) called short interference 
RNA. siRNA is a small macromolecule (approximately 13 kDa) comprising two strands: 
the sense and antisense [20]. siRNA operates in the cytosol where the siRNA antisense 
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strand is integrated into the RNA-induced silencing complex (RISC). RISC binds and 
cleaves complementary mRNA, thereby preventing its translation into a protein [16]. 
siRNA can be synthetically produced and directly introduced in the cell at the level of 
RISC, circumventing the Dicer mechanism [19-21]. The effect of siRNA is normally 
transient due to the dilution of the siRNA in the cytosol for dividing cells, although it is 
possible to observe a longer effect for slowly or non-proliferating cells [17]. 
The first clinical trial of gene therapy took place in 1990 for the treatment of severe 
combined immunodeficiency [22]. However, it was not until 2000 that the first 
successful, clinical gene therapy treatment was reported by Cavazzana-Calvo et al. 
[23]. The condition, X-linked severe combined immunodeficiency (SCID-X1), commonly 
diagnosed in early infancy, is characterized by recurrent infection as a result of an 
absence of cell-mediated and humoral immunity [24]. However, the success of this trial 
was questioned when two of the ten children treated developed a leukaemia-like 
condition [25]. One treatment based in adenoviral vectors (Gendicine) has been 
approved in China and an adenoassociated viral vector (Glybera®) was approved by 
the European Commission for treatment of lipoprotein lipase deficiency, proving that 
reaching the goal of gene therapy is not an impossible task [25, 26].  
 
1.1 Gene Delivery Barriers 
An important prerequisite for plasmid DNA and siRNA to be used as therapeutic 
molecules for different human diseases is the successful delivery to the cells and 
subsequent release in the intracellular space [15]. After administration in the body, the 
nucleic acids need to remain stable and avoid enzymatic degradation, as well as target 
specific cellular sites. Once inside the cell, the nucleic acids need to be released from 
the endosome to be active in the cytoplasm (in the case of siRNA) or migrate to the 
nucleus (for plasmid DNA) [17].  
Extracellular barriers 
Therapeutic genes can be administered in different ways into the body such as via the 
intramuscular or intravenous (IV) routes, as well as by inhalation (intranasal) or 
ingestion (oral). Depending on the route of administration, nucleic acids will encounter 
several barriers such as blood components, the blood brain barrier, immune defence 
mechanisms and enzymatic degradation [27]. Blood is one of the major barriers after IV 
administration. Exogenous materials in the blood led to the activation of the 
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complement system, as well as clearance by the reticuloendothelial system, non-
specific interactions with serum proteins (e.g. albumin) and enzymatic degradation [17, 
27]. The half-life of unprotected nucleic acids in mouse blood is approximately 10 
minutes [15].  
Cellular uptake 
The targets of plasmid DNA and siRNA are located inside the cells, in the nucleus and 
cytoplasm respectively. These large, charged molecules need to cross the lipophilic 
and negatively charged plasma membrane in order to reach their therapeutic targets 
[28]. Endocytosis is the main process of uptake of macromolecules and solutes by 
internalization of membrane vesicles. There are various endocytic pathways such as 
clathrin-mediated endocytosis (via coated pits), caveolae, macropinocytosis and 
clathrin/caveolae-independent endocytosis [28, 29]. After internalization by the cell the 
molecules tend to be entrapped in intracellular vesicles known as endosomes.  
Endosomal release 
Endosomes have an internal pH around 6 and, during maturation, they are either 
recycled back to the membrane internalized content or develop into late endosomes 
which fuse with intracellular organelles called lysosomes. These present a lower pH of 
around 4.5 and contain digestive enzymes which facilitate substrate degradation [15, 
30]. Therefore, the successful release of nucleic acids from the endosomes/lysosomes 
is one of the key steps for nucleic acid delivery.  
Nuclear internalization 
The therapeutic target of plasmid DNA is within the cell nucleus, making the nuclear 
envelope the ultimate obstacle.  The entrance of the necessary macromolecules in the 
nucleus is controlled by the nuclear pore complex, which forms a channel through the 
nuclear envelope. Molecules smaller than 50 kDa are able to passively diffuse through 
the pore complex, while bigger compounds either have a specific target ligand or 
associate with polypeptides [28, 29]. Due to the elevated size of the plasmid DNA, it is 
unlikely that it can reach the nucleus of the cell by passive diffusion.  According to the 
literature, dividing cells present higher transfection ability than non-dividing cells, 
suggesting that the plasmid DNA enters the nucleus during cell division. During mitosis 
the integrity of the nuclear membrane is lost with the disassembly of the nuclear 
envelope, enabling foreign DNA to enter the nucleus [28, 31].  
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1.2 Gene Delivery Systems 
In order to overcome the challenges associated with the nucleic acids reaching their 
therapeutic target, an effective nucleic acid delivery system is needed. This delivery 
system should be able to (i) bind and condense the nucleic acids into nanoparticles, (ii) 
protect the nucleic acids from enzymatic degradation, (iii) promote cellular uptake, (iv) 
release the nucleic acids into the cytoplasm, and (v) promote nuclear entry (for DNA). 
Furthermore, a gene delivery vector should not trigger a strong immune response, but 
should allow sustained and regular expression of the genes [15, 32].  
Regarding their mode of action there are two main gene delivery methods: physical 
and non-physical. 
1.2.1 Physical methods 
Physical gene delivery methods mediate the direct penetration of genes inside the cell 
by forming transient membrane holes. These methods circumvent limitations, such as 
cell penetration and endosomal release, of non-physical methods. Various methods are 
available with different advantages and limitations (Table 1). 
  
Table 1 - Summary table of physical gene delivery methods.  
Method Mode of Action Advantages Limitations 
Needle 
injection[33, 34] 
Direct local injection of naked 
nucleic acids in tissues such as 
muscles, liver, and skin. 
Simple method, 








High-speed, ultrafine stream of 
DNA solution driven by a 
pressurized gas, usually CO2. 
The injection generates pores 
on membranes of target cells. 
Needle free, well 









Increased liquid pressure 
injection of a large volume of 
gene solution to create pores in 
the cell membranes by 
reversible permeability changes 
in the endothelium. 
The simplicity and 
safety of 
hydrodynamic gene 
delivery allows the 
use of this 
technique for the in 
vivo transfection of 
hepatocytes and 





Not possible to 
translate to in vivo 
human gene 
delivery. 
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 21 
Method Mode of Action Advantages Limitations 
Electroporation 
[36] 
An electric field alters the cell 
permeability. Electric pulses 
generate transient pores in the 
cell membrane, followed by 
intracellular electrophoretic 
DNA movement. 
Safe, efficient, with 
good 
reproducibility. 
Gene delivery to in 
vivo solid tissues 
with this method is 
limited as 
electrodes need to 
be placed near the 
internal, target 
organs. 
Gene Gun [37] 
Impact of heavy metal particles 
on target tissues and delivery 
of coated DNA particles. The 
efficiency of the gene gun 
method depends on particle 













Use of ultrasound waves to 












1.2.2 Non-Physical methods 
1.2.2.1 Viral vectors 
Viral vectors are one of the major gene delivery systems due to the capacity of viruses 
to insert a functional gene into the host cell genome. The viral vectors are derived from 
viruses with either RNA (e.g. Retrovirus) or DNA (e.g. Adenovirus) genomes [32]. The 
preparation of a viral vector includes the removal of the pathogenic part of the virus and 
replacement by a therapeutic gene, while the virus retains its non-pathogenic 
structures that allow it to infect the cell [31, 38]. Viruses mediate efficient gene transfer 
through favourable cell uptake and intracellular trafficking machineries [34]. To date, 
viral vectors are the most often used gene delivery vectors since they display good 
transfection properties both in vitro and in vivo [39]. One treatment based in adenoviral 
vectors (Gendicine) has been approved in China and an adenoassociated viral vector 
(Glybera®) was approved by the European Commission for treatment of lipoprotein 
lipase deficiency [25, 26]. Despite the advantages of viruses as gene delivery systems, 
there are still major drawbacks including the risk of immunogenicity, random integration 
of vector DNA into the host chromosome, specific tissue tropism, limited DNA carrying 
capacity and recombination with wild-type viruses and related toxicity [13, 34, 40]. 
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1.2.2.2 Non-Viral vectors 
Liposomes 
Cationic lipids are amphiphilic molecules that contain a hydrophilic positively charge 
polar head group connected by a linker to a hydrophobic domain [41]. The positive 
charge of the head group is due to the presence of amines, which will interact with the 
anionic nucleic acids. The linker that connects the hydrophobic domain and the cationic 
head group may contain a glycerol-type moiety, a phosphate or a phosphonate linker, 
amino acids, peptides or aromatic rings [34, 40]. The hydrophobic domain is 
constituted of a cholesterol derivative or an aliphatic chain with different lengths and 
compositions [34, 41]. The most common chain lengths are C8 or C18 with mono-
unsaturated fatty acids. Amphiphilic lipids are poorly soluble in water, and when 
suspended in water can adopt different structures including micellar, lamellar, cubic 
and inverted hexagonal phase with the hydrophobic tails facing each other and the 
hydrophilic heads facing water [41, 42]. 
Cationic lipids can be mixed with neutral lipids to form cationic liposomes for nucleic 
acid delivery. Dioleoylphosphatidylethanolamine (DOPE) and cholesterol are often 
used as neutral lipids. DOPE reduces the charge ratio of liposomes leading to reduced 
toxicity and increased transfection ability [34, 41]. Liposomes containing cholesterol are 
normally more stable in physiological medium enabling the nucleic acids to reach their 
target cells [34, 41]. 
Liposomes are defined as unilamellar or multilamellar microvehicles consisting of a 
phospholipid bilayer [34]. Cationic liposomes are complexed with nucleic acids by self-
assembly, forming a lipoplex. Lipoplexes can also present different structures, including 
multilamellar, with DNA/siRNA monolayers between cationic membranes, or inverted 
hexagonal structure, with DNA/siRNA encapsulated within cationic lipid monolayer 
tubes. The hexagonal structure has shown advantages in transfection of nucleic acids 
[40].  
After electrostatic interactions between the positively charged lipoplexes and the 
anionic structures (glycoproteins and proteoglycans) of the cellular membrane, the 
lipoplexes may enter the cell by fusion with the plasma membrane or by endocytosis 
[15, 40]. Once inside the cell, the lipoplexes are incorporated into the endosomes. 
Inside the endosomes there is a “flip-flop” mechanism by which anionic lipids diffuse 
from the endosomal membrane into the complex, forming neutral ion pairs with cationic 
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lipids. This leads to destabilization of the endosomal membrane, displacement of the 
nucleic acid from the delivery system, and release to the cytosol [15]. 
The main advantages of liposomes are their biodegradability and low toxicity, both a 
result of their composition from naturally occurring substances. Liposomes are able to 
protect the nucleic acids against enzymatic degradation as well as facilitate cellular 
uptake and endosomal escape, leading to effective gene transfer. They present low 
immunogenicity, and are easy to prepare and handle. 
DNA delivery by liposomes was first reported in 1987 by Felgner et al. using N-[1-(2,3-
dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA) [43]. Since then, 
liposomes have been reported for plasmid DNA and siRNA delivery [44-46]. Cationic 
liposomes showed higher transfection efficiency due to their ability to promote cellular 
internalization and the release of nucleic acids.  
However, due to their positive charge, they may lead to non-specific interactions with 
serum proteins and cause haemolysis, they present low circulation half-life with 
systemic elimination, and low transfection efficiency [38]. Additionally, the presence of 
diethyl ether and chloroform (organic reagents involved in their preparation) may lead 
to cytotoxicity [42].  
 
Cationic polymers 
Cationic polymers are a safer alternative to viral delivery, since the risk of 
immunogenicity is lower [38]. They are easy to prepare, with flexibility regarding the 
size of the nucleic acids to be transfected. Their main drawback falls on the transient 
nature of transfection as well as the lower transfection efficiency when compared with 
the viral vectors [47]. When compared with liposomes, cationic polymers are more 
stable and show good biodegradability, low toxicity, structural diversity and relatively 
higher transfection efficiency [48]. 
Cationic polymers present different molecular weights and structure including linear, 
branched and dendritic structures. These polymers bind to the anionic phosphate 
groups along the backbone of the nucleic acids through electrostatic interactions, 
prompted by cationic primary, secondary, tertiary and quaternary amines present in the 
polymers [49]. These interactions enable the packing of the nucleic acids, reducing the 
DNA/siRNA to nanosized particles called polyplexes [31]. The presence of serum 
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proteins and other blood components may lead to destabilization of the complexes. 
Characteristics of the polymers provide increased stability to the nanoparticles, 
preventing disaggregation in the presence of these biological challenges. Furthermore, 
cationic polymers offer protection from enzymatic degradation [50] (Figure 1).  
The delivery of nucleic acids to specific cells with cationic gene delivery systems can 
be done by passive or active targeting. Passive targeting relies on the tumour 
morphology via the enhanced permeability and retention (EPR) effect. A prolonged 
circulation of small nanoparticles (10-100nm) combined with the leaky blood 
vasculature in these tissues leads to an accumulation in the tumour site. This is a non-
selective targeting approach [17] that presents major drawbacks including 
heterogeneous carrier extravasion comprising delivery efficiency as well as off-target 
delivery to healthy cells, leading to toxicity and adverse side effects [51, 52]. Active 
targeting relies on the presence of specific receptors on target tissues. This allows the 
functionalization of nanoparticles with specific ligands such as transferrin and folic acid. 
This kind of delivery prevents the non-specific, off-target effects described for passive 
targeting [53].  
The polyplexes interact with the negatively charged cell membrane and enter the cell 
mainly by endocytosis. Size, surface potential and the ratio between the number of 
amines in the polymer and phosphates in the nucleic acids (N:P ratio) strongly 
influence the gene delivery capacity of each polymer, as well as endosomal escape 
and unpacking of DNA/siRNA from the complexes [54].  
The release of nucleic acids from the carrier upon entry into the cell is an important 
feature that highly affects the gene delivery outcome. Plasmid DNA needs to migrate to 
the nucleus, while the siRNA mechanism happens at the cytoplasm [17].  Chain length 
and polymer molecular weight are the most important features for nucleic acid 
unpacking. Generally, longer chains and higher molecular weight polymers provide 
improved stability which may impair nucleic acid release. A balance between the 
stability of the polyplexes in serum and salt solutions and release of nucleic acids 
should be obtained [55].  
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Figure 1 - Schematic representation of gene delivery. Adapted from Raemdonck et al. [14]. 
  
Different kinds of cationic polymers have been studied. Here, I will discuss polylysine 
(PLL), Polyethylenimine (PEI), dendrimers and chitosan. PLL was the first cationic 
polymer to be used in gene delivery. However, it presented low transfection efficiency 
[4]. PEI and dendrimers present good transfection capacity, but nevertheless their use 
is still limited by their low biocompatibility [56]. Chitosan presents lower transfection 
efficiency than the previous but it is a biocompatible polymer [57]. These polymers set 
the main characteristics for a successful gene delivery system, and therefore this 
review constitutes an important background to the development of a new gene delivery 
system. 
 
Poly (L-Lysine)  
Poly(L-lysine) was first used for in vitro gene delivery by Wu et al. in 1987 [4]. PLL is a 
cationic linear polypeptide with the amino acid lysine as the repeating unit (Figure 2). It 
is regarded as biocompatible and biodegradable [13]. Nucleic acid condensation and 
transfection efficiency increases with the molecular weight; however, so does toxicity. 
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PLL with molecular weight lower than 3 kDa showed a limited capacity to transfect 
cells, while high molecular weight PLL has shown high toxicity [58]. The structure of 
PLL presents primary amino groups that are all protonated at endosomal pH, resulting 
in poor buffer capacity for the polymer and consequently poor endosomal escape 
leading to low gene expression [59, 60]. In order to increase transfection efficiency, 
several conjugates such as endosomolytic agents, histidine and imidazole have been 
used [59-61]. Substitution of PLL with histidine increased the transfection of the 
polymer 4-fold due to the presence of the imidazole ring that has a pKa around 6 
increasing the buffer capacity of the polymer [15]. 
 
 
Figure 2 - Representative chemical structure of PLL.  
 
Polyethylenimine  
Polyethylenimine has been one of the most studied gene delivery systems since the 
polymer successfully enabled transfection of DNA in 1995 [5]. It is commercially 
marketed as a transfection reagent in preparations such as ExGen500R, jetPEIR and 
PEIproTM.  
PEI is a cationic polymer with one third of its atoms being nitrogens, presented as 
primary, secondary and tertiary amino groups in a 1:2:1 ratio (Figure 3). This high 
number of amines gives the polymer a high charge density, conferring unique features 
such as strong DNA condensation with protection from enzymatic degradation, intrinsic 
endosomal activity, and a unique buffer capacity called the proton sponge effect [60].  
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Figure 3 - Representative chemical structure of a) linear PEI and b) branched PEI. 
 
The primary amines (pKa ≈ 9, higher than the endosomal pH) are generally regarded 
as responsible for nucleic acid condensation, while secondary and tertiary amines (pKa 
≈ 5-7, around the endosomal pH) contribute to the buffer capacity of the polymer [62, 
63]. The degree of protonation of PEI increases from 20 to 45% when the pH 
decreases from 7 to 5 in the endosomes [64]. The pH-buffering property presented by 
PEI is an important feature that allows endosome disruption (proton sponge effect - 
Figure 4) and prevents lysosomal degradation of the nucleic acids. Once the PEI-
DNA/siRNA complexes enter the cell, they are trapped into the endosomes. These 
present membrane ATPase ion channels that pump protons to the inside, leading to 
the acidification of the endosomal compartments and activation of hydrolytic enzymes. 
PEI becomes protonated preventing the acidification of the endosomes and resulting in 
a continuous influx of protons (to attempt to lower the pH), as well as passive entry of 
chloride ions. Consequently there is an increase of ionic concentration, with an influx of 
water leading to endosomal swelling and rupture of the endosomal membrane. In this 
way PEI nanoparticles are able to be released from the endosomes with intact nucleic 
acids [15, 65].  
 
 
Figure 4 - Schematic representation of proton sponge effect. Adapted from Aied et al. [31]. 
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PEI presents as two forms: linear and branched (Figure 3). The degree of branching 
affects complexation with the nucleic acids and transfection efficiency [66].  Linear PEI 
is less effective at condensing DNA compared with the branched form for similar 
molecular weights. Branched PEI presents a higher number of primary amines, 
allowing for the formation of more stable complexes [67, 68]. Nevertheless, linear PEI 
has shown better transfection of plasmid DNA than the branched form [69]. The same 
results were not obtained for the delivery of siRNA, where branched PEI was able to 
achieve gene silencing while the linear polymer did not show any knock-down effect. 
These different results are explained by the stability of the complexes between PEI and 
DNA/siRNA. Linear PEI leads to less stable complexes, which is advantageous for the 
release of plasmid DNA. However, since electrostatic interactions of siRNA with the 
polymer are weaker, due to the small structure and low charge density of the nucleic 
acid, the extra charge density presented by the branched form of PEI is necessary for 
the delivery of siRNA [70].  
The transfection efficiency of PEI also depends on its molecular weight, with polymers 
with molecular weight lower than 25 kDa showing poor transfection ability. Transfection 
efficiency increases with the increase of the molecular weight for molecular weights of 
between 6 and 70 kDa [71]. High molecular weight (800 kDa) PEI is significantly 
cytotoxic due to its high charge density and lack of degradable linkages inducing cell 
membrane disruption followed by apoptosis. An optimum molecular weight seems to 
range between 12 and 70 kDa [71, 72]. However, one study showed that a low 
molecular weight (10 kDa), moderately branched polymer resulted in efficient delivery 
with low toxicity when compared to commercial, high molecular weight PEI [56]. This 
shows that the right balance between molecular weight and branched/linear forms can 
lead to successful gene delivery.  
Despite showing good transfection efficiency in vitro and in vivo, PEI toxicity, related to 
the lack of degradable linkages and high charge density, still presents a major hurdle to 
the translation of the polymer to the clinic [73, 74]. Godbey et al. reported that the 
charge density of free PEI leads to precipitation and aggregation of the polymer when 
administered in vivo due to the interactions with anionic charged proteins 
(e.g. albumin). Also, the interactions of PEI with cellular components inhibit normal 
cellular processes and cause several changes to cells, including cell shrinkage, 
reduced number of mitoses and vacuolization of the cytoplasm [56].  
In order to overcome the cytotoxicity of high molecular weight PEI, degradable linkers 
such as disulfide bonds have been used [75]. This acid-labile PEI may be rapidly 
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degraded into low molecular weight PEI in acidic endosomes. In toxicity assays, the 
modified PEI was much less toxic than PEI with a molecular weight of 25 kDa, due to 
the degradation of the acid-labile linkages [76]. Also, cholesterol and polyethylene 
glycol (PEG) have been introduced to reduce the cytotoxicity of the polymer, by 
masking the positive surface charge of PEI [77, 78]. A PEI-PEG polyelectrolyte 




Dendrimers are monodispersed, hyperbranched macromolecules, with a well-defined 
size and shape and high density of functional groups, that are regarded as good 
candidates for gene delivery [80]. The structure of dendrimers may be divided into 
three parts: (1) a central core, (2) repeating branches called generations and (3) 
terminal functional groups which play a role in gene complexation [81, 82].  
Dendrimers complex with the nucleic acids through electrostatic interactions between 
the positively charged terminal groups of the dendrimers and the anionic phosphates of 
the nucleic acids backbone [80]. The resulting “dendriplex” presents a positive charge, 
enabling interaction with the cell membranes. Dendrimers with a higher number of 
generations are regarded as more toxic due to their high charge density [81].  
Polyamidoamine (PAMAM) dendrimers are the most well characterized and 
commercialized dendrimers (Figure 5). They are water soluble and non-immunogenic, 
with terminal amino groups that can be modified to allow specific targeting [80]. 
PAMAM dendrimers produce high transfection efficiency and are the most commonly 
used dendrimers for gene delivery [82].  
 
Figure 5 - Representative chemical structure of PAMAM dendrimers. 
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1.2.3 Chitosan 
Chitosan is obtained by partial deacetylation of chitin, which is the natural structural 
component of the crustacean exoskeleton [83]. It is a linear polysaccharide composed 
of D-glucosamine and N-acetyl-D-glucosamine subunits linked by (1,4)-glycosidic 
bonds (Figure 6). The relative proportion of the different sub-units determines the 
degree of deacetylation, which in turn influences different characteristics of the polymer 
such as solubility [84]. The polymer displays properties such as biocompatibility and 
biodegradability, and its degradation products are non-toxic, non-immunogenic and 
non-carcinogenic [85]. Chitosan is a biodegradable polymer that can be degraded by 
enzymes which hydrolyse glucosamine–glucosamine, glucosamine–N-acetyl-
glucosamine and N-acetyl-glucosamine-N-acetyl-glucosamine linkages, leading to 
small fragments that are suitable for renal clearance [31, 86]. Chitosan also presents 
mucoadhesive properties, being known for its ability to transiently open the tight 
junctions of the intestinal barrier [87]. Due to these unique features, chitosan and its 
derivatives have found fruitful applications in various fields such as water treatment 
[88], the food industry [89],cosmetics [90] and agriculture [91]. 
 
 
Figure 6 - Representative chemical structure of chitosan. 
 
Biocompatibility 
Chitosan biocompatibility is influenced by different polymer characteristics such as 
molecular weight, polymer structure (including branched derivatives), charge density, 
cationic functionality of derivatives, degree of biodegradability and conformational 
flexibility [71, 92]. 
An increase of cytotoxicity as a function of the molecular weight was previously 
reported for different cationic polymers including PEI [72], PLL [93, 94] and 
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chitosan [95]. Branched molecules were found to be slightly more toxic than linear 
polymers [93, 96]. The toxicity of different cationic groups has also been studied; more 
specifically, the difference between primary, secondary and tertiary amines. Primary 
amines led to red blood cell agglutination, while tertiary amino groups showed lower 
toxicity [97]. However, Fisher et al. concluded that it is not only the kind of amine that 
has an impact on toxicity, but also the overall charge density. It was demonstrated that 
the cytotoxicity of different types of polycationic polymers depend on the number and 
arrangement of the cationic charges [71]. A comparative study between polycationic, 
neutral and polyanionic polymers revealed that the polycationic polymers have the 
highest toxicity, followed by neutral and anionic ones [98]. 
It is hypothesized that the strong ionic interaction between the positive charges of the 
polymers with the anionic structures of the cell membrane affects membrane integrity, 
altering cell function and ultimately leading to cell death [99, 100]. The mechanism of 
cytotoxicity caused by cationic polymers is due to the electrostatic interactions between 
the positively charged polymers and the anionic membranes which can lead to 
destabilization and ultimately rupture of the cell membrane. When exposed to cationic 
polymers, the cell suffers membrane leakage followed by a decrease in metabolic 
activity [71]. Polyethylenimine cytotoxicity was characterized as a two-phase process 
where the polycation-cell interaction induces loss of cell membrane integrity and the 
induction of programmed cell death, leading to cell shrinking and reduced mitoses [56, 
73].  
Chitosan presents low toxicity when compared with other cationic polymers such as 
PEI. For chitosan, IC50 (concentration of polymer at which 50% of cells are viable) 
values have been reported between 0.2-20 mg mL-1 [86] in different cell lines. 
Conversely, PEI presents an IC50 of <20 μg mL-1 [101, 102]. Chitosans with different 
molecular weights and degrees of deacetylation (5 kDa, 65.4%; 5–10 kDa, 55.3%; 
and 10 kDa, 55.3%) showed an IC50 >1 mg mL-1 in CCRF-CEM (human 
lymphoblastic leukaemia cells) and L132 (human embryonic lung cells). Haemolysis 
was not observed (<10%) over 1 h and 5 h with chitosans of 5 kDa, 5–10 kDa and 
10 kDa at concentrations of up to 5 mg mL-1 [103]. 
The molecular weight and charge density (degree of deacetylation) are the main 
factors that contribute to chitosan’s cell biocompatibility [86, 104]. High molecular 
weight polymers (100 kDa) with a high degree of deacetylation were less 
biocompatible [95] than lower molecular weight chitosans (10 kDa) [105]. 
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Huang et al. found higher attenuated cytotoxicity of chitosan when the degree of 
deacetylation decreased, and less attenuation when the molecular weight was 
reduced, suggesting that the degree of deacetylation has a greater effect than the 
molecular weight on chitosan’s biocompatibility [95]. Chitosans with a degree of 
deacetylation of 88% and molecular weight between 10 and 213 kDa showed 
comparable biocompatibility in A549 cells. Decreasing the polymer charge density 
(61% and 46% of deacetylation) resulted in increased viability of the cells (60% of cells 
alive when compared with less than 10% for chitosan 88% deacetylated). Reducing the 
chitosan molecular weight from 213 kDa to 10 kDa did not change the IC50 value (IC50 
1.1 to 1.2 mg mL-1). However when the degree of deacetylation decreased from 88% to 
61%, the IC50 increased from 1.2 to 2.0 mg mL-1 and to 2.2 mg mL-1 with a further 
decrease of the degree of deacetylation to 46% [95]. 
After evaluation of the biocompatibility of chitosan in CaCo-2 and HT29-H cells and in 
situ rat jejunum, Schipper et al. also concluded that toxicity is dependent on the degree 
of deacetylation and molecular weight. At a high degree of deacetylation, the 
biocompatibility of chitosan is related to the molecular weight and the concentration; at 
a lower degree of deacetylation toxicity is less pronounced and less related to the 
molecular weight. However, most of the chitosans tested did not increase 
dehydrogenase activity in CaCo-2 cells significantly in the concentration range tested 
(1–500 μg mL-1) [106, 107].  
The biocompatibility of chitosan with a high degree of deacetylation (92%) and low 
molecular weight (10 kDa) was studied by Nimesh et al. [105]. After 48h of incubation, 
more than 85% of cells were viable at pH 6.5 and 96% at pH 7.1. These results 
corroborate the theory that the charge density may contribute to the biocompatibility of 
chitosan, since the cell viability was lower at lower pH when the protonation of chitosan 
is higher [105]. In the same study, lower biocompatibility for chitosan alone was 
reported when compared with chitosan-DNA complexes, since the charge of the 
polymer is partially neutralized by the binding of DNA. 
The modifications made to chitosan can make it more or less toxic. Carreno-Gomez 
showed that glycol chitosan (GC) is one of the chitosan derivatives with lower toxicity 
[108]. Trimethyl chitosan is more toxic than chitosan, and its toxicity was found to be 
directly related with the degree of trimethylation (charge density) [102].  
 
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 33 
Transfection efficiency 
The transfection efficiency of chitosan is also dependent on polymer characteristics 
such as molecular weight, charge density and buffer capacity [40, 105].  Because of its 
cationic nature, chitosan is a very popular candidate for nucleic acid delivery. Features 
including the pH of transfection medium, degree of deacetylation (charge density), 
molecular weight, and nitrogen to phosphate ratio (N:P ratio) determine the transfection 
efficiency of DNA and siRNA [55, 59, 109].  
At physiological pH, the gene transfection efficiency of chitosan is lower compared with 
other cationic gene delivery systems such as PEI [57, 110, 111] or cationic lipids [112, 
113].  The transfection efficiency of chitosan is dependent on the pH of the transfection 
medium, due to the protonation of its primary amine groups. The pKa of these amines 
has been calculated as 6.5, meaning that at a higher (more basic) pH, the amines will 
not be protonated and the overall positive charge of the polymer will be low [114]. 
Therefore, at pH 7.4 chitosan presents minimal solubility, low intracellular delivery 
resulting in low transfection ability [104, 105].  
The transfection efficiency of a 10 kDa chitosan with a 92% of degree of deacetylation, 
was studied in HEK 293 cells and compared against lipofectamine. The gene 
expression was assessed at different pH values: 6.5, 7.1 and 7.4, in the presence of 
10% serum. Enhanced Green Fluorescent Protein (EGFP) was expressed in 26.3% of 
cells at pH 6.5, with only 9.2% at pH 7.1 and 0.2% at pH 7.4. The cell uptake was also 
studied at different pHs: 100% of the cells internalized the complexes at pH 6.5, while 
only 50 % cellular uptake was observed at pH 7.1. Further studies revealed that 
changing from pH 6.5 to 7.4 at 8, 12 or 24 h after initiating transfection led to higher 
gene expression than the positive control lipofectamine [105].  
Sato et al. evaluated the transfection efficiency of chitosan, DNA complexes (52% and 
92% degree of deacetylation) in A549 cells and found it higher at pH 6.9 than at pH 7.6 
[115]. Additionally, Zhao et al. investigated the effect of transfection medium pH on the 
transfection efficiency of chondrocytes using chitosan-DNA complexes with 800 kDa 
chitosan with an 82% degree of deacetylation. Four pH values were studied: 6.8, 7.0, 
7.2 and 7.6; higher expression levels were obtained at pH 6.8 and 7.0 with more than 
50% of cells transfected [116].  
Finally, Lavertu et al. studied the transfection efficiency of two chitosans with a 
molecular weight of 40 kDa and an 80% degree of deacetylation and a molecular 
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weight of 80 kDa and a 72% degree of deacetylation at pH values 6.5, 6.8, 7.1 and 7.4. 
The percentage of transfected cells was comparable for pH 6.5 and 7.1, with the lowest 
transfection happening at pH 7.4 [104].  
Further to the pH of the transfection media, the degree of deacetylation of chitosan 
plays a role in the polymer’s capacity to condense with nucleic acids and perform gene 
transfection.  
The importance of the degree of deacetylation was showed by Kiang et al.. Three 
different cell lines were used to test the transfection efficiency of chitosan-DNA 
nanoparticles with a chitosan with a molecular weight of 390 kDa. Three different 
degrees of deacetylation were studied (62%, 70% and 90%). For all cell types tested, 
the chitosan formulations with the lower degrees of deacetylation resulted in lower 
gene expression levels. Furthermore, for the chitosans with the lower degrees of 
deacetylation (62% and 72%) the level of gene expression was not significantly greater 
than the background [117].  
The effect of the degree of deacetylation was also studied by Huang et al. with three 
chitosan polymers of high molecular weight (213 kDa). The polymer with a degree of 
deacetylation of 88% showed a transfection efficiency of 12.1% while chitosans with 
lower degrees of deacetylation, 61% and 46%, showed residual transfection 
efficiencies of 0.2 and 0.05%, respectively [95, 118].  
Five chitosans with a molecular weight range between 31 and 190 kDa, and with 
different degrees of deacetylation (31 kDa, 99%; 170 kDa, 99%; 190 kDa, 85%; 170 
kDa, 65%; 98 kDa, 51%) were studied by Koping-Hoggart et al. in the 293 kidney cell 
line. The lowest gene expression was obtained using chitosans 170 kDa, 65% and 
98 kDa, 51% at an N:P ratio of 3.0 and 3.6 respectively. Chitosan 190 kDa, 85% 
showed the highest transfection efficiency at N:P ratio of 3.0 (70 times higher than 
98 kDa, 51%), followed by 31 kDa, 99%, and 170 kDa, 99% both at N:P ratio of 3.6. 
The results showed that the transfection ability of the polyplexes did not depend on the 
molecular weight in the range from 31 to 170 kDa but on the percentage of 
deacetylation; chitosan with a percentage of positive charge lower than 65% did not 
show transfection ability. Following these results, a chitosan (degree of deacetylation of 
83%) with a molecular weight of 162 kDa (N:P ratio 2.4) was studied in comparison 
with PEI, 800 kDa (N:P ratio 9). The percentage of transfected cells was of 35% for PEI 
and 25% for chitosan polyplexes with similar results for gene expression [110].  
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 35 
The previous results demonstrate that the charge density of chitosan is intimately 
related with its transfection efficiency and dependent on two main factors: degree of 
deacetylation of the polymer and pH of the transfection solution. Polymers with higher 
degree of deacetylation at lower pH showed a higher charge density along the chain 
[119]. Furthermore, it has been demonstrated that cellular uptake of chitosan-DNA 
complexes depends strongly on the stability of the nanoparticles in medium as well as 
on their surface charge [118]. It is already recognized in the literature that complexes 
that are not sufficiently stable will dissociate too early and will show little or no 
transgene expression. On the other hand, highly stable complexes might not release 
DNA once inside the cells or may only release it slowly, resulting in low or delayed 
expression. Thus, an intermediate stability is desired [110, 112]. In addition, the 
internalization of chitosan in the cells is non-specific and highly dependent on 
electrostatic interactions between the positive polymer and the negative membrane. 
Therefore, the high positive charge presented by chitosan at lower pH enhances 
cellular uptake [105]. In summary, in order to achieve high transfection efficiency, 
chitosan should present a high degree of deacetylation and the complexes with DNA 
and siRNA should be prepared in a slightly acidic solution (pH lower than 7.1) in order 
to raise the polymer’s positive charge, enhancing in this way the binding efficiency to 
the cell membrane and cellular uptake [95, 110, 117, 118].  
The molecular weight of chitosan is one of the major characteristics of the polymer that 
also influences the gene expression results. Some studies with chitosan as a gene 
delivery system showed that a high molecular weight polymer (100-400 kDa) 
associated with a high degree of deacetylation were essential requirements for nucleic 
acid transfection [112, 120-122]. 
Other authors confirmed that the transfection efficiency was low for chitosan with low 
molecular weights (100 kDa) [112, 120] and decreased with a decrease of the 
molecular weight. MacLaughin et al. described that the highest transfection efficiency 
was achieved with a chitosan of 102 kDa (89.4% degree of deacetylation, N:P 2) when 
compared with chitosans between 7 and 92 kDa. Nevertheless, the gene expression of 
the polymer with 102 kDa was still 250-fold less than that observed with the plasmid- 
lipofectamine positive control complex [112]. 
Leong et al. evaluated the transfection efficiency of Chitosan (390 kDa) in a 293 cell 
line. Chitosan nanoparticles showed lower luciferase expression than lipofectamine 
(positive control) with no improvement of transfection when in presence of chloroquine 
or transferrin conjugated to the surface [113].  
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Huang et al. observed that the transfection efficiency, in A549 cells at an N:P ratio of 6, 
was significantly reduced for a chitosan with molecular weight of 10 kDa (0.6% of 
positive cells), when compared with chitosan with 213 kDa (12.1% of positive cells), 
both polymers with 88% deacetylation [118]. Furthermore, the transfection efficiency 
decreased with the decrease of the molecular weight (213 kDa, 88% = 12.1%; 98 kDa, 
88% = 8.3%; 48 kDa, 88% = 6.4%; 17 kDa, 88% = 2.9%; 10 kDa, 88% = 0.6% of 
positive cells) [95, 118]. Delgado et al. also studied the transfection efficiency of three 
chitosans with molecular weight of 40, 100 and 125 kDa with a degree of deacetylation 
of 85%. The DNA-chitosan aqueous solutions were prepared at different chitosan, DNA 
mass ratios (w/w) 1:1, 2.5:1, 5:1, 7.5:1, 10:1, 12.5:1 and 15:1. The highest transfection 
levels were obtained with the chitosan with 125 kDa of molecular weight at a polymer, 
DNA mass ratio of ratio 2.5:1; however, the results were still considered low (less than 
10% of EGFP positive cells) [121].  
Chitosan of high molecular weight was also used for the delivery of siRNA in different 
studies. Howard et al. showed siRNA delivery with chitosan (114 kDa, 84% degree of 
deacetylation) in vitro. Significant knockdown (77.9%) of EGFP was achieved in human 
lung carcinoma cells 48h post-transfection. The transfection levels were comparable to 
the positive control (78%, TransIT-TKO). Transfection with siRNA was also tested in 
the K562 cell line (N:P 57). Western blotting results demonstrated approximately 90% 
knockdown of BCR/ABL-1 protein [20].  
The work of Katas et al. focused only on high molecular weight chitosans, and showed 
no correlation between chitosan molecular weight and in vitro siRNA delivery for 
chitosans with 110, 160, 270 and 470 kDa [123].  Ji et al. showed knockdown of 70% of 
FHL2 gene expression in human colorectal cancer Lovo cells when using of chitosan 
with a molecular weight of between 190 and 310 kDa and a degree of deacetylation 
between 75 and 85% [124].  
Liu et al. demonstrated EGFP silencing of 45%-65%, with high molecular weight 
chitosans (65, 114 and 170 kDa) and a high degree of deacetylation (78% and 84%) 
whereas only 5% of EGFP down regulation was achieved with low molecular weight 
chitosans (9 and 12 kDa) and with a low degree of deacetylation (54%). It was also 
reported that low N:P ratio (N:P 2 and 10) nanoparticles resulted in lower knockdown 
when compared with higher N:P ratio (50 and 150) nanoparticles formed with 170 kDa 
chitosan. Nanoparticles formed at an N:P ratio of 150 showed the greatest level (80%) 
of EGFP knockdown [125]. 
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Although the previous studies showed good results for high molecular weight chitosans 
(100-400 kDa) in comparison with low molecular weight (˂100 kDa), there are also 
examples in the literature of chitosans with low molecular weight which outperformed 
the high molecular weight polymers [55, 126].  
Strand et al. studied the influence of the molecular weight of chitosan in a range 
between 5 and 146 kDa. Four N:P ratios (3, 5, 10 and 20) were transfected at pH 7. 
The polyplexes formed with chitosans of 8 and 12 kDa of molecular weight showed the 
highest luciferase expression in HEK293 cells. Luciferase expression was 10-fold 
higher than the transfection efficiency of chitosan with 25 and 33 kDa [55]. Gene 
expression was also dependent on the N:P ratio increasing, with the increase of the 
N:P ratios achieving a plateau after which transfection efficiency decreased [55].  
Chitosan with 70 kDa transfected HeLa cells in the presence of 10% serum [57]. The 
highest transfection efficiency was obtained at an N:P ratio of 3, 72h after transfection. 
Over the same timeline, PEI gene expression was lower than the gene expression 
seen with chitosan polyplexes [57]. 
The transfection efficiency of an even lower molecular weight chitosan, 22 kDa, with a 
degree of deacetylation of 72.5% was determined by a transfection assay into 293T 
cells with -galactosidase.  Different mass ratios (chitosan, DNA) were studied, with a 
mass ratio of 3 showing 37% higher transfection efficiency than PLL (20 kDa) at a 
mass ratio of 2 [94]. 
Furthermore, a chitosan oligomer was used to transfect a 293 kidney cell line. Chitosan 
(4.7 kDa) polyplexes were prepared at pH 6 in water. Transfection efficiency was 
studied with three N:P ratios: 10, 30 and 60. N:P 60 showed the highest transfection 
ability, 100-fold higher than transfection results obtained with N:P 10 [126]. The 
efficiency of low molecular weight chitosan was then compared with a high molecular 
weight (162 kDa, 83% deacetylated) polymer for three cell lines: kidney epithelial 293 
cells, airway epithelial Calu-3 cells and cervix epithelial HeLa cells with an N:P ratio of 
60. The low molecular weight chitosan showed a gene expression 4 to 24 fold higher 
than the high molecular weight chitosan. This low molecular weight chitosan was then 
compared with PEI (25 kDa at N:P ratio of 5) for transfection efficiency in the 293 cell 
line. The transfection results were dependent on the pH of the transfection medium. 
PEI showed a higher level of transfection at pH 7.4 while at pH 5 the polyplexes with 
low molecular weight were more efficient (four-fold higher than luciferase gene 
expression) [126].  
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Down-regulation of specific genes through siRNA delivered by low molecular weight 
chitosan was also studied. Three different chitosans (44, 63 and 93 kDa) showed an 
80% down regulation of luciferase expression at chitosan, siRNA mass ratios 2.5 and 
5. The fourth chitosan, with a molecular weight of 143 kDa, was less effective with a 
reduction of only 60%, while lipofectamine (positive control) showed 90% down 
regulation [127].  
Two linear chitosans with molecular weights of 75.7 kDa and 150 kDa, and one self-
branched chitosan polymer of molecular weight 40 kDa, were evaluated as siRNA-
carriers by Jogersen et al. A silencing effect of 60% was obtained with 75.5 kDa 
chitosan, the better of the two polymers in RMS melanoma cell line and SKBR3 breast 
cancer cell line. A higher knockdown effect was obtained in OHS cell line (95%) [128]. 
Techaarpornkul et al. concluded that the molecular weight of chitosan and the chitosan, 
siRNA mass ratios of the nanoparticles influence the final gene knockdown results 
more than the nature of salt forms. Silencing (around 50%) was achieved with low 
molecular weight chitosan of 20 kDa at a chitosan, siRNA mass ratio of 32, while gene 
knockdown of chitosans with molecular weights of 200 and 460 kDa was rather poor 
(below 20%). Gene silencing results, for 20 kDa chitosan, were lower for chitosan, 
siRNA mass ratios of 4 and 8 (chitosan, siRNA mass ratio 4 had a gene silencing of 
20%) when compared with higher chitosan, siRNA mass ratios 16 and 32 [129]. 
The previous literature review, on the effect of molecular weight of chitosan, in its ability 
for gene delivery, showed contradictory results. Initial reports demonstrated that high 
molecular weight polymers (100-400 kDa) [20, 112, 113, 118, 123, 125] performed 
better than low molecular weight chitosan for gene delivery of DNA and siRNA. 
However, other authors reported that chitosans with a molecular weight lower than 
100 kDa are also suitable gene delivery candidates [55, 57, 94, 110, 127-129].  
To try to understand how the different factors that influence transfection efficiency of 
chitosan (molecular weight, degree of deacetylation, pH and N:P) correlate between 
each other and what the ideal characteristics to enhance the gene delivery ability of 
chitosan are, Lavertu et al. studied the transfection efficiency of chitosan with four 
different molecular weights (10, 40, 80 and 150 kDa) and four different degrees of 
deacetylation (72, 80, 92 and 98%). The luciferase expression was evaluated at 
different pH values of the transfected solution (6.5 and 7.1) and different polyplex N:P 
ratios (5 and 10). Two formulations of chitosan (10 kDa, 92% degree of deacetylation, 
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N:P ratio 5 and 10 kDa, 80 % degree of deacetylation, N:P ratio of 10) showed the 
highest luciferase expression and similar results to the positive control (FuGene) [104].  
The comparison of the four different chitosans in different conditions allowed Lavertu et 
al. to understand the importance of the different variables that influence chitosan 
transfection. The results did not show an influence of the degree of deacetylation per 
se in the gene expression. However, in some formulations it was observed that a 
decrease in charge density led to a decrease in transfection efficiency. Regarding the 
molecular weight, Lavertu et al. concluded that a change in the molecular weight either 
had no effect on the gene expression, or this was increased for chitosan with lower 
molecular weight depending on the degree of deacetylation. For some formulations, 
increasing the N:P ratio from 5 to 10 led to an increase in gene expression. Also, a 
decrease in the pH, creating a more acidic environment, resulted in an increase of 
luciferase expression. Overall, for the chitosans with the lowest molecular weight (10 
and 40), the gene expression was lower for low degrees of deacetylation, low N:P 
ratios and high pH due to weaker association of the chitosan with DNA, leading to DNA 
release [104]. 
In conclusion, high molecular weight polymers offered enhanced nucleic acid 
complexation and stability, but also led to aggregation and low solubility at 
physiological pH [130]. The high stability of the nanoparticles may result in difficulty 
releasing the nucleic acids inside the cell, leading to low or delayed transfection [38]. 
Complexes with low molecular weight and low degree of deacetylation are not stable 
enough for transfection due to low complexation. Nevertheless, efficient intracellular 
release would be easy to achieve [104, 130]. Transfection efficiency with this kind of 
chitosan is, however, improved when the complexes are formulated at high polymer, 
nucleic acid mass ratios [104, 126]. A balance between these two extreme situations 
needs to be achieved in order to an enhanced in vitro gene delivery by chitosan.  
 
Chitosan derivatives 
Different derivatives of chitosan have been synthesized to address some of the issues 
that impair the transfection efficiency of chitosan (Table 2). Chitosan was modified to 
enhance solubility at physiological pH [131] and to increase colloidal stability of the 
nanoparticles between chitosan and nucleic acids, in order to increase the circulation 
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time [132], to allow specific targeting by grafting of ligands [133] and to the increase 
proton sponge capacity [134].  
Table 2 - Summary table of chitosan derivatives.  
Chitosan 
derivative 






To increase water 
solubility as well as give a 
permanent positive charge 






To increase buffer 





To increase buffer 
capacity of chitosan. 
Polyethylenimine-
graft-chitosan   
[137-139] 
 
To increase buffer 
capacity of chitosan. 
 
The first of these strategies involves the N-quaternization of chitosan amines to 
increase water solubility as well as give a permanent positive charge independent of 
the pH of the medium. Thanou et al. was the first to test, in COS-1 and Caco-2 cells, 
two substituted low molecular weight chitosans with two different degrees of 
quaternization 40% and 50%. Both polymers showed improved transfection efficiency 
when compared with chitosan (1-fold higher) and naked DNA in both cell lines (52-fold 
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higher than naked DNA for chitosan 50% quaternized and 131-fold higher for chitosan 
40% quaternized in COS-1 cells). Both polymers showed lower gene expression 
results than the positive control lipoplex DOTAP for both cell lines in the absence of 
serum. The viability of the cells was studied by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay after 6h of incubation. Neither chitosan nor 
trimethylated chitosan had an effect on the viability of the two cell lines [135].  
The impact of molecular weight and degree of trimethylation on cell viability and 
transfection efficiency was further evaluated by Kean et al.. The N-trimethyl chitosan 
polymers (100 kDa) and oligomers (3-6 kDa) showed improved transfection efficiency 
when compared with PEI (16- to 50-fold increase). The transfection efficiency was 
dependent on the percentage of quaternization with a maximum obtained for the 
polymer 44% quaternized in COS-7 cells. Toxicity of the different derivatives of 
chitosan was also studied. High molecular weight polymers (100 kDa, 55% degree of 
trimethylation, IC50 ˃ 10000 µg mL-1) had a higher effect on cell viability than oligomers 
(6 kDa, 57% degree of trimethylation, IC50 = 676±329 µg mL-1 in COS-7) at the same 
degree of trimethylation. For both sets of polymers, biocompatibility decreased with an 
increase of the degree of trimethylation. This was observed to a greater extent for 
chitosans with high molecular weights. Nevertheless, all the derivatives presented 
lower toxicity than PEI (25 kDa linear IC50 ˂ 30 µg mL-1) [102]. To overcome toxicity 
and further improve transfection rates, a number of secondary derivatives have been 
made. These include PEG-graft-trimethyl chitosans [131, 140] and thiolated trimethyl 
chitosans [141].  
The increase of the buffer capacity of chitosan was attempted by the synthesis of 
chitosan derivatives with an imidazole ring through the addition of different functional 
groups such as histidine [111] or urocanic acid to the chitosan backbone [136]. Kim et 
al. conjugated chitosan with various ratios of urocanic acid, showing reduced 
cytotoxicity (over 90% cell viability) and enhanced transfection efficiency [136]. The 
transfection efficiency for all derivatives was higher than chitosan (1- to 3-fold) and 
increased with an increase in the substitution. However, the gene expression of all the 
polymers was still lower when compared with the positive control lipofectamine 
(100-fold) in the absence of medium. 
Also, with the objective of increasing the transfection efficiency of chitosan through the 
increase of the buffer capacity of the polymer, several authors reported on the 
modification of chitosan or chitosan derivatives with PEI [137-139]. The objective was 
the combination of a biocompatible and biodegradable backbone (chitosan) with 
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increased charge density (PEI) to enable an increased proton sponge effect. The 
obtained PEI-chitosan polymers revealed transfection efficiencies in HepG2, HeLa, and 
primary hepatocytes, 5.2-, 4.3-, and 1.5-fold higher than PEI (25 kDa). The new 
derivatives also showed higher biocompatibility, with an IC50 of 97.3 µg mL-1 when 
compared with 13.5 µg mL-1 for PEI [137]. Delivery of siRNA was also achieved with 
PEI-chitosan. Down-regulation of EGFP was approximately 2.5-fold higher when 
compared with PEI (25 kDa) in A549 cells. The chitosan derivative showed good 
biocompatibility, with 90% of the cells viable [139]. 
 
Nose to brain delivery of chitosan  
Despite the good results with chitosan and siRNA in vitro, the use of chitosan in vivo is 
impaired by chitosan’s low solubility at physiological pH and its poor buffer capacity. In 
vivo delivery of siRNA by chitosan is characterized by instability due to the presence 
blood components, such as serum proteins and nucleases, and insufficient intracellular 
siRNA release [142].  
The first human clinical trial using siRNA started in 2004 for the treatment of blinding 
choroidal neovascularization by direct intraocular siRNA injections [143]. Other human 
trials have been reported with intranasal administration of siRNA against the N-protein 
of respiratory syncytial virus [144] and intradermal direct injection of siRNA against a 
skin disorder called pachyonychia congenital [145].  
In vivo administration of nucleic acids to the central nervous system is restrained by the 
blood brain barrier (BBB). The BBB is a physical barrier with endothelial tight junctions 
that present very low permeability, with the transport across mainly possible due to the 
presence of selective receptors. Only small (molecular weight < 500 Da), lipophilic 
molecules are able to cross the BBB via transcellular passive diffusion. The majority of 
high molecular weight molecules ( 500 Da) are not able to cross the barrier [146, 147]. 
siRNA is a hydrophilic molecule with a molecular weight of 13 kDa that does not cross 
the BBB passively. Different methods have been used for its delivery to the central 
nervous system. Intraparenchymal, intracerebroventricular, and intrathecal 
injections/infusions were used for siRNA delivery; however, these procedures are 
invasive and not practical for long treatments [147].  
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Intranasal administration is a non-invasive method of bypassing the BBB. This route is 
an appropriate method for the delivery of therapeutic molecules with a specific 
targeting to the brain in a practical, rapid and simple way, avoiding the adverse effects 
of systemic delivery. Nose to brain delivery is mainly mediated by the olfactory and 
trigeminal nerve pathways that connect the brain with the nasal cavity. These routes 
present the most direct, non-invasive entry into the brain [146, 148]. Intranasal delivery 
is a comfortable method of administration that affords an opportunity for repeated self-
dosing. However, this kind of delivery presents some limitations such as a restricted 
compound molecular weight, variability in the concentration achieved in different 
regions of the brain and rapid elimination of the substances from the nasal cavity due 
to mucocilliary clearance. Mucosal damage and irritation can also arise due to frequent 
use of this route [149, 150]. 
The delivery of siRNA to the brain through the nasal cavity has been tried by different 
groups. Some investigators attempted nose to brain delivery of naked siRNA [151, 
152]. Others tested the use of a range of delivery systems to protect the siRNA from 
enzymatic degradation and to enhance its delivery, cellular uptake and release in the 
cell cytoplasm in order to be incorporated in the RNAi machinery [153-155]. 
Kim et al. examined the efficiency of intranasal delivery of naked siRNA to normal rat 
brains. The group also studied specific gene silencing using fluorescence labelled non-
specific siRNA and gene-specific siRNA for the protein B-crystallin. In vivo target 
gene knockdown by the intranasal delivery of B-crystallin siRNA was examined in the 
olfactory bulb, amygdala and hypothalamus. After 3 hours of delivery there was no 
change in B-crystallin immunoreactivity in any of the brain areas studied. However, 
after 12 hours of siRNA delivery, B-crystallin levels were significantly reduced in all 
three regions. For non-specific siRNA transfection there was no change in the B-
crystallin immunoreactivity at any time point. These results indicated that the intranasal 
siRNA delivery enhanced the access to the central nervous system by the olfactory 
nerve pathway, allowing gene silencing in specific regions of the brain [151]. 
The work of Renner et al. confirmed the role of the olfactory nerve pathway in the 
delivery of siRNA to the central nervous system. The route followed by fluorescently-
labelled siRNA after intranasal administration was visualized by confocal laser 
microscopy. Again, the siRNA was administered without any gene delivery system. 
Thirty minutes after administration it was possible to observe siRNA in the olfactory 
epithelia, olfactory bulbs and along the length of the olfactory nerve pathway. 
Furthermore, intact siRNA was extracted from the olfactory bulbs of the mice [152]. 
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Intranasal delivery of fluorescently-labelled siRNA with a biodegradable PAMAM 
dendrimer was reported [153]. The efficiency of intranasal siRNA delivery was studied 
in normal rat brains by triple fluorescent labelling with fluorescein isothiocyanate 
(FITC)-labelled control siRNA, cell-type specific immunostaining, and 4',6-diamidino-2-
phenylindole (DAPI) staining. One hour after intranasal delivery, fluorescently-labelled 
cells were observed in the frontal cortex. The same was observed after 3 and 12 hours.  
Fluorescently-labelled cells were also found in other parts of the brain such as the 
olfactory bulb, amygdala and hypothalamus. Expression levels of HMGB1 (high-
mobility group box 1, a gene implicated in stroke pathology) were studied by 
immunohistochemical analysis using anti-HMGB1 antibody in the olfactory bulb, 
amygdala and hypothalamus after delivery of HMGB1 siRNA or nonspecific siRNA with 
a PAMAM dendrimer. The immunoreactivity of HMGB1 decreased in the three brain 
areas, in the study, after 3 hours of siRNA intranasal delivery. The decrease was 
prolonged for 12 hours.  In contrast, no decrease of HMGB1 expression was found for 
nonspecific siRNA. These results indicated that access to the central nervous system 
through the olfactory pathway was possible after intranasal administration. Gene 
silencing in other parts of the brain was also analysed, showing HMGB1 knockdown in 
the prefrontal cortex as well as in the pons and hippocampus. The previous results 
were confirmed by immunoblot and real-time polymerase chain reaction (PCR) 
analysis. Target gene expression suppression was reported in many brain regions 
[153].  
Intranasal delivery of siRNA with cell-penetrating, peptide-modified, nanosized micelles 
was studied [154]. The micelles were prepared from methoxy poly(ethylene glycol) 
(MPEG) / polycaprolactone (PCL) copolymers conjugated with a cell-penetrating 
peptide, Tat (MPEG-PCL-Tat). The brain distribution of fluorescently-labelled siRNA 
was significantly higher after intranasal administration when compared with intravenous 
administration. Levels in brain tissue after intranasal delivery of siRNA with MPEG-
PCL-Tat were also higher when compared with naked siRNA. The delivery system 
enhanced the distribution in the olfactory bulb when compared with naked siRNA, 
suggesting the delivery of siRNA to the brain is through the olfactory bulb pathway. 
Similar results were obtained in the trigeminal nerve, suggesting that it is also a 
possible way to reach the brain. In addition, fluorescence was also visible in the 
brainstem, rostral brain tissue and caudal brain tissue following intranasal delivery of 
siRNA with the micellar system, suggesting that after migration through the olfactory 
and trigeminal nerve to the olfactory bulb, siRNA was also delivered to other brain 
tissues [154].   
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The intranasal delivery of siRNA with the previous micellar system was studied in a 
Intracranial C6 Glioma Model [155]. Intracellular delivery and antitumour effects of 
siRNA for Raf-1 (involved in cell proliferation and apoptosis) were investigated in rats 
with malignant glioma. The association of siRNA and an anti-cancer drug (CPT) was 
also evaluated. Untreated rats had a mean survival period of 16.6 days and 18.4 days 
for rats treated with naked siRNA solution. Significant differences were observed when 
the previous results were compared with the mean survival period of rats treated with 
MPEG-PCL-Tat/siRaf-1 (20.4 days), CPT-loaded MPEG-PCL-Tat/siRNA Control (20.6 
days), and CPT-loaded MPEG-PCL-Tat/siRaf-1 (28.4 days) [155].  
To date, chitosan has only been used for siRNA delivery from nose to the brain as an 
adjuvant in a dendrimer-siRNA formulation. [32P]-siRNA, complexed with 
Poly(amidoamine) G7 dendrimers, was administered intranasally within an in situ-
forming mucoadhesive gel prepared with thermosensitive poloxamer and 
mucoadhesive chitosan. Brain radioactivity was higher after intranasal delivery of 
dendriplexes both in the gel and in the buffer when compared with the intravenous 
route. After two doses of siRNA gel delivery the brain radioactivity increased by two-
fold when compared with siRNA buffer delivery, and by eight-fold when compared with 
naked siRNA. Radioactivity was higher in the olfactory bulb and hypothalamus after 
siRNA intranasal gel administration than after intravenous or intranasal in buffer 
administration [156]. 
Chitosan presents mucoadhesive properties that make it a good candidate for nasal 
delivery of high molecular weight compounds [157]. Chitosan has been successfully 
used as adjuvant for nose to brain delivery due to its mucoadhesive permeation 
properties [156].  These properties are probably linked to its cationic structure, which 
can interact with the anionic structures present in the mucus layer. The mucoadhesive 
characteristics of the chitosans may help to overcome the rapid turnover rate of the 
secretions allowing prolonged contact between the formulation and the olfactory region 
[149, 158].  
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1.3 Aims 
Despite the efforts to develop chitosan-based vectors, the therapeutic effectiveness of 
chitosan-based gene therapy still needs to be improved in order to achieve clinical 
significance. To date there have been no reports of clinical trials for the delivery of DNA 
or siRNA using chitosan as the delivery system [54]. Chitosans need to overcome the 
different extracellular and intracellular barriers in order to be used successfully as 
nanocarriers for gene therapy [159]. The success of gene therapy is dependent on the 
ability of the delivery system to protect nucleic acids in physiological conditions, to 
reach the target cells, to be internalized and to deliver sufficient DNA/siRNA molecules 
into the cytoplasm or nucleus to obtain gene silencing [160]. 
The research performed with chitosan has helped researchers understand its 
limitations, including poor water solubility at physiological pH, and low buffer capacity, 
which affects its gene delivery efficiency [14, 115]. In order to increase translation from 
bench to bedside, efforts are focusing on the chemical and biological modification of 
chitosan in order to increase its solubility, specificity and endosomal escape [142].  
This work introduces a new chitosan based polymer: Ethylamino Glycol Chitosan. The 
new polymer aims to overcome the previously described disadvantages of chitosan for 
gene delivery, particularly relating to chitosan’s solubility and protonation at 
physiological pH and its low buffer capacity. The aim is to enhance chitosan’s 
transfection efficiency while retaining its main benefits of low toxicity and 
biocompatibility. Nose to brain delivery of a complex formed between siRNA and a 
chitosan derivative will be presented for the first time.  
General Objectives 
1. Synthesis and physicochemical characterization of a new chitosan-based 
polymer for gene delivery: Ethylamino Glycol Chitosan - Chapter 2 
2. Characterization of the nanoparticles formed between Ethylamino Glycol 
Chitosan and DNA/siRNA with regard to size, zeta potential, morphology, and 
behaviour when in the presence of biological challenges - Chapter 3 
3. Study of the biocompatibility of Ethylamino Glycol Chitosan and its in vitro 
transfection efficiency as a delivery system for DNA - Chapter 4 
4. In vitro and in vivo biological studies with Ethylamino Glycol Chitosan as a 
delivery system for siRNA – Chapter 5  
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2. Synthesis and Characterization of Ethylamino Glycol 
Chitosan  
2.1 Introduction 
Chitosan is obtained by partial deacetylation of chitin, which is the natural structural 
component of the crustacean exoskeleton [83]. It is a linear polysaccharide composed 
of D-glucosamine and N-acetyl-D-glucosamine subunits linked by (1,4) glycosidic 
bonds. Because of its cationic nature, chitosan is a very popular candidate among 
natural polysaccharides for nucleic acid delivery. Furthermore, it displays properties 
such as biocompatibility and biodegradability, and its degradation products are non-
toxic, non-immunogenic and non-carcinogenic [85]. Despite these advantages, the low 
water-solubility of chitosan at physiological pH is an important limitation for its clinical 
use. Deacetylated chitosan presents primary amines with a pKa ≈ 6.5, explaining why 
chitosan is only soluble in an acidic aqueous environment [160]. Features including the 
degree of deacetylation, molecular weight, and charge of chitosan determine its 
transfection efficiency when complexed with DNA and siRNA [109]. Chitosan polymer 
chains should have a sufficient charge density to avoid dissociation of the polymer and 
nucleic acids in the extracellular environment. Optimal transfection efficiency of 
chitosan polyplexes was achieved only at acidic pH. Intracellular nucleic acid delivery is 
further restricted by limited endosomal escape, due to the weak buffer capacity of the 
polymer [14, 115]. 
 
 
Figure 7 - Representative chemical structure of chitosan. 
 
To improve the nucleic acid delivery capacity of chitosan, modifications to the polymer 
structure have been made. The chitosan monomer contains two hydroxyl groups and 
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one primary amine that are regarded as potential reactive sites for chemical 
modifications (highlighted in Figure 7). The main objectives of the synthesis of chitosan 
derivatives were to enhance solubility, pharmacokinetics, cationic charge density, 
endosomal escape, transfection efficiency and specific cell targeting [109, 161, 162].  
One potential derivatisation involves the N-quaternization of the terminal amine groups 
on chitosan, increasing its water solubility and resulting in a permanent positive charge 
on the molecule [135]. These N-trimethyl chitosan polymers (100 kDa) and oligomers 
(3-6 kDa) showed a 16- to 50-fold increase in transfection efficiency when compared 
with PEI. The transfection efficiency was dependent on the percentage of 
quaternization, with a maximum obtained for the polymer 44% quaternized in COS-7 
cells. However, increasing the degree of trimethylation increased the toxicity of the 
polymer [102, 135]. To overcome the toxicity issues and further improve transfection 
rates a number of secondary derivatives have been made, including PEG-graft-
trimethyl chitosans [131, 140] and thiolated trimethyl chitosans [141]. 
To increase the cationic charge density and endosomal escape of chitosan, an 
imidazole ring was grafted to the chitosan backbone through the addition of different 
functional groups such as histidine [111] or urocanic acid [136]. Kim et al. conjugated 
chitosan with various ratios of urocanic acid, and showed reduced cytotoxicity (over 
90% cell viability) and enhanced transfection efficiency. All the derivatives tested 
showed a higher transfection efficiency than unmodified chitosan (1- to 3- fold), and 
increased with an increase in the level of substitution. However, the gene expression of 
all the polymers was still lower when compared with the positive control lipofectamine 
(100-fold) in the absence of medium [136].  
Several authors reported on the addition of PEI to chitosan or chitosan derivatives. The 
objective of these studies was the combination of a biocompatible and biodegradable 
backbone (chitosan) with increased charge density (PEI) to enable an increased proton 
sponge effect. The obtained PEI-chitosan polymers showed lower cytotoxicity (IC50 of 
97.3 µg mL-1 when compared with 13.5 µg mL-1 for PEI) and higher transfection 
efficiency for DNA and siRNA when compared with PEI both in vitro and in vivo [137-
139]. In HepG2, HeLa, and primary hepatocytes, the obtained PEI-chitosan polymers 
revealed transfection efficiencies 5.2-, 4.3-, and 1.5-fold higher than PEI alone 
(25 kDa). Delivery of siRNA was also achieved with PEI-Chitosan. Down-regulation of 
EGFP was approximately 2.5-fold higher when compared with PEI (25 kDa) in A549 
cells [139]. 
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This chapter presents the results of the synthesis and characterization of a new 
chitosan-based polymer for gene delivery: Ethylamino Glycol Chitosan. The different 
steps of the synthesis of the new polymer will be discussed as well as the reaction 
conditions that might affect the final product. The molecular weight and buffer capacity 
of three batches of EAGC were determined.  
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2.2 Methods 
2.2.1 Synthesis of Ethyl Amino Glycol Chitosan  
The acid degradation of glycol chitosan was carried out as previously described [163]. 
Glycol Chitosan (1g) (Sigma Aldrich, Dorset, UK) was dissolved in hydrochloric acid 
(4M, 76 mL) and placed for 4 or 8 hours in a preheated water bath at 50ºC. The 
product resulting from the acid degradation was purified by dialysis (Visking seamless 
cellulose tubing, molecular weight cut off 7000 Da) against deionised water (5L) with 
six changes over 24 hours. The dialysed solution was freeze-dried and the product 
recovered looked like cotton with a cream colouration. 
The degraded GC (100 mg) was dissolved in a solution of N-methyl-2-pyrrolidone 
(NMP) (20 mL) (Sigma Aldrich, Dorset, UK) and triethylamine (TEA) (Sigma Aldrich, 
Dorset, UK) in excess (500L). The solution was allowed to stir for 1h at 40ºC in an oil 
bath until the GC was completely dissolved. The primary amino end group of the 
introduced ethylamine was protected with tert-butoxycarbonyl (Boc) to avoid cross-
reaction during synthesis 2-(Boc-amino) ethyl bromide (BrCH2CH2NHCO2C(CH3)3) 
(200 mg) (Sigma Aldrich, Dorset, UK), with a molar ratio between the GC and 
BrCH2CH2NHBoc of 1:2, 1:5 or 1:10 was added. This reaction was left to stir for 24h, at 
40ºC. Finally the solution was mixed with water (40 mL) and washed with diethyl ether 
(3x50 mL) to extract the unreacted 2-(Boc-amino) ethyl bromide. The aqueous phase 
was collected and dialyzed, as previously, against deionised water (5L) with six 
changes over 24 hours. The final polymer solution was freeze-dried. The polymer 
recovered was dissolved in a hydrochloric acid solution (50 ml, 4M) and stirred for 3 
hours at room temperature, allowing the cleavage of the Boc group. This solution was 
dialyzed as previously described and freeze dried to give N-(2-ethylamino)-6-O-glycol 
chitosan. 
 
2.2.2 Characterization of Ethylamino Glycol Chitosan 
2.2.2.1 Laser Light Scattering (LLS) and Gel Permeation Chromatography 
(GPC) 
Gel permeation chromatography, also known as size exclusion chromatography, is a 
chromatographic approach used to separate macromolecules according to their 
hydrodynamic volume, which is dependent on both molecular weight and molecular 
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conformation of a compound in solution [164]. Molecules with large hydrodynamic radii 
cannot diffuse into the pores of the gel filtration medium and elute first from the column, 
while smaller molecules that diffuse inside the pores, elute later from the column based 
on their size. The eluting compound is characterized for molecular weight by an 
interferometric refractometer, which measures changes in the refractive index (RI) of 
the sample, with changes in concentration (dn/dc), and a multi-angle laser light 
scattering (MALLS) detector which measures the intensity of light scattered by the 
polymers.  
The molecular weight of GC and EAGC were determined by GPC-MALLS equipped 
with DAWN® EOS® MALLS, Optilab rEX Interferometric Refractometer (λ = 690 nm) 
and QELS detectors (Wyatt Technology Corporation, USA), using as mobile phase 
sodium acetate buffer (0.5 M CH3COONa (anhydrous) / 0.2 M CH3COOH, pH 4.5). 
Filtered samples were injected using an Agilent 1200 Series into a POLYSEP-GFC-P 
guard column (35 x 7.8 mm, Phenomenex, UK) attached to a POLYSEP-GFC-P 4000 
column at a loading concentration of 5 mg mL-1. The measurements were performed at 
room temperature with a mobile phase flow rate of 0.7 mL min-1. The data were 
processed using ASTRA for Windows version 5 software (Wyatt Technology 
Corporation, USA).  
dn/dc Measurement  
The specific refractive index increment (dn/dc) of GC and EAGC were measured in 
sodium acetate buffer, as previously, with an Optilab rEX Interferometric 
Refractometer. Filtered samples (0.2 μm, 33 mm Millex MP syringe driven filter unit, 
polyethersulfone (PES) membrane for sterilization of aqueous solutions) of 6 different 
concentrations ranging from 0.1-0.6 mg mL-1 were manually injected using an injection 
system (Wyatt Technology Corporation, USA) at a pump flow rate of 0.3 mL min-1. The 
data were processed using Wyatt ASTRA for Windows version 5 software. 
 
2.2.2.2 Nuclear Magnetic Resonance (NMR) Spectroscopy 
Nuclear magnetic resonance spectroscopy is a very important technique in polymer 
characterization, since NMR signals can be assigned to specific atoms along the 
polymer backbone and side chains. The identification of certain atoms or groups in a 
polymer molecule as well as their positions relative to each other can be obtained by 
one- and two-dimensional NMR spectra [164]. 
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The principles of nuclear magnetic resonance (NMR) spectroscopy are based on the 
excitation of protons (1H) or carbon-13 (13C) atoms by radiation in the radiofrequency 
region. When a compound containing protons or carbon nuclei is placed in a very 
strong magnetic field and simultaneously irradiated with electromagnetic energy of the 
appropriate frequency, nuclei of the compound absorb energy through a process called 
magnetic resonance [165]. The range of frequencies required for excitation and the 
signal patterns produced when the excited atoms relax are characteristic of the 
chemical structure of the molecule. The frequency of the signal is known as the 
chemical shift () and is determined in relation to the protons of a standard, usually 
tetramethylsilane (TMS), which are arbitrarily assigned a shift of =0ppm. The area 
under each peak in the 1H NMR spectrum is proportional to the number of contributing 
protons [166]. In the presence of an electronegative group, which withdraws electron 
density from neighbouring protons, the deshielded proton will require less applied 
magnetic field to change the direction of its spin. This results in a downfield shift (i.e. to 
the left of a spectrum) compared to the more shielded protons, which are surrounded 
by circulating electrons. 1H-1H Correlated Spectroscopy (COSY) shows the NMR 
spectra in two dimensions and the interactions between neighbouring protons, while 
Heteronuclear Multiple Quantum Correlation (HMQC) shows correlation between 
carbon atoms and the protons attached to them [165, 166]. 
1H NMR, 1H-1H COSY, 13C Distortionless Enhancement by Polarization Transfer 
(DEPT) NMR and HMQC were performed on GC and EAGC in Deuterium Oxide (D2O, 
Sigma Aldrich, Dorset, UK) (25 mg mL-1) (Bruker AMX 500 MHz spectrometer, Bruker 
Instruments, UK). Number of scans: 128 for 1H, 16 for COSY, 6000 for 13C and 104 for 
HMQC. Full parameters are attached to each spectrum. 
 
2.2.3 Titration 
In a potentiometric titration the potential of a suitable indicator electrode is measured 
as a function of titrant volume [167]. The electrode that is usually used to make the 
measurements is a pH-sensitive glass indicator electrode. 
GC and EAGC were dissolved in water (2 mg mL-1) and titrated with NaOH (0.05M). 
The pH of the initial solutions was adjusted to 2 with HCl (0.1M). Under continuous 
stirring, titrant was added dropwise. The volume of NaOH added and pH values of 
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polymer solutions were recorded thoroughly using a MPT-2 Autotitrator, (Malvern 
Instruments, Malvern, UK). 
The buffer capacity was defined as the percentage of amino groups that become 
protonated in the pH range 5.1 to 7.4, and can be calculated from the following 
equation: 
Buffer capacity (%) = [(VNaOH x 0.05M)/Nmol]*100 
where VNaOH , is the volume of NaOH solution (0.05 M) required to bring the pH value 
of the polymer solution from 5.1 to 7.4, and Nmol is the total moles of protonatable 
amine groups in the known amount of EAGC and GC (20 mg) [168]. 
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2.3 Results 
EAGC was prepared in a two-step reaction (Figure 8). Firstly, 2-(Boc-amino) ethyl 
bromide (BrCH2CH2NHCO2C(CH3)3) was reacted in a basic environment with the 
primary amines of GC. TEA was added to maintain a basic environment that avoids 
protonation of the GC primary amines. The primary amino end group of the introduced 
ethylamine was protected with Boc to avoid cross-reaction during synthesis. A 
water/ether extraction was performed to solubilize the substituted polymer in water and 
extraction with ether of the unreacted products. Finally, the Boc-protection was 
removed from the amino groups by acidic cleavage. EAGC was isolated as its HCl-salt 
by dialyses and freeze-drying, with a final yield range between 31 and 88% (Table 3). 
The number of ethylamino groups per mole of GC was controlled regarding the initial 
molar ratio between GC and BrCH2CH2NHBoc.  
 
 
Figure 8 - Expected chemical reaction between GC and 2-(Boc-amino) ethyl bromide with N-(2-
ethylamino)-6-O-glycol chitosan as final product. 
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Table 3 - Yield of the different polymers synthesized. 
Polymer Yield (%) 
EAGC14 (Figure 23) 31% 
EAGC11 (Figure 27) 76% 
EAGC13 (Figure 33) 88% 
EAGC17 (Figure 38) 65% 
EAGC21 (Figure 42) 60% 
EAGC30 (Figure 46) 60% 
 
2.3.1 Laser Light Scattering and Gel Permeation Chromatography 
Figure 9 shows the chromatogram of degraded Glycol Chitosan (8h) and Figure 10 
dn/dc curve. Figure 11 shows the chromatogram of Ethylamino Glycol Chitosan 
(EAGC21) and Figure 12 the dn/dc curve (the chromatograms and dn/dc curves of GC 
(4h), EAGC17 and EAGC30 can be found in appendix). Table 4 summarizes the 
molecular weights obtained by GPC-MALLS for two batches of GC and three batches 
of EAGC. The molecular weight results were expressed as Mn, the number averaged 
molecular weight, and Mw, the weight averaged molecular weight. The polydispersity 
was calculated as a ratio Mw/Mn. 
The Mn of Glycol Chitosan was 28480 Da for GC28 (4h) and 17430 Da for GC17 (8h) 
and Mw/Mn 1.026 and 1.006 respectively. Increasing the acid degradation time 
decreased the molecular weight of the resulting polymer. Two different polymers with 
different molecular weight were used to synthesize EAGC different batches. EAGC17 
and 21 were synthesized from GC17 and EAGC30 was synthesized from GC28. Mn, 
Mw and Mw/Mn of the three batches of EAGC are presented in Table 4. It is of note 
that EAGC17 presents a slightly smaller molecular weight than the starting material, 
GC17. Nevertheless, the difference is so small that it is probably related with the 
sensitivity of the technique used. In the following text, GC17 will refer to glycol chitosan 
with 17 kDa and GC28 to glycol chitosan with 28 kDa. EAGC, however, will be referred 
to regarding the degree of substitution. Therefore EAGC17 has a degree of substitution 
of 17%, EAGC21 of 21% and EAGC30 of 30%.  
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 Figure 9 - GPC-MALLS Chromatogram of degraded Glycol Chitosan (8h) (5 mg mL-1). 
 
 
Figure 10 - dn/dc curve of Glycol Chitosan (8h). 
 
 
Figure 11 - GPC-MALLS Chromatogram of Ethylamino Glycol Chitosan (EAGC21) (5 mg mL-1). 
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 57 
 
Figure 12 - dn/dc curve of Ethylamino Glycol Chitosan (EAGC21). 
 
 Table 4 - GPC-MALLS results for GC and EAGC. 
Polymer dn/dc (mL g-1) Mw (Da) Mn (Da) Mw/Mn 
GC17 0.1443±0.0026 17430 17330 1.006 
GC28 0.0149±0.0002 28480 27750 1.026 
EAGC17 0.1565±0.0005 16910 16730 1.011 
EAGC21 0.1642±0.0072 17620 17340 1.016 
EAGC30 0.1544±0.0036 29850 28290 1.055 
 
2.3.2 NMR Spectroscopy 
The structure and degree of substitution of the new polymer, EAGC, was confirmed by 
comparing its NMR spectra with those of the initial material, GC (Figure 13). The 
protons assignments for degraded GC (Figure 14) are given in Table 5.  
 
Figure 13 - Chemical Structure of Glycol Chitosan. 
 





Figure 14 - 1H-NMR for degraded Glycol Chitosan 17 (8h). 
 
Table 5 - Protons assignments and chemical shifts for GC17. 




Corresponding proton on 
the structure 
a 1.9 ppm CH3 (acetyl group) 
b 3 ppm CH (C2)  
c 3.4-4.1ppm CH (C3, C4, C5 and Glycol) 
d 4.5ppm CH (C1)  
e 4.5-5ppm D2O (water protons) 
 
In the 1H-1H COSY NMR it is possible to observe a cross peak between the protons on 
C1 and C2 (d,b) and between the protons on C2 and C3 (c,b) (Figure 15). 
 
 





Figure 15 -1H-1H COSY NMR for degraded Glycol Chitosan 17 (8h). 
 
In the 13C-DEPT NMR spectrum the positive peaks represent CH and CH3 carbons and 
the negative peaks CH2 carbons. The carbon assignments for degraded GC are 
presented in Table 6 and Figure 16. 
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Figure 16 - 13C-DEPT NMR for degraded Glycol Chitosan 17 (8h). 
 
Table 6 - Carbons assignments and chemical shifts for GC. 




Corresponding carbon on 
the structure 
a 20 ppm CH3 (acetyl group) 
b 56 ppm CH (C2)  
c 60, 69, 72ppm CH2 (Glycol) 
d 73, 75, 78ppm CH (C3, C4, C5) 
e 100ppm CH (C1)  
 
In 1H-13C HMQC NMR spectrum (Figure 17) it is possible to observe the bond 
connection between carbons and hydrogens. The acetyl group protons 1.9ppm=CH3 
correlated with the carbon at 20ppm=CH3 (acetyl carbon).  The proton on the C2 at =3 
ppm is aligned with carbon at =56 ppm. The glycol protons =3.4-4.1ppm correlated 
with CH2 at =60, 69, 72 ppm. The protons C3, C4 and C5 at =3.5-4.1ppm are aligned 
with the carbons at =73, 75 and 78 ppm. The proton on C1 at 4.7ppm correlated with 
the carbon at =100 ppm. 





Figure 17 -1H-13C HMQC NMR for degraded Glycol Chitosan 17 (8h). 
 
The potential mechanism of the reaction between GC and BrCH2CH2NHBoc was 
considered. Among the factors evaluated were the structure of the substrate, the 
reactivity of the nucleophile, the effect of the solvent, the nature of the leaving group, 
and temperature. In the reaction, the primary amines of GC behaved like a nucleophile 
while BrCH2CH2NHBoc was the substrate, with the bromide anion as the leaving group. 
Each of these limiting steps were studied, and decisions were made, using NMR 
results, to achieve the best protocol conditions. As it will be discussed below, the 
reaction was concluded to be a 2nd order nucleophilic substitution (SN2) (Figure 8). This 
type of reaction proceeds in one step (without any intermediates) through an 
arrangement of atoms called a transition state [169].  
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Structure of the substrate  
The BrCH2CH2NHBoc was chosen as the substrate considering 2 main characteristics 
of its structure: the stability of the carbocation (formed during the reaction) and 
favourable leaving group.  
The stability of the carbocation is related to the number of alkyl groups attached to the 
positively charged trivalent carbon. Tertiary carbocations are the most stable, and the 
methyl carbocation is the least stable. The reactivity proceeds as follows: methyl  
primary  secondary  tertiary (unreactive) [165]. Tertiary cations are not present in a 
SN2 reaction since the nucleophile would have to thread its way into the carbon atom 
through the alkyl groups. It is better for an SN2 reaction if there are only small hydrogen 




Two main factors should be considered when evaluating the leaving group: the 
strength of the C–X bond and the stability of the resultant ion. The best leaving groups 
are those that become either a relatively stable anion or a neutral molecule. Among the 
halogens, an iodide ion is the best leaving group and a fluoride ion is the poorest. (I-  
Br-  Cl-  F-). The order is the opposite of the basicity. The best leaving groups are 
weak bases since these stabilize a negative charge effectively. The negative charge on 
the leaving group stabilizes the transition state of SN2 reactions and therefore the free 
energy of activation is lower increasing the rate of the reaction [165, 169].  
Also important was the presence of the Boc group as protection for the amines of 
[GC]-CH2CH2NH2. Without protection these primary amines would behave as 
nucleophiles and attack the primary carbocation of the ethyl group, resulting in more 
than one product with different substitutions (Figure 18). These introduced amines 
would be at least as nucleophilic as the primary amines on the GC backbone. These 
cross-reactions are well known in the nucleophilic substitution of amines, and the 












Figure 18 - Cross reaction between primary amines on GC and unprotected amines in BrCH2CH2NH2. 
 
Reactivity of the nucleophile 
GC presents three possible nucleophiles, the primary amine (C2 amine) and the 
hydroxyl groups on the sugar ring and glycol chain, all of which can be modified. The 
majority of the chemical grafting of molecules or polymers happens on the C2 amine. 
The higher basicity of the amine group (compared to the hydroxyls) makes it the more 
reactive nucleophile [165, 170]. In order to modify the hydroxyl groups the amine group 
needs to be protected [171].  
Effect of the solvent 
Two sets of solvents were tested for the solubility of GC: ethanol/water and NMP. The 
objective was to find a solvent able to solubilize GC without interfering with the 
synthesis. NMR results obtained after the first step of the reaction (Figure 8) were used 
as an indicator of its success. The Boc group presents 3 methyl groups that, regarding 
their chemical structure, would be more shielded when compared with the other 




  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 64 
Choice of Solvent 
 
Figure 19 - Proposed chemical structure of [GC]-CH2CH2NHBoc. 
 
GC, being a water-soluble derivative of chitosan, was easily soluble in the mixture 
water/ethanol. In the 1H-NMR spectra (Figure 20) of the product between GC and 
BrCH2CH2NHBoc, the Boc protons signal at 1.5 ppm is very low (integration=0.05). A 
protic solvent (such as water/ethanol) has a hydrogen atom attached to a strongly 
electronegative element (oxygen or nitrogen). Therefore molecules of these solvents 
can form hydrogen bonds with nucleophiles [165]. It is possible that hydrogen bonding 
hampered the nucleophile and obstructed its reactivity in the substitution reaction 
resulting in a very poor degree of substitution revealed by the NMR results (Figure 20). 
 
 
Figure 20 - 1H-NMR of [GC]-CH2CH2NHBoc (ratio 1:2). GC solubilized in water/ethanol. 





Table 7 - Protons assignments and chemical shifts for [GC]-CH2CH2NHBoc. GC solubilized in 
water/ethanol. 




Corresponding proton on 
the structure 
Boc  1.5 ppm (CH3)3 (Boc Group) 
imp  1.9ppm Solvent Impurity 
a  2.1ppm CH3 (acetyl group) 
A 2.6 ppm CH (C2 substituted)  
b  2.7ppm CH (C2 unsubstituted) 
B 2.9 and 3ppm CH2 (ethyl amino group) 
c 3.5-4.1ppm CH and CH2 (C3, C4, C5 and 
Glycol 
d 4.5ppm CH (C1) 
e 4.7-4.9ppm D2O (Water protons) 
 
GC was not as soluble in NMP as in water/ethanol, though the NMR results were more 
promising with an integration of the Boc methyl groups twenty times higher, 
(integration=1.03) (Figure 21). Polar aprotic solvents (e.g. N,N-dimethylformamide 
(DMF), dimethyl sulfoxide (DMSO), NMP) do not have a hydrogen atom bonded to an 
electronegative atom, and therefore do not hinder nucleophiles through hydrogen 
bonding. In these solvents anions are unencumbered by a layer of solvent molecules 
and they are consequently poorly stabilized by solvation. This makes them highly 
reactive as nucleophiles [165]. Furthermore, the rates of SN2 reactions generally are 
vastly increased when they are carried out in aprotic solvents [165, 172]. NMR results 










Figure 21 - 1H-NMR of [GC]-CH2CH2NHBoc (ratio 1:2). GC solubilized in NMP. 
 
Table 8 - Protons assignments and chemical shifts for [GC]-CH2CH2NHBoc. GC solubilized in NMP 




Corresponding proton on 
the structure 
Boc  1.5 ppm (CH3)3 (Boc Group) 
imp 1.9ppm Solvent Impurity 
a  2.1ppm CH3 (acetyl group) 
imp  2.4ppm Solvent Impurity 
A 2.6 ppm CH (C2 substituted) 
b  2.7ppm CH (C2 unsubstituted) 
B 2.9 and 3.1ppm CH2 (ethyl amino group) 
c  3.5-4.1ppm CH and CH2 (C3, C4, C5 and 
Glycol 
d  4.5 CH (C1) 
e 4.7-4.9 D2O (Water protons) 
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Choice of Molar Ratio 
 
 
Figure 22 - Proposed chemical structure of EAGC.  
 
The number of amines substituted with the new ethylamino group were characterized 
by NMR after deprotection of the Boc group with HCl. Different molar ratios of 
GC:BrCH2CH2NHBoc were tested. The protons assignments for EAGC (Figure 23) are:  
 
 
Figure 23 - 1H-NMR EAGC with a level of substitution of 14% (ratio 1:2). 
 




Table 9 - Protons assignments and chemical shifts for EAGC (ratio 1:2, room temperature).  




Corresponding proton on 
the structure 
imp 1.7 ppm Solvent Impurity 
a 1.9ppm CH3 (acetyl group) 
A 2.5ppm CH (C2 substituted) 
b  2.6-2.9ppm CH (C2 unsubstituted) 
B 2.6-2.9ppm CH2 (ethyl amino group) 
c 3.3-4ppm CH and CH2 (C3, C4, C5 and 
Glycol 
d  4.5ppm CH (C1) 
e 4.7-4.9ppm D2O (Water protons) 
 
 
Comparing the EAGC 1H-NMR spectra (Figure 23) to the GC 1H-NMR spectra (Figure 
14) it is possible to observe a new peak at 2.5ppm. This new peak (A) corresponds to 
the proton of the substituted C2. It is in a more shielded position due to the new group 
introduced (-CH2CH2NH2). This group behaves like an electron donor dispersing the 
negative charge of the amine and moving the C2 proton upfield to a more shielded 
position. The new CH2CH2 of the ethylamino group (peak B) appeared in the spectra at 
3ppm in the same position as the unsubstituted C2. In the original spectra of 
BrCH2CH2NHBoc (Appendix – Figure A.8) the CH2CH2 peaks appeared at 3.5ppm. 
However, when reacted with GC the CH2CH2 peaks moved upfield due to the lower 
electronegativity of the amines when compared with Br-. COSY spectra (Figure 24) 
showed cross peaks between the substituted C2 and C1 (d,A) and substituted C2 and 
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The degree of substitution was calculated with the following formula: 
 
In this first reaction the degree of substitution was:  
 
The new CH2 protons (B) from the substituted group -CH2CH2NH2 were also visible in 
the Carbon DEPT spectra (Figure 25) and HMQC (Figure 26) as well as the C2 
substituted (A).  
 
 
Figure 24 - COSY NMR of EAGC with a level of substitution of 14% (ratio 1:2). 
 
 
Degree of substitution = 
(Area under the peak of the C2 proton substituted / 1 proton) 
(Area under the C3,C4,C5 and Glycol protons peak / 9 protons) 
Degree of substitution (%) = 
(0.66/1) 
(42.68/9) 
X 100 = 13.9% 





Figure 25 - 13C–DEPT NMR of EAGC with a degree of substitution of 14% (ratio 1:2). 
 
 
Table 10 - Carbons assignments and chemical shifts for EAGC (ratio 1:2, room temperature). 




Corresponding carbon on 
the structure 
a 20 ppm CH3 (acetyl group) 
B 39 ppm and 
50ppm 
CH2 (-CH2CH2NH2) 
b 56 ppm CH (C2) 
A 63ppm CH (C2 substituted)  
c 60, 69, 72ppm CH2 (Glycol) 
d 73-78ppm CH (C3, C4, C5) 
e 100ppm CH (C1)  
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Figure 26 - 1H-13C HMQC NMR of EAGC substituted 14% (ratio 1:2). 
 
The molar ratio of GC:BrCH2CH2NHBoc was further increased to increase the degree 
of substitution, with the ultimate objective of increasing the charge ratio of the polymer. 
Results for molar ratios of 1:10 are present in Figure 27 and Table 11. It is possible to 
observe that when the ratio was increased there are two new peaks (A1 and A2) 
between 2.5 and 3ppm on the 1H-NMR of EAGC (Figure 27) compared with 1H-NMR of 
GC (Figure 14). The COSY (Figure 28) revealed that these peaks interact with C1 
(interaction d,A1 and d,A2) and C3 (interaction c,A1 and c,A2) exactly like the proton 
of unsubstituted C2 (interaction c,b and d,b). This means that these two new peaks 
also represent protons of C2 but substituted with the new ethylamino group. Since they 
(A1 and A2) appeared at different chemical shifts the kind of substitution in each of 
them needs to be different. Regarding the previous results a new chemical structure of 
EAGC was proposed with a double substitution in some of the primary amines of GC 
(Figure 29).  
 





Figure 27 - 1H-NMR EAGC with a level of substitution of 11% (ratio 1:10). 
 
Table 11 - Protons assignments and chemical shifts for EAGC (ratio 1:10, room temperature). 




Corresponding proton on 
the structure 
imp 1.9ppm Solvent Impurity 
a  2.0ppm CH3 (acetyl group) 
A1  2.5ppm CH (C2 double substituted) 
A2    2.7ppm CH (C2 single substituted) 
b   2.9-3.2ppm CH (C2 unsubstituted) 
B 2.9-3.2ppm CH2 (ethyl amino group) 
c   3.5-4.2ppm CH and CH2 (C3, C4, C5 and 
Glycol 
d   4.7ppm CH (C1) 
e  4.7-4.9ppm D2O (Water protons) 
protons)Water protons  
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Figure 28 - COSY NMR EAGC with a level of substitution of 11% (ratio 1:10). 
 
The double substitution was possible due to the reactivity of the secondary amines. 
When a hydrogen in an amine is substituted by an electron-releasing alkyl group, the 
basicity of the amine group increases. All secondary amines have slightly higher pKa 
than primary, meaning they behave as stronger nucleophiles [165, 169]. The charge 
density was increased with this double substitution, allowing the introduction of a higher 
total number of amines and the presence of tertiary amines. The degree of substitution 




Degree of substitution = 
 (Area under the peak of the C2 proton single substituted / 1 proton) + 
(Area under the peak of the C2 proton double substituted / 1 proton) 
(Area under the C3,C4,C5 and Glycol protons peak / 9 protons) 
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It is not possible to distinguish the two new peaks (A1 and A2) in the 13C-DEPT NMR 
spectrum (Figure 30). Only a new peak appears at 63ppm. Furthermore, in the 1H -13C 
HMQC NMR spectrum (Figure 31) is not possible to observe the one bond connection 
between the proton and carbons of A1 and A2. This was probably due to the poor 
resolution of the spectrum since even the interaction between C1 proton and C1 
carbon is missing.  
 
Figure 30 - 13C-DEPT NMR of EAGC with a degree of substitution of 11% (ratio 1:10). 
 
Table 12 - Carbons assignments and chemical shifts for EAGC (ratio 1:10, room temperature). 




Corresponding carbon on 
the structure 
a 20 ppm CH3 (acetyl group) 
B 39 ppm CH2 (-CH2CH2NH2) 
b 56 ppm CH (C2 unsubstituted) 
A 63ppm CH (C2 double substituted) 
and (C2 single substituted) 
c 60, 69, 72ppm CH2 (Glycol) 
d 73-78ppm CH (C3, C4, C5) 
e 100ppm CH (C1)  




Figure 31 - 1H -13C HMQC NMR of EAGC substituted 11% (ratio 1:10). 
 
The molar ratio of GC:BrCH2CH2NHBoc was further increased and the following 
spectra (Figures 33 to 36) present the results for the reaction between GC and 
BrCH2CH2NHBoc with a molar ratio of 1:20. It is possible to observe in the 13C DEPT 
NMR three new CH2 signals at 39, 45 and 50ppm (Figure 35). These peaks confirm the 
proposed double substitution. When in presence of a double and single substitution 
three different CH2 are present (peak B1, B2 and B3) (Figures 32 and 35). On the 
HMQC spectrum (Figure 36) it is possible to see the interaction between carbons B1 
and protons B confirming that the protons of the CH2 of the ethylamino group are 
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Table 13 - Protons assignments and chemical shifts for EAGC (ratio 1:20, room temperature). 




Corresponding proton on 
the structure 
Imp  1.9ppm Solvent Impurity 
a  2.0ppm CH3 (acetyl group) 
A1   2.5ppm CH (C2 double substituted) 
A2  2.7ppm CH (C2 single substituted) 
b   2.9-3.1ppm CH (C2 unsubstituted) 
B  2.9-3.1ppm CH2 (ethyl amino group) 
c  3.5-4.1ppm CH and CH2 (C3, C4, C5 and 
Glycol 
d  4.7ppm CH (C1) 
e  4.7-4.9ppm D2O (Water protons)  
 
 
Figure 34 - COSY-NMR EAGC with a level of substitution of 13% (ratio 1:20). 
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Figure 35 - 13C – DEPT NMR of EAGC with a degree of substitution of 13% (ratio 1:20). 
 
Table 14 - Carbons assignments and chemical shifts for EAGC (ratio 1:20, room temperature). 




Corresponding carbon on 
the structure 
a 20 ppm CH3 (acetyl group) 
B1  39ppm CH2 (-CH2CH2NH2) double 
substitution 
B2 45ppm  CH2 (-CH2CH2NH2) single 
substitution 
B3 50ppm CH2 (-CH2CH2NH2) double 
and single substituted 
b  56 ppm CH (C2 unsubstituted) 
A 63ppm CH (C2 double substituted) 
and (C2 single substituted) 
c  60, 69, 72ppm CH2 (Glycol) 
d 73-78ppm CH (C3, C4, C5) 
e 100ppm CH (C1)  
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Figure 36 - 1H -13C HMQC NMR of EAGC substituted 13% (ratio 1:20). 
 
 

















1:2 13.9 87 89 11 0 
1:10 9.5 86 93 6 1 









The total number of amines in this reaction (Molar ratio 1:20) is not much higher than in 
the previous one (Molar ratio 1:10) despite the number of moles of BrCH2CH2NHBoc 
being double (Table 15). The importance of the solvent for GC solubility has been 
discussed before. It was found that even though GC was not completely soluble in 
NMP, the level of substitution with -CH2CH2NHBoc was higher with NMP when 
compared with water/ethanol (integration of the Boc methyl groups was twenty times 
higher with GC dissolved in NMP than dissolved in water/ethanol). Still, the solubility of 
GC was probably a limiting step regarding the maximum number of amines that it is 
possible to introduce in the polymer backbone. As seen previously, even increasing the 
amount of substrate did not increase considerably the number of new amines, (Table 
15) perhaps due to the amount of GC available. To increase the solubility of GC the 
temperature of the reaction was raised to 40ºC. This increase not only benefited the 
solubility of GC but also amplified the reaction rate since, for SN2 reactions, higher 
temperatures amplifies the number of collisions between reactants [165]. Three new 
batches of EAGC (EAGC17, EAGC21 and EAGC30) were synthesized at this higher 




Figure 37 - Chemical Structure of EAGC. 
  




Figure 38 - 1H NMR EAGC with a level of substitution of 17% (ratio 1:2). 
 
Table 16 - Protons assignments and chemical shifts for EAGC (ratio 1:2, 40°C). 




Corresponding proton on 
the structure 
a  2.0ppm CH3 (acetyl group) 
A1  2.5ppm CH (C2 double substituted) 
A2  2.7ppm CH (C2 single substituted) 
b  2.9-3.1ppm CH (C2 unsubstituted) 
B  2.9-3.1ppm CH2 (ethyl amino group) 
c 3.5-4.1ppm CH and CH2 (C3, C4, C5 and 
Glycol 
d  4.7ppm CH (C1) 
e  4.7-4.9ppm Water protons 
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Figure 39 - COSY NMR EAGC with a level of substitution of 17% (ratio 1:2). 
 
Figure 40 - 13C – DEPT NMR of EAGC with a degree of substitution of 17% (ratio 1:2). 
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Table 17 - Carbons assignments and chemical shifts for EAGC (ratio 1:2, 40°C). 




Corresponding carbon on 
the structure 
a 20 ppm CH3 (acetyl group) 
B1 39ppm 
CH2 (-CH2CH2NH2) double 
substitution 
B2 45ppm  
CH2 (-CH2CH2NH2) single 
substitution 
B3 50ppm 
CH2 (-CH2CH2NH2) double 
and single substituted 
b  56 ppm CH (C2 unsubstituted) 
A 63ppm 
CH (C2 double substituted) 
and (C2 single substituted) 
c  60, 69, 72ppm CH2 (Glycol) 
d  73-78ppm CH (C3, C4, C5) 
e  100ppm CH (C1) 
 
 
Figure 41 - 1H -13C HMQC NMR of EAGC substituted 17% (ratio 1:2). 
 




Figure 42 - 1H-NMR EAGC with a level of substitution of 21% (ratio 1:5). 
 
Table 18 - Protons assignments and chemical shifts for EAGC (ratio 1:5, 40°C). 




Corresponding proton on 
the structure 
a  2.0ppm CH3 (acetyl group) 
A1  2.5ppm CH (C2 double substituted) 
A2  2.7ppm CH (C2 single substituted) 
b  2.9-3.1ppm CH (C2 unsubstituted) 
B  2.9-3.1ppm CH2 (ethyl amino group) 
c  3.5-4.1ppm CH and CH2 (C3, C4, C5 and 
Glycol 
d  4.7ppm CH (C1) 
e  4.7-4.9ppm Water protons 
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Figure 43 - COSY NMR EAGC with a level of substitution of 21% (ratio 1:5). 
 
Figure 44 - 13C – DEPT NMR of EAGC with a degree of substitution of 21% (ratio 1:5). 
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Table 19 - Carbons assignments and chemical shifts for EAGC (ratio 1:5, 40°C). 




Corresponding carbon on 
the structure 
a 20 ppm CH3 (acetyl group) 
B1 39ppm CH2 (-CH2CH2NH2) double 
substitution 
B2 45ppm  CH2 (-CH2CH2NH2) single 
substitution 
B3 50ppm CH2 (-CH2CH2NH2) double 
and single substituted 
b  56 ppm CH (C2 unsubstituted) 
A 63ppm CH (C2 double substituted) 
and (C2 single substituted) 
c  60, 69, 72ppm CH2 (Glycol) 
d 73-78ppm CH (C3, C4, C5) 
e 100ppm CH (C1) 
 
 
Figure 45 - 1H -13C HMQC NMR of EAGC substituted 21% (ratio 1:5). 





Figure 46 - 1H-NMR EAGC with a level of substitution of 30% (ratio 1:10).  
 
Table 20 - Protons assignments and chemical shifts for EAGC (ratio 1:10, 40°C). 




Corresponding proton on 
the structure 
a  2.0ppm CH3 (acetyl group) 
A1  2.5ppm CH (C2 double substituted) 
A2  2.7ppm CH (C2 single substituted) 
b  2.9-3.1ppm CH (C2 unsubstituted) 
B  2.9-3.1ppm CH2 (ethyl amino group) 
c  3.5-4.1ppm CH and CH2 (C3, C4, C5 and 
Glycol 
d  4.7ppm CH (C1) 
e  4.7-4.9ppm Water protons 
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Figure 47 - COSY-NMR EAGC with a level of substitution of 30% (ratio 1:10). 
 
 
Figure 48 - 13C – DEPT NMR of EAGC with a degree of substitution of 30% (ratio 1:10). 
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Table 21 - Carbons assignments and chemical shifts for EAGC (ratio 1:10, 40°C). 




Corresponding carbon on 
the structure 
a 20 ppm CH3 (acetyl group) 
B1 39ppm CH2 (-CH2CH2NH2) double 
substitution 
B2 45ppm  CH2 (-CH2CH2NH2) single 
substitution 
B3 50ppm CH2 (-CH2CH2NH2) double 
and single substituted 
b 56 ppm CH (C2 unsubstituted) 
A 63ppm CH (C2 double substituted) 
and (C2 single substituted) 
c 60, 69, 72ppm CH2 (Glycol) 
d 73-78ppm CH (C3, C4, C5) 
e 100ppm CH (C1) 
 
 
Figure 49 - 1H -13C HMQC NMR of EAGC substituted 30% (ratio 1:10). 
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The 1H-NMR spectra revealed an increase of substitution with an increase in molar 
ratio at 40 degrees. It is possible to observe that the overall increase of substitution is 
due mainly to an increase in the number of double substituted primary amines (peak 
A1 Figure 38, Figure 42 and Figure 46). With this substitution the percentage of tertiary 
amines increased (Table 22). With the increase of the double substitution (peak A1) it 
is possible to see in the 1H -13C HMQC NMR the one bond connection between the 
proton and carbon of A1 (Figure 45 and Figure 49). 
 

















1:2 16.4 89 87 10 3 
1:5 21.3 97 85 9 6 




The potentiometric titration curves of GC and EAGC (Figure 50) were based on the 
following chemical reactions:  
HCl + GC-NH3+ + NaOH  NaCl + GC-NH2 + H2O 
HCl + GC-+NR2H + NaOH  NaCl + GC-NR2 + H2O 
where R is hydrogen or ethylamino. Figure 50 shows two inflection points. The first 
point corresponds to the neutralization of excess hydrochloric acid and the second to 
the neutralization of available amine groups. It was not possible to separate out the 
neutralization of primary, secondary and tertiary amine groups, and calculate the 
correspondent pKa values, due to the effects of local groups, which led to different 
ionization constants for every amino group [78, 173]. However, a lower pKa would be 
expected for the tertiary amines (pKa 5-7), and higher for the primary amines (pKa 9-
10) [174]. 
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Figure 50 - Titration curves of GC28, GC17, EAGC17, EAGC21 and EAGC30. A polymer solution 
(2 mg mL-1 adjusted to pH 2 with 0.1M HCl) was titrated with NaOH (0.05M). 
 
In the graph (Figure 50) it is possible to observe that the volume of NaOH required to 
bring the pH from 5.1 to 7.5 in the case of EAGC17, EAGC21 and EAGC30 was higher 
than the volume required for GC. This indicated a higher buffer capacity for the new 
synthesized polymers compared with GC. EAGC17, EAGC21 and EAGC30 were the 
polymers with the highest degree of substitution from all the polymers synthesized and 
therefore were chosen for the determination of their buffer capacity. 
The buffer capacity of the different batches of EAGC and GC (Table 23), was defined 
as the percentage of amino groups that become protonated in the pH range 5.1 to 7.4, 
and can be calculated from the following equation: 
Buffer capacity (%) = [(VNaOH x 0.05M)/Nmol]*100 
where VNaOH , is the volume of NaOH solution required to bring the pH value of the 
polymer solution from 5.1 to 7.4, and Nmol is the total moles of protonatable amine 
groups in the known amount of EAGC and GC [168]. 
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Table 23 - Buffer Capacity of the different polymers in a pH range of 5.1 to 7.4. 







EAGC17 and 21 were synthesized from GC17 and EAGC30 from GC28. EAGC30 
almost doubles its buffer capacity regarding the initial GC28. EAGC17 and EAGC21 
also present higher buffer capacity than GC17. Increasing the degree of substitution 
increased the buffer capacity of EAGC (Table 23). The introduction of the new 
ethylamino groups provided the polymer with secondary and tertiary amines. These 
amines present pKa values in the range of 5-7 and consequently 
protonation/deprotonation of these determined the buffering capacity of the polymers 
[78, 174-176].  
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2.4 Discussion 
This chapter introduced a new chitosan based polymer, Ethylamino Glycol Chitosan 
that was synthesized with four important considerations in mind: (i) the resulting 
polymer should be soluble at physiological pH, (ii) it should efficiently complex the 
nucleic acids to provide stable polyplexes (iii) it should have improved buffering 
capacity to be able to release the nucleic acids inside the cell and (iv) it should retain 
the biocompatibility and low cell toxicity of the parent polymer chitosan.  
Glycol chitosan was chosen as the starting material for the synthesis of EAGC due to 
its higher solubility in water when compared with chitosan and low cytotoxicity 
regarding other chitosan salts [108, 159]. 
The molecular weight and charge density of EAGC is an important factor to be 
considered, since it influences the polymer biocompatibility, the size and stability of 
polymer-nucleic acid complexes as well as its transfection efficiency. Different studies 
with chitosan as a gene delivery system showed that a high molecular weight polymers 
(100-400 KDa) associated with a high degree of deacetylation were essential 
requirements for nucleic acid transfection and performed better than low molecular 
weight chitosan for gene delivery of DNA and siRNA [112, 118, 120-122]. Transfection 
efficiency in A549 cells increased with the molecular weight of chitosan polyplexes (213 
kDa > 98 kDa > 48 kDa > 17 kDa) [118]. Decreasing either the polymer molecular 
weight or degree of deacetylation led to decreased protection of the condensed nucleic 
acids and less efficient cellular uptake, causing low transfection efficiency [117, 118]. 
Plasmid-chitosan complexes made with higher molecular weight chitosan were more 
stable to salt and serum challenge [112]. Nevertheless, high molecular weight polymers 
(100 kDa) with a high degree of deacetylation were associated with high toxicity [103, 
112] and were less biocompatible [95] than lower molecular weight chitosans (10 kDa) 
[105]. 
Recent work has shown that low molecular weight chitosans (˂100 kDa) are also 
suitable gene delivery candidates, and in some studies had out-performed the high 
molecular weight polymers [55, 57, 94, 110, 127-129]. Down-regulation of specific 
genes through siRNA delivered by low molecular weight chitosan was studied. Three 
different chitosans (44, 63 and 93 kDa) showed an 80% down regulation of luciferase 
expression at chitosan, siRNA mass ratios 2.5 and 5. The fourth chitosan, with a 
molecular weight of 143 kDa, was less effective with a reduction of only 60%, while 
lipofectamine (positive control) showed 90% downregulation [127].  
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Furthermore, chitosans with 24 monomer units (4.7 kDa) formed stable complexes with 
high transfection efficiency in vitro. The efficiency of low molecular weight chitosan was 
compared with a high molecular weight (162 kDa, 83% deacetylated) polymer for three 
cell lines at an N:P ratio of 60. The low molecular weight chitosan showed a gene 
expression 4- to 24-fold higher than the high molecular weight chitosan [119]. 
In summary, high molecular weight polymers with high degree of deacetylation offered 
enhanced nucleic acid complexation and stability, but also led to aggregation, low 
solubility at physiological pH and low biocompatibility [130]. The high stability of the 
nanoparticles may result in difficulty releasing the nucleic acids inside the cell, leading 
to low or delayed transfection [38]. Complexes with low molecular weight and low 
degree of deacetylation are not stable enough for transfection due to low complexation. 
Nevertheless, efficient intracellular release would be easy to achieve [104, 130]. 
Transfection efficiency with this kind of chitosan is improved when the complexes are 
formulated at high polymer, nucleic acid mass ratios and with a high degree of 
deacetylation [104, 126].  
Considering the previous findings for chitosan, it was believed that an appropriate 
polymer molecular weight was needed to confer enough stability to the EAGC 
complexes for nucleic acid protection, but also allowing efficient intracellular 
DNA/siRNA release to obtain high levels of transfection [159]. The molecular weight of 
the three different EAGC polymers was confirmed by GPC (Table 4). Two molecular 
weights (17 and 27 kDa) were chosen for EAGC. The larger polymer was required 
because the maximum charge density of the smaller molecule was not enough to 
provide complete condensation with DNA and siRNA. Low molecular weight polymers 
were preferred to avoid the drawbacks of high molecular weight such as toxicity and 
low intracellular release of nucleic acids. 
However, low molecular weight polymers may lead to instability of the nanoparticles in 
physiological media and result in early dissociation of the complexes. To address this 
instability it was decided to substitute the initial glycol chitosan with ethylamino groups 
in order to increase the charge density of the polymer. The influence of the charge 
density of chitosan in transfection efficiency of the polymers was previously addressed.  
Five chitosans with a molecular weight range between 31 and 190 kDa, and with 
different degrees of deacetylation (51%-99%), were studied by Koping-Hoggart et al. in 
the 293 kidney cell line. The results showed that the transfection ability of the 
polyplexes depended on the percentage of deacetylation, since chitosan with a 
percentage of positive charge lower than 65% did not show transfection ability. 
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 96 
Furthermore, chitosan with 50 kDa grafted with PEI (1.8 kDa) showed the same buffer 
capacity as PEI. The transfection efficiency of these copolymers was significantly 
enhanced when compared with chitosan and PEI, and similar to the positive control 
lipofectamine towards chondrocytes and synoviocytes. The copolymers showed 
increased cell biocompatibility when compared with PEI [177]. 
The pKa of chitosan primary amines has been calculated as 6.5, meaning that at 
higher pH (more basic), the amines will not be protonated and the overall positive 
charge of the polymer will be low [114]. Therefore, at pH 7.4 chitosan presents minimal 
solubility, and low intracellular delivery resulting in low transfection ability [104, 105]. 
The ethylamino group introduced in glycol chitosan had the objective of increasing 
EAGC condensation with nucleic acids at physiological pH and the polymer buffer 
capacity. 
The chemical structure and degree of substitution of EAGC were confirmed by NMR. 
The 1H-NMR spectra of EAGC17, 20 and 30 revealed that increasing the molar ratio of 
GC:BrCH2CH2NH2 increased the overall substitution of the polymers. The substitution 
of the primary amines of chitosan with one or two ethylamino groups provided the new 
polymers with primary, secondary and tertiary amines that are required for good 
buffering, proper binding and release of nucleic acids [138, 178].   
 
The buffer capacity of the polymers is a relevant parameter for the endosomal escape 
capability of the polyplexes. The remarkable nucleic acid delivery ability of cationic 
polymers is attributed to a “proton sponge effect” that induces endosomal disruption 
and prevents degradation of nucleic acids in the lysosome. This buffering effect causes 
an increase in osmotic pressure in the endosome, leading to the disruption of the 
endosomal membrane to facilitate polyplex transport into the cytoplasm [15, 168]. 
The buffer capacity of EAGC polymers, expressed as the percentage of amino 
nitrogens that become protonated in the pH range 7.4–5.1, was determined from the 
acid–base titration curves (Fig. 2). All the EAGC polymers showed an increased buffer 
capacity compared with unmodified GC. Also, it was possible to observe that the buffer 
capacity of EAGC increased with the increasing degree of substitution.  
 
It has been previously described that tertiary amines, with a pKa similar to the pH of the 
endosome, contribute to the increase of the buffer capacity of cationic polymers [138, 
178]. The calculation of the percentage of the different amino groups in each 
synthesized EAGC polymer revealed that the more substituted polymer presented the 
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highest percentage of tertiary amines. This is likely to have been responsible for the 
trend in increasing buffer capacity across the EAGC polymers with increasing degrees 
of substitution. 
 
The final degree of substitution of the different batches of EAGC was controlled by the 
molar ratio of GC:BrCH2CH2NHBoc. However, it was not possible to control the number 
of double or single substitutions during synthesis. This was due to the reactivity of the 
secondary amines (with a slightly higher pKa than primary) behaving as stronger 
nucleophiles [165, 169]. It is believed that increasing the amount of substrate 
(BrCH2CH2NHBoc), increased the number of secondary amines available to react, 
leading to a higher percentage of tertiary amines in the final polymer. Different batches 
of polymer synthesized with the same molar ratio presented equivalent percentages of 
primary, secondary and tertiary amines, confirming a reproducible reaction.  
In conclusion, three new batches of EAGC – EAGC17, EAGC21 and EAGC30 – with 
different degrees of substitution were synthesized and characterized. These polymers 
presented a higher buffer capacity when compared with the initial GC that may favour 
the uptake process and the nucleic acid delivery in the cell, increasing the transfection 
efficiency. 
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3. Characterization of Ethylamino Glycol Chitosan-
nucleic acid nanoparticles 
3.1 Introduction 
Cationic polymers have been widely used for nucleic acid delivery. The positive charge 
on the polymer backbone facilitates the electrostatic interaction with the negative 
phosphates along the nucleic acid chains. Polymers such PLL, PEI, and Chitosan 
possess amino groups that, once protonated, enable spontaneous polyplex formation 
upon mixing with DNA or siRNA [176]. The condensation of nucleic acids allows the 
neutralization of the negative charge of the phosphates, which normally prevents 
intracellular uptake of naked DNA and siRNA due to charge repulsion between the 
DNA/siRNA and the anionic cell surface [176, 179]. 
The result of the interaction between nucleic acids and cationic polymers are small 
particles with size, normally, in the nanometre range (nanoparticles). Of the different 
characteristics presented by these nanoparticles, size is one of the most important 
since it determines tissue distribution as well as cellular uptake [110, 180]. It has been 
described that the size of the complexes formed between polymers and nucleic acids 
should be between 50 to several hundred nanometres for efficient cell uptake by 
endocytosis. Each polyplex particle may comprise of several DNA/siRNA molecules 
along with many polymer chains [70, 181, 182]. 
Surface charge is also an important feature of the nanoparticles. Proteoglycans, highly 
anionic molecules, at the surface of the cell membrane are responsible for the cell’s 
overall negative charge [183, 184]. Unless a specific ligand is attached to the polyplex 
structure, the binding of polyplexes to the cell surface is due to nonspecific electrostatic 
interactions between the positive charge of the complexes and the negative charge of 
the cell surface [183, 185]. The adsorption of the nanoparticles at the cell surface is the 
first step for internalization of nanoparticles by endocytosis [29, 186]. 
After systemic administration, nanoparticles face biological challenges related to the 
extra- and intracellular environments. Examples of these challenges are negatively 
charged molecules, like serum albumin, and other extracellular proteins as well as 
nucleases [187]. Negatively charged proteins interact with the complexes and can 
result in aggregation followed by immune system clearance, or complex disassembly 
and release of DNA or siRNA [176, 185]. Unprotected plasmid DNA and siRNA are 
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rapidly degraded by nucleases in vivo. When protected by polymers, nucleic acids can 
remain stable for hours [185, 187].  
In summary, for successful nucleic acid delivery it is necessary to employ a vector that 
is able to condense the DNA and siRNA into small particles, to provide the right charge 
surface for cell interaction and cell internalization, and to protect the nucleic acids from 
the different biological challenges. 
This chapter will present the results for the characterization of the nanoparticles formed 
between EAGC, DNA and siRNA. These particles were studied with respect to the size, 
zeta potential, morphology, and behaviour when in the presence of biological 
challenges. Different techniques including nanoparticle tracking analysis, zeta potential 
measurements, gel retardation (in presence and absence of displacing polyanions such 
as heparin) and nuclease resistance assays were performed.  
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3.2 Methods 
3.2.1 Plasmid DNA preparation 
E. coli DH5α strain was used to produce plasmid DNA. Briefly, a medium of LB broth 
base (25 g L-1, 2L, Sigma Aldrich, Dorset, UK) in MilliQ water was autoclaved. Using 
aseptic techniques, ampicillin (50 μg mL-1, Sigma Aldrich, Dorset, UK) was 
supplemented in the medium at room temperature and an aliquot of the solution was 
transferred to a 25 mL centrifuge tube. The seed culture of E. coli DH5α strain was 
transferred to the centrifuge tube and incubated at 37ºC for 4 hr. Subsequently, the 
whole bacterial solution from the centrifuge tube was expressed in the autoclaved 
medium culture and fermented at 37ºC for 16 h with shaking at 120 rpm. The bacterial 
cells were harvested by centrifugation at 6000 rpm and 4ºC for 15 min (Hermle Z323K, 
Baltimore, USA). The supernatant was removed and the pellet was processed by a 
plasmid extraction kit according to the manufacturer’s instruction (Qiagen: EndoFree 
Plasmid Giga Kit, Manchester, UK). The DNA solution in MilliQ water was desalted 
through the illustra NAP™ Columns (GE Healthcare life Sciences, London, UK). The 
final solution was measured for the DNA concentration (260 nm) and purity 
(260/280 nm) by UV-VIS spectroscopy. The obtained concentration range was 600 -
1200 ng mL-1 and the total yield of the extracted plasmid DNA was in the range of 
6-12 μg for each batch.  
 
3.2.2 Nanoparticles Preparation  
a. EAGC-DNA nanoparticles 
The complexes were prepared to a final DNA concentration of 0.1 mg mL-1. Each 
polymer stock solution (EAGC17, EAGC21 and EAGC30) was prepared in sterile 
dextrose (5% (w/v) filtered with a 0.22 μm Millex filter) to which was added equal 
volumes of the DNA stock solution (in MiliQ water) to give polymer, DNA mass ratios of 
1-60. The complexes were allowed to incubate at room temperature before use.  
b. EAGC-siRNA nanoparticles 
The complexes were prepared to a final siRNA concentration of 0.1 mg mL-1. The 
polymer stock solution (EAGC30) was prepared in sterile dextrose (5% (w/v) filtered 
with a 0.22 μm Millex filter) to which was added an equal volume of the siRNA stock 
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solution (in insiMAX universal buffer) to give polymer, siRNA mass ratios of 1-60. The 
complexes were allowed to incubate at room temperature before use.  
 
3.2.3 Agarose gel retardation assay 
Gel electrophoresis is the standard procedure to analyse the binding affinity between a 
polymer and DNA/siRNA. Electrophoresis uses an electrical field to move the 
negatively charged DNA toward a positive electrode through an agarose gel matrix. 
The nucleic acids are visualized in the gel by addition of ethidium bromide. This binds 
strongly to DNA/siRNA by intercalating between the bases, and when exposed to a UV 
light transmits energy as visible orange light. 
An agarose gel solution (1% w/w) in (1X) Tris Acetate EDTA (TAE) buffer was heated 
in a microwave oven and stained with ethidium bromide (0.3 μg mL-1, Sigma Aldrich, 
Dorset, UK). After cooling, the solution was set to solidify at room temperature in the 
casting tray containing a sample comb. The comb was then removed and the solidified 
gel-tray was inserted into the electrophoresis chamber covered with (1X) TAE buffer. 
Complex samples (prepared as previously described in section 3.2.2, and incubated for 
30min or 1h) and naked DNA/siRNA (control) mixed with loading buffer (2 μL consisted 
of bromophenol blue and xylene cyanol dyes) were pipetted (12 μL) into the sample 
wells with the end of the lane towards the cathode. The power supply (PowerPac™, 
Bio Rad, Hemel, UK) was connected with the chamber and applied for 1 h at 60 V. The 
results were imaged on a UV Transilluminator (ChemiDoc™ MP System, Bio Rad, 
Hemel, UK) to illustrate the ethidium bromide-stained DNA/siRNA in gels. 
. 
3.2.4 Transmission Electron Microscopy (TEM) 
TEM produces high-resolution, black and white images from the interaction that takes 
place between prepared samples and energetic electrons in a vacuum chamber. A 
"light source" at the top of the microscope emits the electrons that travel through 
vacuum in the column of the microscope. The electrons then pass through multiple 
electromagnetic lenses to focus the electrons into a very thin beam. The electron beam 
then travels through the sample in study. At the bottom of the microscope the beam 
makes contact with a screen where the electrons are converted to light and form an 
image with varied darkness according to sample density. The lighter areas of the image 
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represent the places where a greater number of electrons were able to pass through 
the sample and the darker areas reflect the dense areas of the object. The image is 
finally photographed with a camera [188]. 
One drop of polymer-DNA/siRNA complexes (prepared as previously described, 
section 3.2.2, 1h incubation, polymer, DNA/siRNA mass ratios 5, 10, 30 and 60) was 
placed onto a carbon/Formvar coated 200 mesh copper grid (Agar Scientific, Stansted, 
UK) and negatively stained with 1% aqueous uranyl acetate solution. Polymer and 
naked nucleic acid solutions were used as negative controls. Imaging was carried out 
under Philips CM120 Biotwin Transmission Electron Microscope (Philips, Eindhoven, 
The Netherlands). Digital images were captured using a 5MP AMT camera (Deben Uk 
Ltd, Suffolk, UK). 
 
3.2.5 Size and Zeta Potential 
Nanoparticle Tracking Analysis is a new approach to the measurement of size 
compared to more traditional techniques such as Dynamic Light Scattering. A 
microscope, incorporating a camera, captures an image of the particles scattering of 
the laser light.  Each individual particle seen is ‘tracked’ by the nanoparticle tracking 
analysis software. The particle size may be calculated from the Brownian motion with 
the Stokes–Einstein equation [189].  
The size of the complexes was determined by nanoparticle tracking analysis 
(NanoSight LM20, NanoSight Limited, Malvern, UK). The samples were prepared as 
previously described (section 3.2.2) and allowed to incubate at room temperature for 
1h. A volume of the sample (0.2 mL) was injected into the sample chamber. Videos of 
30s in length were made and repeated 3 times with 0.2 mL of sample being injected 
each time. The camera settings for the instrument were set using the ‘Autosettings’ 
option on the software. The focus used was judged by eye, and was adjusted so that 
the majority of particles seen were in focus at any one time. The minimum expected 
particle size was set at 30 nm for all samples and the minimum track length set to 
automatic. The mean obtained from the NanoSight instrument is a number weighted 
average. The size is presented as an average of three measurements. In the 
nanoparticle tracking analysis the standard deviation measures the spread of the sizes 
in the particle size distribution. The higher the value of the standard deviation, the more 
polydisperse is the sample. 
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Surface charge was measured by determination of zeta potential using a Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK). The samples were prepared as 
previously described (section 3.2.2) and incubated for 1h at room temperature. A 
disposable folded capillary cell (0.5 mL) was used for zeta potential measurements. 
Zeta potential is presented as the average of three measurements ± standard 
deviation.  
 
3.2.6 Biological challenges 
a. Heparin  
Nanoparticles were prepared as previously described (section 3.2.2) at polymer, 
DNA/siRNA mass ratios 5, 10, 30 and 60, and incubated for 1h at room temperature. 
Each heparin concentration (0.1 and 1 mg mL-1, 1 μL, Sigma Aldrich, Dorset, UK) was 
added to the complex dispersion and incubated for 15 min. Samples were subjected to 
gel electrophoresis (1X TAE buffer) for 1 h at 60 V to investigate the stability of the 
binding complex in the presence of heparin. The results were imaged on a UV 
Transilluminator (ChemiDoc™ MP System, Bio Rad, Hemel, UK). 
b. Salt 
Nanoparticles were prepared as previously described (section 3.2.2) at polymer, 
DNA/siRNA mass ratios 5, 10, 30 and 60 and incubated for 1h at room temperature. 
NaCl (0.5 M, 3 μL, Sigma Aldrich, Dorset, UK) was added to the complex dispersion 
and incubated for 15 min. Samples were subjected to gel electrophoresis (1X TAE 
buffer) for 1 h at 60 V to investigate the stability of the binding complex. The results 
were imaged on a UV Transilluminator (ChemiDoc™ MP System, Bio Rad, Hemel, 
UK). 
c. Nuclease  
Resistance to nuclease digestion was determined using a deoxyribonuclease (DNase) 
and ribonuclease (RNase) protection assay. Nanoparticles were prepared as 
previously described (section 3.2.2) at polymer, DNA/siRNA mass ratios 5, 10, 30 and 
60, and incubated for 1h at room temperature. DNase/RNase (1 unit μL-1, 1 μL, Sigma 
Aldrich, Dorset, UK) was added to the complex or to naked DNA/siRNA. The samples 
were incubated at 37 °C for 15 min. Immediately following incubation, all samples were 
treated with ethylenediaminetetraacetic acid (EDTA, 50 mM, 10 μL, Sigma Aldrich, 
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Dorset, UK) for 10 min to deactivate the DNase/RNase. Finally, heparin solution 
(20 mg mL-1, 1 μL, Sigma Aldrich, Dorset, UK) was added and the mixture was 
incubated for 30 min at room temperature to allow complete dissociation of the 
complexes. Samples were subjected to gel electrophoresis (1X TAE buffer) for 1 h at 
60 V to investigate the stability of the complex against enzymatic degradation. The 
results were imaged on a UV Transilluminator (ChemiDoc™ MP System, Bio Rad, 
Hemel, UK). 
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3.3 Results  
3.3.1 Agarose gel retardation essay 
Agarose gel electrophoresis was performed to investigate the binding capability of GC 
and EAGC polymers with plasmid DNA (Figure 51). The complexes were allowed to 
interact for 30min or 1h before electrophoresis. Naked DNA (red, Figure 51) was used 
as the control. It is possible to observe (Figure 51) that both GC17 and GC28 were 
unable to condense with DNA, even at high polymer, DNA mass ratios. This was due to 
the non-protonation of the primary amines in the glycol chitosan backbone at 
physiological pH, preventing the polymer from interacting with the negatively charged 
plasmid DNA. Figure 51 also shows that the less substituted polymers, EAGC14, 
EAGC11 and EAGC13, were unable to condense the plasmid DNA after 30min of 
incubation for all polymer, DNA mass ratios. Increasing the degree of substitution 
(EAGC17 and EAGC21) increased the capacity of the polymers to retain the plasmid 
DNA for smaller polymer, DNA mass ratios. EAGC30 had the strongest DNA binding 
capacity, with full condensation of the plasmid at EAGC30, DNA mass ratios as low as 
5. 
When the incubation time was increased to 1 hour, the series of less-substituted 
polymers enhanced their capacity to condense the DNA at low polymer, DNA mass 
ratios (Figure 51). The exception was EAGC14 which released some plasmid, even for 
the high polymer, DNA mass ratios (50 and 60). The influence of the increase of the 
incubation time is mainly visible for EAGC13 and EAGC17 (Figure 51). These polymers 
were able to fully retard the plasmid mobility for polymer, DNA mass ratios as low as 
10. EAGC21 after 1h completely retained the plasmid DNA for all polymer, DNA mass 
ratios to the same extent as EAGC30 (Figure 51).  
The agarose gel experiments were used to screen the binding capacity of all the 
polymers synthesized in Chapter 2. Regarding the previous results it was decided that 
the polymers EAGC17, EAGC21 and EAGC30 were the best candidates for gene 
delivery, and therefore the following experiments (TEM, size, zeta and biological 
challenges) were only performed with these three polymers.  
  
























































































































































































































































































































Figure 51 -   
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It has been described that siRNA polyplexes with chitosan are more unstable when 
compared with DNA complexes. Liu et al. studied the capacity of chitosan to complex 
with siRNA. Agarose gel results showed that chitosans with low molecular weight (9 
and 12 kDa) were not able to retain siRNA at N:P ratio of 50 [125]. On the other hand, 
a low molecular weight chitosan (4.7 kDa) was able to fully condense plasmid DNA at a 
N:P ratio of 60 [126]. The difference of chitosan condensation with DNA and siRNA for 
low molecular weight polymers may be due to the longer DNA strands, that are able to 
compensate the shorter chitosan chains in the assembly process. The smaller strands 
of siRNA need longer chitosan chains to achieve stable complexes [125].  
Furthermore, chitosan with a low degree of deacetylation (54%, 173 kDa) led to 
unstable polyplexes when compared with chitosans with higher charge density (78%), 
that were able to better retard the migration of siRNA in the agarose gel [125]. The 
difference of negative charge in the backbone of the two nucleic acids, with plasmid 
DNA providing a much higher amount of anionic charge (and consequently a higher 
charge interaction between polymer and DNA), contributes to the difference of stability 
of complexes formed with DNA or siRNA [190]. 
 
 
Figure 52 - Agarose gel electrophoresis of EAGC30 with siRNA at different EAGC30, siRNA mass ratios 
after a) 30min and b) 1h incubation. Polyplexes in 5% dextrose. siRNA concentration 0.1 mg mL-1. Naked 
siRNA (red) and increasing EAGC30, siRNA mass ratios (green). 
 
 




EAGC30 was able to fully retain the DNA for all polymer, DNA mass ratios, after just 30 
min incubation, due to its higher charge density and molecular weight compared with 
the other EAGC polymers. Considering the molecular differences between DNA and 
siRNA described above, EAGC30 was concluded to be the best candidate for siRNA 
condensation and cell transfection.  
Agarose gel electrophoresis was performed to investigate the binding capability of 
EAGC30 with siRNA. The complexes were allowed to interact for 30min or 1h before 
electrophoresis. Naked siRNA was used as control. Figure 52 shows that EAGC30 was 
able to completely condense siRNA for EAGC30, siRNA mass ratios as small as 5 after 
30min of incubation. The same results were observed for 1h incubation.  
 
3.3.2 Transmission Electron Microscopy  
Morphological characterization of the nanoparticles formed between EAGC17, 
EAGC21 and EAGC30 and DNA was performed by TEM. Areas of greater electron 
density (such as particles) are visible as dark patches. Four polymer, DNA mass ratios 
were studied 5, 10, 30 and 60.  
 
Figure 53 - TEM pictures of a) naked plasmid DNA at a concentration of 0.5 mg mL-1 in dextrose 5% and 
b) EAGC21 alone at a concentration of 1 mg mL-1 in dextrose 5%. No particles were observed. 
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Figure 54 - Morphological characterization of EAGC17, DNA nanoparticles using TEM. EAGC17 was 
incubated with DNA in dextrose 5% for 1h. DNA concentration 0.1 mg mL-1. EAGC17, DNA mass ratio of 
a) 5 b) 10 c) 30 d) 60. Nanoparticles are seen as the darker patches. 
 
Figure 55 - Morphological characterization of EAGC21, DNA nanoparticles using TEM. EAGC21 was 
incubated with DNA in dextrose 5% for 1h. DNA concentration 0.1 mg mL-1. EAGC21, DNA mass ratio of 
a) 5 b) 10 c) 30 d) 60. Nanoparticles are seen as the darker patches. 
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Figure 56 - Morphological characterization of EAGC30, DNA nanoparticles using TEM. EAGC30 was 
incubated with DNA in dextrose 5% for 1h. DNA concentration 0.1 mg mL-1. EAGC30, DNA mass ratio of 
a)5 b)10 c)30 d)60. Nanoparticles are seen as the darker patches. 
 
TEM pictures showed that DNA alone presents a network structure as previously 
described [191]. EAGC21 alone presented quite homogenously through the entire grid, 
with no aggregation or particle formation observed (note the lack of dark patches in 
Figure 53). In the presence of the different polymers, the long interconnecting fibres of 
the anionic charged molecules of DNA were compacted into nanoparticles. The 
particles presented a spherical or toroid shape, with a relatively homogenous size 
between 50 and 200 nm. This was seen with all three polymers, at each polymer, DNA 
mass ratio (visible as dark patches in Figure 54, Figure 55 and Figure 56). For 
EAGC30 at the polymer, DNA mass ratio 60 (Figure 56d) it is possible to observe some 
polymer aggregation.  
TEM pictures showed that siRNA alone has a network structure similar to plasmid DNA 
(Figure 57). When in presence of EAGC30 the siRNA was compacted into 
nanoparticles (Figure 58). These particles were spherical or in toroid shape with a size 
again between 50 and 200 nm for each of the four EAGC30, siRNA mass ratios. 
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Figure 58 - Morphological characterization of EAGC30, siRNA nanoparticles using TEM. EAGC30 was 
incubated with siRNA in dextrose 5% for 1h. siRNA concentration 0.1 mg mL-1. EAGC30, siRNA mass 
ratio of a)5 b)10 c)30 d)60. Nanoparticles are seen as the darker patches. 
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3.3.3 Size and Zeta Potential 
Particle size was determined by nanoparticle tracking analysis for the three polymers 
EAGC17, EAGC21 and EAGC30 with plasmid DNA. The higher the value of the 
standard deviation, the more polydisperse is the sample. The particles presented sizes 
of between 100 and 450 nm (Figure 59 and Table 24). The nanoparticle tracking 
analysis data is in agreement with the TEM results. 
EAGC17 nanoparticles presented smaller sizes and lower polydispersity with an 
increase of the polymer, DNA mass ratios (Table 24 and Figure 59). The smallest size 
was obtained for EAGC17, DNA mass ratio 60 (167nm). The size of EAGC17 
nanoparticles was statistically (***p≤0.001) higher than the size of the nanoparticles 
formed with EAGC21 and EAGC30 for lower polymer, DNA mass ratios (Figure 59). 
These results are probably a consequence of the incapacity of EAGC17 to fully 
compact the DNA molecules at low polymer, DNA mass ratios, as revealed by the 
agarose gel assay (Figure 51). Since EAGC17 was the polymer with the lowest charge 
density (compared with EAGC21 and EAGC30) it was necessary to use more polymer 
(i.e. to have a higher polymer, DNA mass ratios) to compact the DNA in smaller 
nanoparticles.  
EAGC21 showed uniform sizes through all the polymer, DNA mass ratios (Table 24 
and Figure 59), while the size of the nanoparticles formed with EAGC30 increased with 
an increase of the polymer, DNA mass ratios (Table 24 and Figure 59). EAGC30 
presented the highest charge density, and therefore at small polymer, DNA mass ratios 
the polymer was able to fully condense the DNA into particles with small size. With an 
increase of the polymer, DNA mass ratios the size of the particles grew, probably due 
to an aggregation of the polymer as observed in the TEM pictures (Figure 56d). The 
size of the nanoparticles formed between EAGC30 and DNA was statistically 
(###p≤0.001) higher when compared with nanoparticles formed with EAGC17 and 
EGCC21 for high polymer, DNA mass ratios (Figure 59).  
For each polymer, the particle size distribution was measured three times. The 
software calculated the mean (the average particle size measured), mode (the most 
frequent particle size found) and standard deviation (the breadth of the log-normal 
distribution fitted to the data). In addition, each value is reported with its standard error. 
In this work the size is presented as mean values ± standard error and standard 
deviation ± standard error. 
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Table 24 - Mean size and standard deviation (± standard error (SE)) of EAGC17, EAGC21 and EAGC30 
complexes at various polymer, DNA mass ratios from nanoparticle tracking analysis measurements. 
EAGC17, EAGC21 and EAGC30 were incubated with DNA in dextrose 5% for 1h. DNA concentration 0.1 





EAGC17 EAGC21 EAGC30 
Mean Size 
± SE (nm) 
Standard 
Deviation 
 ± SE (nm) 
Mean Size 
± SE (nm) 
Standard 
Deviation 
± SE (nm) 
Mean Size 
± SE (nm) 
Standard 
Deviation 
± SE (nm) 
1 356±21.6 140±18 157±3.2 82±4.5 169±6.2 47±0.9 
5 401±11.8 178±19.1 222±2.5 96±3 221±3.1 183±5.2 
10 338±11.7 130±10.9 228±3.0 102±4.2 143±6.1 66±1.6 
20 187±3.8 87±3.3 184±2.5 93±6.7 206±4.4 101±4.5 
30 299±3.6 99±2.9 174±1.2 86±1.9 225±4.2 130±5.0 
40 183±1.5 79±1.4 212±3.4 91±0.7 243±4.8 118±5.7 
50 281±3 100±4.2 296±5.5 106±6.7 441±17.8 181±23.2 




Figure 59 - Average particle size of EAGC17/21/30-DNA complexes at various polymer, DNA mass ratios. 
EAGC17, EAGC21 and EAGC30 were incubated with DNA in dextrose 5% for 1h. DNA concentration 
0.1 mg mL-1. The data was expressed as mean values (standard error) of three experiments. Two way 
ANOVA, Bonferonni post hoc test, EAGC17 vs EAGC21 and EAGC30 *p≤0.05, **p≤ 0.01, ***p≤0.001 and 
EAGC30 vs EAGC17 and EAGC21 #p≤0.05, ##p≤ 0.01, ###p≤0.001. 
 
The zeta potential provides an indirect measurement of particle surface charge density. 
The values of zeta potential may depend on the pH and ionic strength of the 
measurement solution, the N:P ratio of the nanoparticles and the polymer 
characteristics [115]. Nanoparticles with high surface charge density present colloidal 
stability and high cellular uptake and transfection efficiency in vitro [105]. 
Regarding the surface charge of the nanoparticles formed between the three polymers 
and plasmid DNA, it was possible to observe a positive charge (+30mV to +40mV) for 
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all polymer, DNA mass ratios higher than 5 (Figure 60). At a polymer, DNA mass ratio 
of 1 all the nanoparticles showed a negative charge, since the excess of polymer that 
provided the positive charge at higher polymer, DNA mass ratios was absent. 
Nanoparticles formed with EAGC30 at a polymer, DNA mass ratio of 60 showed the 
highest zeta potential for all the polymers and polymer, DNA mass ratios measured 
(***p≤0.001). This high value of zeta is probably due to the presence of a higher 
number of protonated amines on the EAGC30 backbone when compared with EAGC17 
and EAGC20. It should also be noted that the polymer by itself showed positive zeta 
values around +40mV. 
 
 
Figure 60 - Average zeta potential of EAGC17/21/30-DNA complexes at various polymer, DNA mass 
ratios. EAGC17, EAGC21 and EAGC30 was incubated with DNA in dextrose 5% for 1h. DNA 
concentration 0.1 mg mL-1. The data was expressed as mean values (standard error) of three experiments. 
Two way ANOVA, Bonferonni post hoc test, EAGC30 vs EAGC17 and EAGC21 *p≤0.05, **p≤ 0.01, 
***p≤0.001. 
 
The particles formed between EAGC30 and siRNA presented a size between 150 and 
500nm. The highest size was reported for EAGC30, siRNA mass ratio 1 (***p≤0.001, 
Table 25 and Figure 61). The high level of standard deviation for EAGC30, siRNA 
mass ratio 1 indicates a polydisperse solution where siRNA molecules, polymer 
aggregates and nanoparticles may be present. These results are in accordance with 
the agarose gel results where there was no retardation of siRNA for EAGC30, siRNA 
mass ratio 1 (Figure 52). To allow a full condensation of the siRNA in small 
nanoparticles it was necessary to increase the EAGC30, siRNA mass ratios. The size 
of the nanoparticles decreased for higher EAGC30, siRNA mass ratios. 
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Table 25 - Mean size and standard deviation (± standard error (SE)) of EAGC30 complexes at various 
polymer, siRNA mass ratios from nanoparticle tracking analysis measurements. EAGC30 was incubated 
with siRNA in dextrose 5% for 1h. siRNA concentration 0.1 mg mL-1. The data was expressed as mean 








 ± SE  (nm) 
1 484±53.5 217±35 
5 225±10.7 101±9.5 
10 167±3.1 85±0.8 
20 218±19.2 99±6.2 
30 205±13.1 106±7.1 
40 254±9.2 120±6.9 
50 278±10.1 139±2 
60 255±4.5 135±1.3 
 
 
Figure 61 - Average particle size of EAGC30-siRNA complexes at various polymer, siRNA mass ratios. 
EAGC30 was incubated with siRNA in dextrose 5% for 1h. siRNA concentration 0.1 mg mL-1. The data 
was expressed as mean values (standard deviation) of three experiments. Mean  SEM (n=3), One way 
ANOVA, Bonferonni post hoc test, EAGC30, siRNA mass ratios >5 vs EAGC30, siRNA mass ratio 1 
*p0.05, **p 0.01, ***p0.001. 
 
 
Figure 62 - Average zeta potential of EAGC30-siRNA complexes at various polymer, siRNA mass ratios. 
EAGC30 was incubated with siRNA in dextrose 5% for 1h. siRNA concentration 0.1 mg mL-1. The data 
was expressed as mean values (standard deviation) of three experiments.  
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 118 
 
Regarding the surface charge of the nanoparticles formed between EAGC30 and 
siRNA (Figure 62) it was possible to observe a positive charge for all EAGC30, siRNA 
mass ratios higher than 5. At an EAGC30, siRNA mass ratio of 1, the nanoparticles 
presented a negative charge. At this EAGC30, siRNA mass ratio there was not an 
excess of amines when compared with the negative charge in the siRNA backbone, 
resulting in negative values for the overall charge.  
 
3.3.4 Biological Challenges 
a. Heparin  
In the extracellular compartments, the presence of negatively charged molecules such 
as serum albumin and other extracellular proteins that interact with the positively 
charged nanoparticles may introduce instability in the gene delivery systems [185]. 
These anionic molecules may lead to aggregation of the nanoparticles and 
displacement of the nucleic acids from the delivery system due to competition [185]. 
 
 
Figure 63 - Agarose gels of EAGC-DNA complexes (polymer, DNA mass ratios 5, 10, 30 and 60) after 
incubation with heparin (0.1 and 1 mg.mL-1) for 15min. Polymers were incubated with DNA in dextrose 5% 
for 1h. DNA concentration 0.1 mg mL-1. a) EAGC17-DNA b) EAGC21-DNA c) EAGC30-DNA.  
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The stability of the complexes in biological fluids was investigated through incubation of 
the former with increasing concentrations of heparin (0.1 and 1 mg mL-1). Heparin is an 
anionic protein that competes with the nucleic acids to bind to cationic polymers. This 
competition can lead to the dissociation of the polyplexes.  
It is possible to observe in Figure 63a that EAGC17 is just able to retain the plasmid 
DNA for high EAGC17, DNA mass ratios (EAGC17, DNA mass ratio 60) for both 
heparin concentrations. With the increase of the number of amines in the polymer 
backbone (and consequently the charge ratio), EAGC21 was able to keep stable 
nanoparticles for EAGC21, DNA mass ratio 30 in the presence of the smallest 
concentration of heparin (0.1 mg mL-1, Figure 63b). Finally, EAGC30 showed total 
condensation of DNA for EAGC30, DNA mass ratios 10, 30 and 60 in the presence of 
0.1 mg mL-1 of heparin and for EAGC30, DNA mass ratios 30 and 60 with the highest 
concentration (Figure 63c). EAGC30 nanoparticles were the most stable in the 
presence of both concentrations of heparin, due probably to the molecular weight and 




Figure 64 - Agarose gels of EAGC30-siRNA complexes (EAGC30, siRNA mass ratios 5, 10, 30 and 60) 
after incubation with heparin (0.1 and 1 mg mL-1) for 15min. Polymers were incubated with siRNA in 
dextrose 5% for 1h. siRNA concentration 0.1 mg mL-1.  
 
It is possible to observe in Figure 64 that EAGC30 was able to retain the siRNA for 
high EAGC30, siRNA mass ratios, 30 and 60, in the presence of 0.1 mg mL-1 of 
heparin. When the concentration of heparin was increased the complexes appeared to 
be quite unstable and the release of some siRNA occurred even for the highest 
EAGC30, siRNA mass ratio (EAGC30, siRNA mass ratio of 60). These results are in 
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line with the previously described instability of siRNA nanoparticles [125]. Chitosans 
with high molecular weight and/or high degree of deacetylation were required to obtain 
chitosan siRNA, complexes as stable as chitosan, DNA complexes [125]. This 
instability in the presence of negatively charged molecules, such as heparin, resulted in 
the release of the siRNA for smaller EAGC30, siRNA mass ratios (Figure 64) when 
compared with EAGC30, DNA results (Figure 63 c).  
 
b. Salt 
The high ionic strength of the in vivo environment may disturb the colloid stability of the 
complexes, and release of the nucleic acids may occur due to charge screening. The 
complexes were incubated with 150mM of NaCl for 15 minutes and compared by gel 
electrophoresis to complexes in 5% dextrose.  
As described before (agarose gel experiments, Section 3.3.1) an increase of the 
polymer substitution, associated with an increase in charge density, delivered more 
stable complexes. The same was observed in the presence of salt. Furthermore, the 
presence or absence of salt did not influence the DNA release for any EAGC polymer 
(Figure 65).  
 
 
Figure 65 - Agarose gels of EAGC-DNA complexes (polymer, DNA mass ratios 5, 10, 30 and 60) after 
incubation with NaCl (150mM) for 15min. Polymers were incubated with DNA in dextrose 5% for 1h. DNA 








The presence of 150 mM NaCl in the nanoparticle solution formed between EAGC30 
and siRNA led to disassembly of the complexes and release of siRNA. siRNA was 
released for EAGC30, siRNA mass ratios 5 and 10 in the presence of salt. There was 
no release of siRNA for EAGC30, siRNA mass ratios 30 and 60 in the absence or 
presence of 150mM NaCl (Figure 66).  
 
 
Figure 66 - Agarose gels of EAGC30-siRNA complexes (MR 5, 10, 30 and 60) after incubation with NaCl 
(150mM) for 15min. Polymers were incubated with siRNA in dextrose 5% for 1h. siRNA concentration 
0.1 mg mL-1.  
 
c. Nuclease  
One of the challenges upon administration of nucleic acids in vivo are the endogenous 
nucleases. Gene delivery systems need to protect the nucleic acids from enzymatic 
degradation in order to enhance bioavailability and improve the pharmacokinetic profile 
[192]. DNase is an endonuclease that hydrolyses the double-stranded DNA. DNase is 
present in vivo on the extra- and intracellular spaces, and is one of the major barriers 
for gene delivery. Unprotected DNA is easily degraded by DNase in a matter of 










Figure 67 - Agarose gels of EAGC – DNA complexes (MR 5, 10, 30 and 60) after incubation with DNAse 
(1 unit) for 15min. Polymers were incubated with DNA in dextrose 5% for 1h. DNA concentration 
0.1 mg mL-1. a) EAGC17-DNA b) EAGC21-DNA c) EAGC30-DNA. i) EAGC-DNA complexes 
ii) EAGC-DNA complexes + DNase iii) EAGC-DNA complexes + DNase + Heparin.  
 
It is possible to observe that DNA alone in the presence of DNase was completely 
degraded (red: DNA+DNase, Figure 67) when compared with DNA without DNase 
(red: DNA, Figure 67). For all the polymer, DNA mass ratios, the complexes were 
incubated with DNase and heparin (that would release the DNA) to confirm if there was 
nucleic acid degradation or not. All polymers were able to offer some protection to DNA 
from nuclease degradation for all polymer, DNA mass ratios. EAGC17 (Figure 67a) and 
EAGC21 (Figure 67b) agarose gels show some degradation of DNA for all polymer, 
DNA mass ratios when compared with EAGC30. EAGC30 was able to completely 
protect DNA from degradation. At polymer, DNA mass ratio 60 for EAGC21 and 
EACG30, the amount of heparin was not enough to release the DNA. However it was 
possible to visualize the DNA fluorescence in the application point, which indicates that 
there was no degradation of the DNA by the DNase.  
  




Figure 68 - Agarose gel of EAGC30-siRNA complexes (EAGC30, siRNA mass ratios 5, 10, 30 and 60) 
after incubation with RNase (1 unit) for 15min. Polymers were incubated with siRNA in dextrose 5% for 1h. 
siRNA concentration 0.1 mg mL-1. A) EAGC-siRNA complexes B) EAGC-siRNA complexes + RNase + 
Heparin.   
 
RNase is an endonuclease that hydrolyses the molecules of siRNA. Like DNase, 
RNase is present in vivo in the extra- and intracellular spaces, and is one of the major 
barriers for gene delivery [187]. EAGC30 protected the siRNA against degradation, for 
all EAGC30, siRNA mass ratios as it is possible to observe in Figure 68. RNA alone in 
the presence of RNase was completely degraded (red: RNA+RNase, Figure 68) when 
compared with siRNA without RNase (red: RNA, Figure 68). For all the EAGC30, 
siRNA mass ratios the complexes were incubated with RNase and then heparin, to 
release the siRNA in order to verify if there has been degradation or not.  
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3.4 Discussion 
A gene delivery vector should be able to interact with the nucleic acid molecules, in 
order to condense their structure to appropriate sizes that will allow DNA and siRNA 
delivery to the cells. The capacity of cationic polymers, like EAGC, to compact the 
structure of nucleic acids relies on electrostatic interactions between the positively 
charged polymer and negatively charged DNA/siRNA. These interactions are highly 
dependent on different factors, for example EAGC charge density and polymer, nucleic 
acid mass ratio.  
The results of the agarose gel retardation assay revealed that GC28 and GC17 were 
not able to completely condense with DNA at any polymer, DNA mass ratios. Since the 
primary amines of the glycol chitosan backbone are not protonated at physiological pH 
(pKa=6.5), an electrostatic interaction with the negatively charged DNA was not 
possible and therefore the entire DNA was released.  
EAGC14, with the smallest amount of amines introduced on the GC backbone, 
revealed condensation results as poor as GC17. However, when the number of amines 
was increased, through the introduction of the ethylamino double substitution, 
EAGC11, EAGC13 and EAGC17 showed improved retention capacity of the DNA after 
1h of incubation. EAGC30 presented the strongest DNA binding ability, as the DNA 
mobility was fully retarded at polymer, DNA mass ratios as low as 5 after 30min of 
incubation.  
The results indicated that the binding ability of EAGC with DNA increased with the 
increasing charge density of the polymer, which is in agreement with the literature [193, 
194]. Howard et al. studied several chitosans with different molecular weights and 
degrees of deacetylation. Only chitosans with a high degree of deacetylation (85% and 
99%) were able to retain the plasmid DNA for low N:P ratios, (N:P ratio 1.8:1) [110]. 
Chitosans with a degree of deacetylation of 51% and 65% were not able to completely 
retain the plasmid DNA [110].  
EAGC30 presented the highest total number of amines of the polymers synthesized, 
including primary amines that are an important factor when considering the 
condensation of DNA. It has been described that a high density of positive charges, i.e. 
primary amino groups, is required to obtain stable polyplexes [110, 180, 195]. The high 
pKa of the primary amines of the ethylamino groups of all EAGC polymers, between 9 
and 10, makes them fully protonated at physiological pH, and the positive charge 
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readily enables condensation with the negatively charged nucleic acids. This is in 
particular contrast to chitosan, where the pKa of the amine groups, as previously 
discussed, does not allow them to be protonated at physiological pH [114]. 
As previously explained, EAGC30 was the polymer chosen to condense siRNA due to 
the characteristics of the nucleic acid. Previously authors had demonstrated that to 
achieve stable nanoparticles, siRNA requires polymers with high molecular weight and 
high charge density [125, 190]. The difference of chitosan condensation with DNA and 
siRNA for low molecular weight polymers may be due to the longer DNA strands that 
are able to compensate for the shorter chitosan chains in the assembly process. The 
smaller strands of siRNA need longer chitosan chains to achieve similarly stable 
complexes [125]. Also, the difference of the negative charge in the backbone of the two 
nucleic acids, with plasmid DNA providing a much higher amount of anionic charge 
(and therefore higher charge interaction between polymer and DNA) contributes to the 
difference of stability of complexes formed with DNA or siRNA [190]. 
Agarose gel results for EAGC30 with siRNA showed that the polymer was able to 
retain the nucleic acid for EAGC30, siRNA mass ratios above 5. These are similar 
results to the ones obtained for EAGC30 with DNA, but are nevertheless in contrast 
with the literature. Techarporknoly et al. showed that chitosans with low molecular 
weight (20 and 45 kDa, 85% degree of deacetylation) required higher polymer, siRNA 
mass ratios, above 16, when compared with high molecular weight polymers (200 and 
460 kDa, 85% degree of deacetylation) that were able to completely retain the siRNA 
for polymer, siRNA mass ratios above 8 [129].  
Alaemah et al. demonstrated that different factors may influence the stability of the 
nanoparticles and therefore influence the final results in the agarose gel assay. 
Nanoparticle stability regarding incubation time (0.5, 4 and 20h), pH of the buffer (pH 
6.5 and 8) and N:P ratio (0, 0.5, 2 and 10) was studied. Low molecular weight chitosan 
(12 kDa) was able to completely retain siRNA at low N:P ratios (above 2) after 
condensation between the polymer and the nucleic acid for 20h. The electrophoresis 
was performed at a pH of 6.5, leading to a higher degree of protonation of the chitosan 
amines and therefore increased electrostatic interactions with the nucleic acids. After 
0.5 and 4 hours of complexation, release of siRNA was observed for all N:P ratios at 
pH 8.  No release was observed at pH 6.5. Therefore, an increase in the condensation 
time and decrease in the pH of the electrophoresis buffer results in more stable 
particles for lower N:P ratios [192]. Due to the characteristics of EAGC30 (higher 
charge density and primary amines with pKa ≈ 9-10) the nanoparticles formed with this 
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polymer and siRNA were stable after only 30min of incubation and at a pH 8 of the 
electrophoresis buffer.  
Particle size and shape are important characteristics for intracellular delivery of genes 
as well as tissue distribution [123, 192]. Morphological characterization of the 
polyplexes formed between EAGC and DNA/siRNA was made by TEM. The complexes 
were spherical or toroid for all EAGC-DNA and EAGC30-siRNA nanoparticles. 
Spherical nanoparticles have been described as result of the complexation between 
low molecular weight chitosans and DNA. High molecular weight polymers when in the 
presence of DNA resulted in elongated and irregular nanoparticles with a polydisperse 
morphology [127].  
It has been reported that particles in the nanometre range (20-500nm) are more 
successful for intracellular uptake when compared with microparticles [193, 196]. 
Particle size was determined by nanoparticle tracking analysis for the three polymers 
EAGC17, EAGC21 and EAGC30 with plasmid DNA. EAGC17 nanoparticles presented 
smaller sizes and polydispersity with the increase of the polymer, DNA mass ratios. 
Due to the polymer lower charge density (compared with EAGC21 and EAGC30) it was 
necessary to use more polymer (higher polymer, DNA mass ratios) to compact the 
DNA in small nanoparticles. A decrease of chitosan nanoparticle size with an increase 
of the N:P ratio was previously described by Romeren et al. A decrease in size was 
observed when the N:P ratio was increased from 0.5 to 5 [130]. Conversely, the size of 
the nanoparticles formed with EAGC30 increased with an increase of the polymer, 
DNA mass ratios, probably due to aggregation of the polymer. Similar findings were 
described for chitosan with 32 kDa where an excess of polymer relative to plasmid 
DNA resulted in an increase of the nanoparticle size [112]. EAGC21 showed uniform 
sizes and standard deviation through all the polymer, DNA mass ratios. Regarding the 
previous results it is possible to conclude that the right balance between polymer 
molecular weight and charge density is necessary to obtain a monodisperse 
formulation with nanoparticles in the nanometre range (20-500nm). 
The particles formed between EAGC30 and siRNA presented a size between 150 and 
500nm. The biggest size was reported for EAGC30, siRNA mass ratio 1. These results 
are in accordance with the agarose gel results, where there was no retardation of 
siRNA for EAGC30, siRNA mass ratio 1. To allow a full condensation of the siRNA in 
small nanoparticles it was necessary to increase the EAGC30, siRNA mass ratios.  
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The surface charge of the complexes is very important for the interaction with the cell 
surface. The cellular membrane is negatively charged, making it a good target for the 
positively charged nanoparticles [196, 197]. Zeta potential values for chitosan 
nanoparticles depend mainly on the pH of the media [104] as well as on the chitosan, 
DNA/siRNA ratios [129] and characteristics of chitosan such as degree of deacetylation 
[104]. The high surface charge density of the polyplexes formed with cationic polymers 
such as chitosan determines the complexes colloidal stability which correlates with the 
transfection efficiency of the nanoparticles [105]. The polyplexes formed between 
EAGC17, EAGC21, EAGC30 and DNA presented a positive charge of around +40mV 
for all polymer, DNA mass ratios above 5. These results confirm the high protonation of 
EAGC polymers at physiological pH. Similar results were obtained for siRNA 
nanoparticles with EAGC30. Previous studies had reported that in the presence of an 
excess of chitosan, nanoparticles formed between chitosan and DNA/siRNA presented 
positive zeta potential [125]. However, N:P ratios higher than 32 were necessary to 
obtain chitosan, siRNA polyplexes with a positive zeta potential [129].  
The extra and intracellular environment has a strong impact on the stability of the 
nanoparticles formed with cationic polymers. Anionic proteins, salt and nucleases are 
among the major hurdles that polyplexes need to overcome even before reaching the 
cell surface [179]. The biological stability tests studied the EAGC particles’ stability in 
challenging environments. After preparation of the polyplexes they were incubated with 
heparin, NaCl and DNase or RNase.  
Non-specific interactions of serum proteins with the polyplexes may lead to aggregation 
of the nanoparticles and displacement of the nucleic acids from the delivery system 
due to competition [185]. Heparin is a strongly negatively charged protein that was 
incubated with the nanoparticles at two different concentrations (0.1 mg mL-1 and 
1 mg mL-1). EAGC17 nanoparticles with DNA showed poor stability in the presence of 
heparin even at the lowest concentration. Increasing the substitution of the polymer, 
leading to higher charge density, improved the capacity of the polymers to retain the 
DNA at lower polymer, DNA mass ratios. EAGC30 completely condensed the DNA for 
a polymer, DNA mass ratio of 10. When compared with chitosan nanoparticles it is 
possible to conclude that the introduction of the ethylamino group provided higher 
stability to the nanoparticles formed with EAGC30. Strand et al. reported that the DNA 
release from chitosan polyplexes decreased with an increase in the N:P ratio and the 
molecular weight of chitosan in the presence of 0.1 mg mL-1  of heparin. Nanoparticles 
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prepared with chitosans with molecular weight of 17 and 33 kDa were only able to 
retain the DNA for N:P ratios higher than 20 after 4 and 14h of incubation [55].  
siRNA nanoparticles did not show the same stability with EAGC30 in the presence of 
heparin as DNA nanoparticles formulated with the same polymer. The polymer was 
only able to completely retain the siRNA for EAGC30, siRNA mass ratio of 60 in the 
presence of the higher concentration of heparin. These results confirm the higher 
instability of nanoparticles formed with siRNA previously described for other polymers 
[125]. 
The increased ionic strength present in in vivo environments can lead to aggregation or 
disassembly of the complexes due to screening of the electrostatic interactions [185]. 
EAGC complexes showed good stability when in presence of NaCl. There was no 
difference in the release of DNA from the complexes in the presence of NaCl. 
EAGC30-siRNA particles were unstable in the presence of NaCl for small EAGC30, 
siRNA mass ratios with release of siRNA at EAGC30, siRNA mass ratios of 5 and 10. It 
was not possible to conclude from the agarose gel results if there was aggregation of 
the complexes. The measurement of the nanoparticles size over the time in the 
presence of NaCl would be one of the possible experiments to detect aggregation.  
Finally, the complexes were tested against the presence of nucleases. When naked 
nucleic acids are introduced in the blood stream they are easily degraded. One of the 
major functions of polymers is to protect the nucleic acid so they are able to reach the 
cell surface intact [29, 185]. The EAGC complexes were incubated with nucleases 
(DNase and RNase) and subsequently with heparin, which caused the release of the 
nucleic acid from the complexes in order to confirm their intact structure. All polymers 
were able to offer some protection to DNA from nuclease degradation for all polymer, 
DNA mass ratios. EAGC17 and EAGC21 agarose gels show some degradation of DNA 
for all polymer, DNA mass ratios when compared with EAGC30. These results are 
probably a consequence of the degree of substitution of the polymers and stability of 
the nanoparticles. The more substituted polymer (EAGC30) previously showed more 
stable nanoparticles, that probably led to a higher degree of protection when in the 
presence of DNase. EAGC30 was also able to protect siRNA for all EAGC30, siRNA 
mass ratios. Similar results were obtained by Lee et al. for polyplexes formed with low 
molecular weight chitosan, 22 kDa for a mass ratio (DNA, chitosan) of 1:1 and 1:2 [94]. 
Low molecular weight chitosan (10 kDa at pH 6.5) has been previously described as 
able to effectively protect siRNA from degradation in the presence of RNase [192]. 
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In summary, three polymers (EAGC17, EAGC21 and EAGC30) were condensed with 
DNA and the resultant complexes were characterized. All the polymers formed small 
nanoparticles with positive surface charge. EAGC30 nanoparticles showed the best 
stability when in presence of biological challenges, meaning that the increase of the 
charge density on the polymer backbone delivered more stable particles. 
EAGC30-siRNA polyplexes showed small size and a positive surface charge. The 
stability of the siRNA nanoparticles in biological conditions (in the presence of heparin 
and salt) was reduced when compared with DNA particles, for low EAGC30, siRNA 
mass ratios.  
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4. Biological Studies with plasmid DNA 
4.1 Introduction 
In the previous chapters was presented the synthesis and characterization of N-(2-
ethylamino)-6-O-glycol chitosan (EAGC) with three levels of ethylamino substitution 
(EAGC17, EAGC21 and EAGC30). The three polymers showed the ability to complex 
with plasmid DNA. The resultant nanoparticles were of an acceptable size and zeta 
potential, and displayed stable behaviour in biological fluids. All of these are important 
characteristics that may contribute to the transfection efficiency of the polymers in vitro. 
Also, the biocompatibility of EAGC in cells is an aspect that can impair the gene 
delivery capacity of the polymers. 
The toxicity of cationic polymers is mostly related with the charge density that these 
vectors present [99, 100]. The strong ionic interaction between the positive charges of 
the polymers and the negatively charged cell membrane components is purported to 
affect membrane integrity, causing changes to the overall function of the cell and 
ultimately leading to its death [99, 100]. 
Chitosan presents low toxicity when compared with other cationic polymers such as 
PEI. For chitosan, IC50 (the concentration of polymer at which 50% of cells are viable) 
values have been reported between 0.2-20 mg mL-1 in different cell lines [86]. 
Conversely, PEI presented an IC50 <20 μg mL-1 [101, 102]. Chitosans with different 
molecular weights and degrees of deacetylation (5 kDa, 65.4%; 5–10 kDa, 55.3%; 
and 10 kDa, 55.3%) showed an IC50 >1 mg mL-1 in CCRF-CEM (human 
lymphoblastic leukaemia cells) and L132 (human embryonic lung cells). Haemolysis 
was not observed (<10%) over 1 h and 5 h with chitosans of 5 kDa, 5–10 kDa and 
10 kDa at concentrations of up to 5 mg mL-1 [103]. 
As well as the charge density (determined by degree of deacetylation), the molecular 
weight contributes to chitosan’s cell biocompatibility [86, 104]. High molecular weight 
polymers (100 kDa) with a high degree of deacetylation were less biocompatible [95] 
than lower molecular weight chitosans (10 kDa) [105]. 
Huang et al. suggested that the degree of deacetylation has a greater effect than the 
molecular weight on chitosan’s biocompatibility [95]. IC50 values for chitosans with 
degrees of deacetylation of 88%, 61% and 46% showed an increasing trend with 
values of 1.2, 2.0 and 2.2 mg mL-1, respectively [95]. 
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The results of Nimesh et al. corroborate the theory that the charge density may 
contribute to the biocompatibility of chitosan, since the cell viability was lower at lower 
pH when the protonation of chitosan is higher. After 48h of incubation with chitosan 
(10 kDa, 92% degree of deacetylation), more than 85% of cells were viable at pH 6.5 
and 96% at pH 7.1 [105]. In their studies, Schipper et al. also concluded that toxicity of 
chitosan is dependent on the degree of deacetylation and molecular weight. At a high 
degree of deacetylation, the biocompatibility of chitosan is related to the molecular 
weight and the concentration; at a lower degree of deacetylation toxicity is less 
pronounced and less related to the molecular weight. [106, 107].  
The modifications made to chitosan can make it more or less biocompatible. Carreno-
Gomez showed that glycol chitosan (IC50 = 2.47 mg mL-1) is more biocompatible when 
compared with other chitosan salts such as chitosan hydroglutamate 
(IC50 = 1.73 mg mL-1) [108]. Trimethyl chitosan is more toxic than chitosan, and its 
toxicity was found to be directly related with the degree of trimethylation (charge 
density) [102]. Trimethyl chitosan (100 kDa) with a percentage of trimethylation of 93% 
presented an IC50 of 0.293 mg mL-1 after 6h in contact with human breast epithelial 
cells (MCF-7 cells). 
The gene transfection efficiency of chitosan is lower when compared with other cationic 
gene delivery systems like PEI [57, 110, 111] or cationic lipids [112, 113]. This lower 
transfection ability is attributed mainly to chitosan’s minimal solubility and low buffering 
capacity at endosomal pH [31]. The transfection efficiency of chitosan is dependent on 
polymer characteristics such as molecular weight, degree of deacetylation (charge 
density) and polymer buffer capacity [40, 105]. Furthermore, solution pH and nitrogen 
to phosphate ratio (N:P ratio) determine the transfection efficiency of DNA [55, 59, 
109].  
The transfection efficiency of chitosan is dependent on the pH of the transfection 
medium due to the protonation of its primary amine groups. The pKa of these amines 
has been calculated as 6.5, meaning that at a higher (more basic) pH, the amines will 
not be protonated and the overall positive charge of the polymer will be low [114]. 
Therefore, at pH 7.4 chitosan presents minimal solubility, low intracellular delivery and 
low buffering capacity, resulting in low transfection ability [104, 105].  
The transfection efficiency of a 10 kDa chitosan with a 92% of degree of deacetylation, 
was studied in HEK 293 cells and compared against lipofectamine. The gene 
expression was assessed at different pH values: 6.5, 7.1 and 7.4, in the presence of 
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10% serum. There was a marked decrease in expression of Enhanced Green 
Fluorescent Protein (EGFP) with an increase of pH. EGFP was expressed in 26.3% of 
cells at pH 6.5, but in only 9.2% at pH 7.1 and 0.2% at pH 7.4 [105].  
Sato et al. evaluated the transfection efficiency of chitosan-DNA complexes (52 and 
92% degree of deacetylation) in A549 cells. Higher transfection was obtained at pH 6.9 
than at pH 7.6 [115]. Additionally, Lavertu et al. studied the transfection efficiency of 
two chitosans (40 kDa, 80% degree of deacetylation and 80 kDa, 72% degree of 
deacetylation) at pH values 6.5, 6.8, 7.1 and 7.4. The percentages of transfected cells 
were comparable for pH 6.5 and 7.1, with the lowest transfection results obtained at the 
highest pH [104].  
Further to the pH of the transfection media, the degree of deacetylation of chitosan 
plays a role in the polymer’s capacity to condense with nucleic acids and perform gene 
transfection. The importance of the degree of deacetylation was demonstrated by 
Kiang et al.. Chitosan-DNA nanoparticles with a chitosan with molecular weight of 
390 kDa and degrees of deacetylation of 62%, 70% and 90% were tested. The 
formulations with the lower two degrees of deacetylation resulted in lower gene 
expression levels, not significantly greater than the background [117]. The effect of the 
degree of deacetylation was also studied by Huang et al. with a chitosan of molecular 
weight 213 kDa. The polymer with a degree of deacetylation of 88% showed a 
transfection efficiency of 12.1% while chitosans with lower degrees of deacetylation, 
61% and 46%, showed only residual transfection efficiency 0.2 and 0.05%, respectively 
[95, 118].  
Five chitosans (molecular weights 31-190 kDa, degrees of deacetylation 51-99%) were 
studied by Koping-Hoggart et al. in the 293 kidney cell line. The lowest gene 
expression was obtained using the chitosans with the lowest degrees of deacetylation 
(170 kDa, 65% and 98 kDa, 51%). Chitosan 190 kDa, 85% showed the highest 
transfection efficiency, 70-times higher than 98 kDa, 51%. The results showed that the 
transfection ability of the polyplexes did not depend on the molecular weight in the 
range from 31 to 170 kDa but on the percentage of deacetylation, since chitosan with a 
percentage of positive charge lower than 65% did not show transfection ability [110].  
In summary, in order to achieve high transfection efficiency chitosan should present a 
high degree of deacetylation, and the complexes with DNA should be prepared in a 
slightly acidic solution (pH lower than 7.1) in order to raise the polymer’s positive 
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charge. This enhances the binding efficiency to the cell membrane and subsequent 
cellular uptake [95, 110, 117, 118].  
Several studies have reported that chitosan with a molecular weight lower than 
100 kDa is a suitable gene delivery candidate [55, 57, 94, 110, 127-129]. Strand et al. 
studied a range of chitosans (5-146 kDa) at N:P ratios 3, 5, 10 and 20. Gene 
expression was found to be dependent on the N:P ratio, increasing with the increase of 
the N:P ratios and achieving a plateau after which transfection efficiency decreased 
[55].  
The transfection efficiency of a low molecular weight chitosan (22 kDa), with a degree 
of deacetylation of 72.5% was determined by a transfection assay into 293T cells with 
-galactosidase.  Different chitosan, DNA mass ratios were studied, with a mass ratio 
of 3 showing 37% higher transfection efficiency than PLL (20 kDa) at a polymer, DNA 
mass ratio of 2 [94]. Furthermore, a chitosan oligomer was used to transfect a 293 
kidney cell line. Chitosan (4.7 kDa) polyplexes were prepared at pH 6 in water. 
Transfection efficiency was studied with three N:P ratios: 10, 30 and 60. N:P 60 
showed the highest transfection ability, 100-fold higher than transfection results 
obtained with N:P 10 [126]. 
To try to understand how the different factors that influence transfection efficiency of 
chitosan (molecular weight, degree of deacetylation, pH and N:P) correlate between 
each other, Lavertu et al. studied the transfection efficiency of chitosan with four 
different molecular weights (10, 40, 80 and 150 kDa) and four different degrees of 
deacetylation (72, 80, 92 and 98%). The luciferase expression was evaluated at 
different pH values (6.5 and 7.1) and different N:P ratios (5 and 10). Two formulations 
of chitosan (10 kDa, 92% degree of deacetylation, N:P ratio 5 and 10 kDa, 80 % 
degree of deacetylation, N:P ratio of 10) showed the highest luciferase expression, and 
similar results to the positive control (FuGene) [104].  
The comparison of the four different chitosans in different conditions allowed Lavertu et 
al. to understand the importance of the different variables that influence transfection 
with chitosan. In some formulations it was observed that a decrease in charge density 
led to a decrease in transfection efficiency. Regarding the molecular weight, Lavertu et 
al. concluded that a change in the molecular weight either had no effect on the gene 
expression, or this was increased for chitosan with lower molecular weight depending 
on the degree of deacetylation. For some formulations, increasing the N:P ratio from 5 
to 10 led to an increase in gene expression. Also, a decrease in the pH, creating a 
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more acidic environment, resulted in an increase of luciferase expression. Overall, for 
the chitosans with the lowest molecular weight (10 and 40 kDa), the gene expression 
was lower for low degrees of deacetylation, low N:P ratios and high pH due to weaker 
association of the chitosan with DNA, leading to premature DNA release [104]. 
This chapter will present the cytotoxicity results for EAGC17, EAGC21 and EAGC30. 
Furthermore, different factors, such as transfection time, presence of proteins, 
presence of chloroquine, dose of DNA and cell type, that may affect the transfection 
efficiency of the polymers, will be analyzed. Finally, the transfection ability of the three 
polymers will be studied and a comparison between EAGC17, EAGC21 and EAGC30 
will be made to evaluate how the characteristics of the polymers can affect the 
transfection results.  
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4.2 Methods 
4.2.1 MTT Assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is a 
colorimetric cytotoxicity assay. MTT is a yellow, water-soluble tetrazole salt that is 
reduced to purple, water-insoluble formazan crystals by metabolically active cells [198]. 
The cleavage of MTT has several desirable properties for assaying cell survival and 
proliferation since the cleavage is effected by all living, metabolically-active cells, but 
not by dead cells. The amount of formazan generated is directly proportional to the 
number of live cells. The absorbance of the formazan produced by the cells can be 
measured with a spectrophotometer at 500–600 nm after dissolving the formazan 
crystals in DMSO [198].  
The MTT reagent (Thiazolyl Blue tetrazolium bromide) was purchased from Alfa Aesar 
(Ward Hill, USA). Cells were seeded at 500 cells per well in 96-well plates. They were 
allowed to grow for three days and then treated with EAGC17, EAGC21, EAGC30 or 
Lipofectamine 2000 (Invitrogen, Paisley, UK) at increasing concentrations (1 x 10-9 to 
10 mg mL-1, 50 μL per well) for 6h. Subsequently, cells were washed with Dulbecco’s 
phosphate-buffered saline (DPBS, Invitrogen, Paisley, UK) and incubated for another 
48h with normal medium. Medium was discarded, cells washed with DPBS and MTT 
solution (50 μg, 0.5 mg mL-1, 100μl) was added. Cells were incubated with the MTT 
solution for 2 h at 37°C, after which medium was removed, and DMSO (100 μL, Sigma 
Aldrich, Dorset, UK) was added to each well to ensure complete solubilization of the 
formed formazan crystals. After incubation for 10min at 37°C, the absorbance at 
570 nm was measured using an ELx808 microplate reader (Bio-tek instruments, 
Potton, UK). For analysis, background values were subtracted. The cytotoxicity was 
determined as the ratio between the measured absorbance value of treated and 
untreated cells. Lysed cells (with Triton X-100 from Sigma Aldrich, Dorset, UK) were 
used as a control - 100% effect.  
The IC50 values (concentration of polymer at which 50% of cells are viable) were 
determined by analysis of the data using Prism4. The sigmoidal dose response was 
analysed with Rmax fixed at 100 and Rmin at 0. Cytotoxicity results are presented as 
the average of three measurements ± standard deviation. 
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4.2.2 Cell Transfection efficiency 
β-Galactosidase, the product of the lacZ gene of Escherichia coli, is one of the most 
widely used reporters of gene expression. In the standard assay for quantifying the 
amount of β-galactosidase activity in cells, the O-nitrophenyl-β-D-galactopyraniside 
(ONPG) is used as the β-galactosidase substrate. The hydrolytic product is a yellow 
chromophore, o-nitrophenol, which is measured by spectrophotometry.  
Briefly, 96-well plates were seeded with 10000 cells (A431, U87MG or MiaPaCa-2) per 
well and incubated overnight. The complexes were prepared to a final DNA 
concentration of 0.1 mg mL-1. Each polymer stock solution (EAGC17, EAGC21 and 
EAGC30) was prepared in sterile dextrose (5% (w/v) filtered with a 0.22 μm Millex filter) 
to which was added equal volumes of the DNA stock solution (in MiliQ water) to give 
polymer, DNA mass ratios of 1 to 60. The complexes were allowed to incubate at room 
temperature, for 1 hour, after which the polymer-DNA complexes were added to the 
cells (50 μL, 1 μg plasmid DNA per well) and incubated for 6h in Dulbecco's Modified 
Eagle Medium (DMEM, Life Technologies, Paisley, UK) for U87MG or MiaPaCa-2 cells 
or Minimum Essential Medium (MEM, Life Technologies, Paisley, UK) for A431 cells 
serum free. The complexes were replenished with fresh DMEM or MEM daily and 
incubated for a further 48 hr. The transfection efficiency was determined by measuring 
the enzyme activity of β-galactosidase using the ONPG assay. The cells were lysed 
with Triton X-100 (2% w/v, 50 μL) and stored at -80ºC for at least 15 min. After 
defrosting, deactivated Foetal Bovine Serum (FBS) (0.5 % v/v, 50 μL in DPBS) was 
added to make the total volume to 100 μL. Finally, ONPG solution (2 mg mL-1, 100 μL, 
Sigma Aldrich, Dorset, UK) was transferred to each well. The absorption was 
measured at 420 nm in an ELx808 microplate reader (Bio-tek instruments, Potton, UK). 
Values were expressed in mU per well and compared to the data observed with the 
naked plasmid DNA, polymer by itself, untreated cells and the positive control 
lipofectamine. 
Lipofectamine 2000 (Invitrogen, Paisley, UK)-DNA complexes were prepared with a 
1:2.5 ratio of DNA(μg):Lipofectamine(μL) according to the manufacturer´s 
specifications, and were used as a positive control. Cells were incubated for six hours 
with lipofectamine-DNA complexes (0.1μg DNA/well) in serum-free medium, and then 
replenished with complete media and incubated for further 48h.  
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Transfection with Chloroquine 
Chloroquine is a cationic, amphiphilic compound with a hydrophobic aromatic ring and 
a positively charged side chain. It has two tertiary amines on its side chain behaving as 
a weak base. In acidic environments, such as inside lysosomes, chloroquine becomes 
fully protonated due to the low pH in these compartments [199]. Consequently there is 
a swelling and rupture of the endocytic vesicles allowing the release of the genetic 
material introduced in the cell to the cytoplasm [180, 200]  
Transfection experiments were carried out using chloroquine to investigate the 
endosomal escape of the polyplexes. All experiments were performed with the same 
methods as detailed in section 4.2.2, except that the cells were incubated with cell 
medium containing 100μM chloroquine (Sigma Aldrich, Dorset, UK). The cells were 
transfected for 4 hours before the medium was changed.  
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4.3 Results 
4.3.1 MTT Assay 
 
Figure 69 - MTT assay results in A431cells for, EAGC17, EAGC21, EAGC30 and lipofectamine after 6h 
incubation with treatments. Relative cell viability is presented as relative value (%) to untreated cells. The 
data was expressed as mean values ± standard error of 3 experiments.  
 
The cytotoxicity of EAGC17, EAGC21, EAGC30 and lipofectamine to A431 cells was 
investigated by MTT assay, as shown in Figure 69. Lipofectamine was the comparison 
reagent since it is a well-described in vitro transfection agent, and it was used as 
positive control for the transfection experiments. Relative cell viability for lipofectamine 
abruptly decreased to 50% at approximately 0.1 mg mL-1 and to 5% at 1 mg mL-1 
(Figure 69). All the EAGC polymers were statistically more biocompatible than 
lipofectamine (Table 26). EAGC30 (IC50 = 0.522 ± 0.17 mg mL-1) was the polymer with 
the lowest IC50 (i.e. the highest toxicity); however, it was still more biocompatible than 
lipofectamine (*p0.05, IC50 = 0.071 ± 0.01 mg mL-1). EAGC17 was the least toxic 
polymer (IC50 = 1.826 ± 0.09 mg mL-1) followed by EAGC21 (IC50 = 0.863 ± 
0.16 mg mL-1); both of the polymers were statistically significantly less toxic than 
lipofectamine (***p0.001, Table 26). When compared with PEI (25 kDa, IC50 = 
0.0019 mg mL-1) the polymers also showed lower toxicity to the A431 cell line [101]. 
The difference between the three EAGC polymers, with EAGC17 being statistically less 
toxic than all the other EAGC polymers (###p0.001), was probably due to molecular 
weight and charge density disparities. There was no statistical difference between the 
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IC50 of EAGC21 and EAGC30. It has been described that chitosan toxicity is intimately 
related with its molecular weight and charge density. Chitosans of high molecular 
weight (˃100 kDa) and degree of deacetylation (higher charge density) were more toxic 
than low molecular weight polymers [95, 103, 104]. The toxicity results of EAGC follow 
this trend. EAGC17, with the lowest toxicity, also had the lowest charge density and 
molecular weight of the three polymers. EAGC21 presented the same molecular weight 
of EAGC17 but higher charge density. The polymer with the highest molecular weight 
and charge density of the three polymers was EAGC30, which consequently showed 
the highest toxicity.  
 
 Table 26 - IC50 values of EAGC17, EAGC21, EAGC30 and Lipofectamine in A431 cells lines after 6h of 
incubation with treatments. The data was expressed as mean values ± standard error of 3 experiments. 
One way ANOVA, Bonferonni post hoc test, EAGC17, EAGC21 and EAGC30 vs Lipofectamine *p0.05, 
**p 0.01, ***p0.001 and EAGC17 vs EAGC21 and EAGC30  #p0.05, ##p 0.01, ###p0.001. 
 
Reagent IC50 (mg mL-1) 
EAGC17 1.826 ± 0.09 *** / ### 
EAGC21 0.863 ± 0.16 *** 
EAGC30 0.522 ± 0.17 * 
Lipofectamine 0.071 ± 0.01 
 
4.3.2 Cell Transfection efficiency 
The transfection efficiency of EAGC polymers was evaluated in vitro by delivery of 
plasmid DNA into A431 cells. The polyplexes between the three polymers (EAGC17, 
EAGC21 and EAGC30) and DNA (1 μg per well) were prepared at increasing polymer, 
DNA mass ratios (1-60). The positive control was lipofectamine, a well-described in 
vitro transfection agent [201]. Lipofectamine transfection was performed with 0.1μg 
DNA per well due to its toxicity at high plasmid DNA levels. The negative controls were 
naked plasmid DNA, naked polymer and untransfected cells. The transfection 
efficiency was determined by measuring the enzyme activity of β-galactosidase (in 
mU/well) using the ONPG assay. 
Different parameters that might influence the transfection efficiency of plasmid DNA 
were studied in order to optimize the transfection protocol. Preliminary experiments 
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were made with EAGC21. EAGC21 was chosen due to its characteristics regarding 
complexation with DNA, stability in biological medium and biocompatibility. EAGC17 
produced less stable particles when compared to EAGC21 and EAGC30 was less 
biocompatible. Once optimum transfection conditions had been achieved these were 
later applied to the transfection of the three polymers (EAGC17, EAGC21 and 
EAGC30). 
 
a. Endosomal escape  
The main objective of EAGC synthesis was to increase the buffer capacity of chitosan 
and in this way enhance its transfection ability. The first study performed was 
transfection of A431 cells in the presence of chloroquine. Chloroquine is a transfection 
enhancement agent, buffering the endosomes, causing its disruption and therefore 
increasing the transfection efficiency of polymers without buffer capacity [180]. 
 
 
Figure 70 - Effect of the presence of chloroquine on -Galactosidase gene expression in A431 cell line. 
The transfection was performed for 4h in MEM without serum. Lipofectamine 0.1μg DNA per well. Polymer 
treatments 1μg DNA per well. Mean  SEM (n=5), Two way ANOVA, Bonferonni post hoc test, No 
Chloroquine vs With Chloroquine *p0.05, **p 0.01, ***p0.001 and EAGC21, DNA mass ratios (No 
Chloroquine) vs Lipofectamine (No Chloroquine) #p0.05, ##p 0.01, ###p0.001 . 
 




It was reported that chloroquine can support endosomal escape of polyplexes via its 
own proton sponge effect and thus enhance the transfection efficiency of the polyplex 
[180]. Exogenous chloroquine did not improve the transfection efficiency for any 
polymer, DNA mass ratio (Figure 70).  EAGC21 showed transfection ability in the 
absence of chloroquine for all polymer, DNA mass ratios. Furthermore, for polymer, 
DNA mass ratios 5, 10 and 20 the transfection efficiency of EAGC21 was higher in the 
absence of chloroquine (***p0.001). These results reveal that EAGC21 may have its 
own ability for endosomal escape, probably due to its buffer capacity, as previously 
shown in the titration experiments (Section 2.3.3). These results confirm that EAGC 
was able to deliver plasmid DNA into the cells in vitro. The transfection results in the 
absence of chloroquine were at least as good as lipofectamine, and for polymer, DNA 
mass ratios 10, 20, 30 and 50 were higher (###p0.001). No transfection was seen in 
the negative controls, or EAGC21, DNA mass ratio 1. The positive control, 
lipofectamine, showed its best results in the absence of chloroquine.  
b. Incubation time 
 
Figure 71 - Effect of the transfection time on -Galactosidase gene expression in A431 cell line. The 
transfection was performed with MEM without serum. Lipofectamine 0.1μg DNA per well. Polymer 
treatments 1μg DNA per well.  Mean  SEM (n=5), Two way ANOVA, Bonferonni post hoc test, 4h vs 6h 
*p0.05, **p 0.01, ***p0.001 and EAGC21, DNA mass ratios (6h) vs Lipofectamine (6h) #p0.05, ##p 
0.01, ###p0.001. 
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The optimal time of incubation of the complexes with cells should balance detectable 
expression with limited toxicity [179]. Two lengths of incubation of the complexes with 
cells were studied: 4 and 6 hours. After each time point, the cell medium was 
substituted for new medium without complexes. It is possible to observe in Figure 71 
that the transfection values, after 6h, were statistically significantly higher (p0.001) for 
all polymer, DNA mass ratios when compared with 4h incubation (except for polymer, 
DNA mass ratio 1). No transfection was seen in the negative controls at any time point. 
Lipofectamine presented very low transfection (less than 1 mU per well) for both time 
points. The transfection efficiency for all polymer, DNA mass ratios, except 1, was 
statistically higher (p0.001) when compared with Lipofectamine. The improved 
transfection results after 6h of incubation were only possible due to the good 
cytotoxicity profile of EAGC21. The MTT results revealed that after 6h of incubation the 
EAGC21 IC50 (IC50 = 0.863 ± 0.16 mg mL-1) was higher than the maximum polymer 
concentration transfected (0.6 mg mL-1), allowing a good cell viability throughout the 
incubation period. Regarding these results it was decided to perform the following 
transfection experiments with an incubation time of 6 hours. 
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c. Presence of proteins 
The composition of the cell medium can highly affect the final results of an in vitro 
transfection experiment. As seen in the previous chapters, the presence of proteins can 
affect the characteristics of the complexes and, consequently, their transfection ability.  
 
Figure 72 - Effect of the presence of proteins on cell medium on -Galactosidase gene expression in A431 
cell line with an incubation time of 6h. Lipofectamine 0.1μg DNA per well. Polymer treatments 1μg DNA 
per well.  Mean  SEM (n=5), Two was ANOVA, Bonferonni post hoc test, No proteins vs proteins *p0.05, 
**p 0.01, ***p0.001 and EAGC21, DNA mass ratios (with proteins) vs Lipofectamine (with proteins) 
#p0.05, ##p 0.01, ###p0.001. 
 
The impact of the presence of proteins on the transfection efficiency of EAGC21 was 
studied as shown in Figure 72. The complexes were added to the cell medium with or 
without FBS. It is possible to observe that the presence of proteins did not impair the 
transfection of the plasmid DNA by EAGC21. The transfection efficiencies in the 
presence or absence of proteins were comparable for all EAGC21, DNA mass ratios 
with the exception of EAGC21, DNA mass ratio 30 and 50. For EAGC, DNA mass ratio 
30, the transfection efficiency in the absence of serum was significantly higher 
(***p0.001). EAGC21, DNA mass ratio 1 did not show any transfection with or without 
proteins in the medium, and the same results were obtained for the negative controls 
(naked plasmid DNA, naked polymer and not transfected cells). Lipofectamine showed 
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higher transfection in the presence of serum (not statistically significant) but lower 
transfected units when compared with all EAGC21, DNA mass ratios greater than 5 
(###p0.001). The good performance of the EAGC21 in the presence of serum is 
comparable to the behaviour of chitosan nanoparticles in cell medium with FBS [57, 
122]. Despite the probability of aggregation of the chitosan polymers due the ionic 
interactions with negatively charged proteins, leading to lower transfection results, the 
presence of serum allows an increased cell viability that in the end led to better 
transfection efficiency [105]. 
 
d. Comparable amount of DNA 
The amount of DNA used in cell transfection experiments should be chosen such that 
expression can be detected while toxicity remains limited. The DNA dose may vary 
from 0.1 to 1μg DNA per well (on 96 well plates) but higher doses have been used. 
Higher doses of DNA may result in higher expression levels but with increased toxicity 
[104, 120].  
 
 
Figure 73 - Comparison on -Galactosidase gene expression in A431 cell line between different EAGC21, 
DNA mass ratios and Lipofectamine using the same amount of plasmid DNA (0.1μg per well). The 
complexes were incubated for 6h in MEM without serum. Mean  SEM (n=5), One way ANOVA, 
Bonferonni post hoc test, EAGC21, DNA mass ratios vs Lipofectamine *p0.05, **p 0.01, ***p0.001. 
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Lipofectamine is a powerful transfection reagent that is able to achieve high 
transfection efficiency with low doses of DNA [201]. However, MTT results showed that 
lipofectamine was statistically more toxic (***p0.001) than EAGC21 in the A431 cell 
line. This lower toxicity of the polymer enabled a higher concentration of polymer per 
well and consequently a higher dose of transfected DNA. In previous experiments the 
dose of DNA per well in the polymer treatments was 0.1 to 1μg of DNA with 
lipofectamine (following the manufacturer’s instructions). The objective of this 
experiment was to compare the transfection efficiency of the nanoparticles formed with 
EAGC21 and lipofectamine with the same dose of DNA per well (0.1 μg).  In Figure 73 
it is possible to observe that the polymer achieved better results for all EAGC21, DNA 
mass ratios higher than 10 (***p0.001) with the exception of EAGC21, DNA mass 
ratio 40 (*p0.05).  
 
e. Cell line 
Transfection efficiency is highly dependent on the cell line chosen to perform the in 
vitro studies [179]. EAGC21 gene expression was studied in more than one cell line in 
order to confirm the polymer’s transfection capacity. Three human adherent monolayer 
cell types (A431, MiaPaCa-2 and U87MG) were chosen, considering that the majority 
of the published transfection studies use cell models with these characteristics. 
U87MG, a human brain cell line, was specifically chosen considering the final 
therapeutic target for gene delivery system of this study.  
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Figure 74 – Comparison between three different cell lines, MiaPaCa-2, A431 and U87MG on -
Galactosidase gene expression with an incubation time of 6h in medium without serum. Lipofectamine 
0.1μg DNA per well. Polymer treatments 1μg DNA per well.  Mean  SEM (n=5), Two way ANOVA, 
Bonferonni post hoc test, U87MGvs A431 and MiaPaCa-2 *p0.05, **p 0.01, ***p0.001.  
 
There is a clear cell dependence regarding transfection results of plasmid DNA (Figure 
74). U87MG showed the highest transfection values, being statistically different 
(***p0.001) from A431 and MiaPaCa-2 cell lines for all EAGC21, DNA mass ratios, 
except 1. In fact, the MiaPaCa-2 cell line did not show any transfection for any of the 
EAGC21, DNA formulations. The transfection results for U87MG were comparable 
between EAGC21, DNA mass ratios 5 to 40 with a decrease on the mU values for the 
higher EAGC21, DNA mass ratios (50 and 60). This decrease in transfection may be 
due to polymer toxicity or stability of the nanoparticles.  
 
f. Polymer substitution 
The EAGC17, EAGC21 and EAGC30 transfection efficiencies were evaluated in the 
A431 cell line after 6h of incubation and in the absence of serum. As shown in Figures 
75 to 78, the transfection efficiency is dependent on the degree of substitution of the 
polymers and the mixing ratio of polymer to plasmid DNA.  




Figure 75 – -Galactosidase gene delivery by EAGC17 in A431 cell line with an incubation time of 6h in 
MEM without serum. Lipofectamine 0.1μg DNA per well. Polymer treatments 1μg DNA per well.  Mean  
SEM (n=5), One way ANOVA, Bonferonni post hoc test, EAGC17, DNA mass ratios vs Lipofectamine 
*p0.05, **p 0.01, ***p0.001 and EAGC17, DNA mass ratios 1 and 5 vs other EAGC17, DNA mass 
ratios #p0.05, ##p 0.01, ###p0.001. 
 
The transfection efficiency of EAGC17 at EAGC17, DNA mass ratios 1 and 5 was very 
low when compared with all the other EAGC17, DNA mass ratios (###p0.001, Figure 
75). In the agarose gel retardation assay (Section 3.3.1) EAGC17 showed no ability to 
fully retard the plasmid DNA for EAGC17, DNA mass ratio 1 and 5. The agarose gel 
results explain the lack of transfection for EAGC21, DNA mass ratios 1 and 5 since the 
polymer did not have ability to condense the DNA to allow gene delivery. The 
transfection ability of EAGC17 increased with the increase of the EAGC17, DNA mass 
ratios with the maximum transfection efficiency being achieved at EAGC17, DNA mass 
ratio 60. Transfection results for EAGC17, DNA mass ratios higher than 5 were 
statistically higher than lipofectamine (***p0.001).  
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Figure 76 – -Galactosidase gene delivery by EAGC21 in A431 cell line with an incubation time of 6h in 
MEM without serum. Lipofectamine 0.1μg DNA per well. Polymer treatments 1μg DNA per well. Mean  
SEM (n=5), One way ANOVA, Bonferonni post hoc test, EAGC21, DNA mass ratios vs Lipofectamine 
*p0.05, **p 0.01, ***p0.001. 
 
EAGC21 also did not show any transfection at EAGC21, DNA mass ratio 1. However, 
EAGC21, DNA mass ratio 5 presented a transfection of 2mU per well (Figure 76). With 
the increase of the EAGC21, DNA mass ratios, transfection efficiency increased with 
the exception of EAGC21, DNA mass ratios 40 and 50. Transfection with EAGC21 was 
superior to lipofectamine for all polymer, DNA mass ratios apart from the EAGC21, 
DNA mass ratio 1 (***p0.001).  
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Figure 77 – -Galactosidase gene delivery by EAGC30 in A431 cell line with an incubation time of 6h in 
MEM without serum. Lipofectamine 0.1μg DNA per well. Polymer treatments 1μg DNA per well.  Mean  
SEM (n=5), One way ANOVA, Bonferonni post hoc test, EAGC30, DNA mass ratios vs Lipofectamine 
*p0.05, **p 0.01, ***p0.001. EAGC30, DNA mass ratios 60 vs other EAGC30, DNA mass ratios 
#p0.05, ##p 0.01, ###p0.001. 
 
EAGC30 showed high transfection efficiency even for low EAGC30, DNA mass ratios 
(Figure 77). EAGC30, DNA mass ratio 5 had a transfection of 4 mU per well, compared 
with 2mU for EAGC21 and there was no transfection for EAGC17 at an EAGC17, DNA 
mass ratio of 5. The polymer presented the best results regarding complexation with 
DNA and the highest stability in biological fluids (Chapter 3). This behaviour was 
reflected in the transfection efficiency of EAGC30, reaching higher values of 
transfected units for all EAGC30, DNA mass ratios when compared with lipofectamine 
(***p0.001). The transfection ability of the polymer increased with the increase of the 
EAGC30, DNA mass ratio until it reached a plateau for EAGC30, DNA mass ratios 30, 
40 and 50. The values of transfection decreased for EAGC30, DNA mass ratio 60 
(###p0.001 when compared with EAGC30, DNA mass ratios 20, 30, 40 and 50) 
probably due to polymer toxicity or stability of the nanoparticles. The polymer 
concentration transfected for EAGC30, DNA mass ratio 60 was 0.6 mg mL-1 very close 
to the IC50 of EAGC30 (0.523 ± 0.17 mg mL-1). The cells’ viability might have been 
compromised at this polymer, DNA mass ratio, and consequently lower transfection 
results were obtained. Furthermore, the agarose gel assay in the previous chapter 
showed how stable the nanoparticles were with EAGC30. This stability may have 
inhibited the release of DNA inside the cell causing the low gene expression observed.  




Figure 78 – Comparison between EAGC17, EAGC21 and EAGC30 with respect to -Galactosidase gene 
expression in the A431 cell line with an incubation time of 6h in MEM without serum. Lipofectamine 0.1μg 
DNA per well. Polymer treatments 1μg DNA per well. Mean  SEM (n=5), Two way ANOVA, Bonferonni 
post hoc test, EAGC17 vs EAGC21 and EAGC30 *p0.05, **p 0.01, ***p0.001. EAGC17, EAGC21, 
EAGC30 vs Lipofectamine #p0.05, ##p 0.01, ###p0.001. 
 
When comparing the three polymers (Figure 78) it is possible to observe that EAGC17 
(with the lowest charge density due to a lower degree of substitution with ethylamino 
groups) did not show any transfection for low EAGC17, DNA mass ratios 1 and 5. 
Furthermore, its transfection results were statistically significantly lower (***p0.001) for 
EAGC17, DNA mass ratios 5, 10, 20 and 30 when compared with EAGC21 and 
EAGC30. In the previous chapter it was concluded that the increase of the number of 
amines in the EAGC backbone led to more stable nanoparticles for lower EAGC, DNA 
mass ratios. This stability led to increased levels of transfection, as it is possible to 
observe in Figure 78. EAGC17 and EAGC21 showed a maximum transfection 
efficiency for EAGC, DNA mass ratio 60 while EAGC30 achieved a plateau for 
EAGC30, DNA mass ratios 30, 40 and 50 and then a decrease in transfection for 
EAGC30, DNA mass ratio 60. All the polymers produced higher transfection results 
than lipofectamine for all EAGC, DNA mass ratio higher than 5 (###p0.001) 
confirming the polymers may have its own ability for endosomal escape, probably due 
to its buffer capacity, leading to a higher gene expression.  
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4.4 Discussion 
Different polymer characteristics can influence the toxicity of gene delivery vectors. 
Molecular weight as well as charge density of cationic polymers were described as key 
parameters that can exacerbate cytotoxic effects [71, 180]. Polymers with a high 
charge density like PEI present higher toxicity when compared with chitosan and 
chitosan derivatives [72, 86, 92, 102]. 
It has been described that chitosan cell biocompatibility is intimately related with its 
molecular weight and charge density. Chitosans of high molecular weight (100 kDa) 
and degree of deacetylation were less biocompatible than low molecular weight 
polymers [95, 103, 105]. Moreover, the number of positive charges has a greater effect 
on chitosan toxicity than the molecular weight [95, 104]. The same was reported for 
chitosan derivatives. Trimethyl chitosan is less biocompatible than chitosan and its 
toxicity was found to be directly related with the degree of trimethylation (charge 
density) [102]. These findings corroborate the biocompatibility results for EAGC 
polymers. EAGC17 (IC50 = 1.826 ± 0.09 mg mL-1), with the highest biocompatibility, 
also had the lowest charge density and molecular weight of the three polymers. 
EAGC21 (IC50 = 0.863 ± 0.16 mg mL-1) presented the same molecular weight of 
EAGC17 but higher charge density leading to a lower IC50. The polymer with the 
highest molecular weight and charge density of the three polymers was EAGC30 that 
also showed the highest toxicity (IC50 = 0.522 ± 0.17 mg mL-1). Nevertheless, all 
polymers were less toxic than lipofectamine (IC50 = 0.071 ± 0.01 mg mL-1) and PEI 
[101]. 
EAGC is a chitosan derivative that was synthesized with the main objective of 
increasing chitosan transfection efficiency. An ethylamino group was introduced on to 
the glycol chitosan backbone in order to enhance the condensation of the polymer with 
nucleic acids at low polymer, DNA mass ratios and physiological pH as well as to 
improve the buffer capacity of the synthesized polymer, and allow endosomal escape 
resulting in improved gene expression.  
Different parameters that might influence the transfection efficiency of plasmid DNA 
were studied in order to optimize the transfection protocol. In the absence of 
chloroquine, EAGC21 showed increased transfection for low EAGC21, DNA mass 
ratios. The lower transfection efficiencies in the presence of chloroquine may be due to 
the displacement of the polymer, by chloroquine, from the plasmid DNA [180, 200]. 
When compared with the positive control, lipofectamine in the absence of chloroquine, 
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EAGC21 performed better for EAGC21, DNA mass ratios 10, 20, 30 and 50 
(###p0.001). For the other polymer, DNA mass ratios the results were comparable in 
the presence and absence of chloroquine. In summary, exogenous chloroquine did not 
improve the transfection efficiency for any polymer, DNA mass ratio. These results 
revealed that EAGC21 may have its own ability for endosomal escape, probably due to 
its buffer capacity, previously studied in Chapter 2. 
One of the factors that affects transfection is the incubation time of complexes with 
cells. The optimal time should balance detectable expression with limited toxicity [179]. 
Previous studies had demonstrated that genetic expression tends to increase sharply 
with increasing incubation times up to a certain time point (normally around four hours). 
After four hours expression levels may either reach a plateau, continue to increase less 
steeply, or decrease [179]. The transfection efficiency of EAGC21 was studied for two 
time points: 4 and 6 hours. After 6 hours, transfection values were three times higher 
when compared with 4 hours of incubation for all EAGC21, DNA mass ratios 
(***p0.001). Also, for 6h of incubation the results of the polymer-DNA treatments were 
significantly better when compared with lipofectamine (###p0.001). The increased 
transfection with time confirmed the viability of the cells when in contact with the 
complexes for 6 hours leading to an increase of the mU. This was only possible due to 
the good cell biocompatibility of EAGC21.  
After in vivo administration, release of DNA from the polyplex can occur due to an 
interaction of the complex with serum proteins. These negatively charged proteins can 
also led to aggregation and serum clearance of the DNA complexes from the 
bloodstream [31, 202]. In vitro, the presence of proteins can impair the transfection of 
the plasmid DNA due to non-specific interactions between the nanoparticles and the 
serum components in the cell medium [120]. In the previous chapter, complexes made 
with EAGC21 showed good stability in the presence of heparin with the release of 
plasmid only occurring at high heparin concentration and small polymer, DNA mass 
ratios. The presence of 10% of FBS in cell medium did not interfere with the 
transfection ability of the EAGC21 nanoparticles. Similar transfection results were 
obtained in the presence and absence of proteins. In fact, for EAGC21, DNA mass 
ratios higher than 5, the transfection results were better when compared with 
lipofectamine in the presence of proteins (###p0.001). These results confirm that 
EAGC polymers are able to condense and deliver plasmid DNA in the presence of the 
biological challenges posed by serum proteins. The good performance of the EAGC21 
in the presence of serum is comparable to the behaviour of chitosan nanoparticles in 
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cell medium with FBS but contrary to PEI behaviour [57, 122]. In the presence of serum 
PEI transfection efficiency decreased for all the N:P ratios studied [57]. Despite the 
probability of aggregation of the chitosan polymers due the ionic interactions with 
negatively charged proteins, leading to lower transfection results, the presence of 
serum allows an increased cell viability that in the end leads to better transfection 
efficiency [105].  
In summary, preliminary studies with EAGC21 showed that the newly synthesized 
polymer is capable of gene delivery to A431 and U87MG cells in vitro. The polymer 
showed good transfection efficiency in the absence of chloroquine and in the presence 
of serum proteins. Furthermore, the low toxicity of the EAGC21 allowed a prolonged 
incubation time (6h) and a higher dose of DNA transfected per well. When compared 
with lipofectamine the polymer showed lower toxicity and increased transfection 
efficiency. 
It has previously been demonstrated that the transfection efficiency of chitosan is 
dependent on the pH of the transfection medium, requiring a slightly acid solution in 
order to condense DNA and provide an overall positive charge to the particles that 
allow binding to the cell membrane [95, 110, 114, 117, 118]. The presence of the 
ethylamino group on EAGC increased the charge density of the polymer at 
physiological pH.  Due to the primary amines of the EAGC (pKa ≈ 9-10), the polymer 
was soluble at physiological pH and presented a positive charge allowing condensation 
with plasmid DNA and formation of nanoparticles with a positive surface charge. This 
characteristic of EAGC allowed transfection at physiological pH without the need to 
prepare the complexes in acidic buffers.  
The transfection results for EAGC17, EAGC21 and EAGC30 showed transfection 
ability is dependent on the degree of substitution of the polymers (charge density). The 
transfection ability increased with the number of amines in the polymer backbone (i.e. 
increased charge density), correlating with results previously described for chitosan in 
the literature. Kiang et al. studied chitosan-DNA nanoparticles with a chitosan with 
molecular weight of 390 kDa and degrees of deacetylation of 62%, 70% and 90% were 
tested. The formulations with the lower two degrees of deacetylation resulted in lower 
gene expression levels, not significantly greater than the background [117]. Huang et 
al. reached the same results for a chitosan with 213 kDa and degrees of deacetylation 
of 61% and 46% [95, 118]. Koping-Hoggart et al. only obtained gene transfection for a 
chitosan with a minimum degree of deacetylation of 65% [110]. 
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The increase of the transfection efficiency of the EAGC polymers with the increase of 
the degree of substitution may be due to the increase of the nanoparticles’ stability. 
The agarose gel assay in Chapter 3 showed that there was a higher ability of EAGC21 
and EAGC30 to condense with plasmid DNA. Also, the nanoparticles formed with 
EAGC30 showed higher stability in biological fluids. This has been previously 
described by Strand et al. [55], who found that increasing the N:P ratio resulted in lower 
gene expression due to complexes high stability that impaired the release of DNA 
inside the cell.  
Furthermore, the buffer capacity of EAGC increased with the degree of substitution 
(Chapter 2). The buffer capacity of cationic polymers is intimately related with their 
capacity for gene expression due to the “proton sponge effect” [183, 203]. EAGC30 
was the polymer with the highest buffer capacity and this could explain the good results 
for all EAGC30, DNA mass ratios. Overall, in the assays described in this chapter, 
EACG polymers were superior transfection agents to the positive control, 
lipofectamine.  
EAGC polymers with a low molecular weight (17 kDa and 27 kDa) showed good 
transfection capacity even at low polymer, DNA mass ratios such as EAGC30, DNA 
mass ratio 5, due to the increased charge density introduced by the ethylamino group. 
The gene expression results for low polymer, DNA mass ratios increased with the 
increase of the polymer substitution. For the three polymers, an increase of EAGC, 
DNA mass ratio led to an increased transfection, with EAGC30 reaching a plateau at 
EAGC30, DNA mass ratio of 30.  
These results were also seen in a study by Strand et al., who studied a range of 
chitosans (5-146 kDa) at N:P ratios 3, 5, 10 and 20. Gene expression was found to be 
dependent on the N:P ratio, increasing with the increase of the N:P ratios, and 
achieving a plateau after which transfection efficiency decreased [55].  
Furthermore, the polymer, DNA mass ratios required for successful transfection of 
EACG-DNA complexes were lower than those reported for chitosan alone. Chitosan 
(4.7 kDa) transfection efficiency was studied at three N:P ratios: 10, 30 and 60. N:P 
60 showed the highest transfection ability, 100-fold higher than transfection results 
obtained with N:P 10 [126].  
In a wide-ranging study, Lavertu et al. demonstrated a trend between molecular weight, 
degree of acetylation and polymer, DNA mass ratios. High transfection efficiency of 
chitosan required high molecular weight and degree of deacetylation at low polymer, 
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 155 
DNA mass ratios. If low molecular weight and degree of acetylation are chosen then 
the charge ratio needs to be high to deliver stable complexes [104]. The results 
presented in this chapter suggest that for EAGC, good transfection can be achieved 
using a low molecular weight chitosan derivative at low polymer, DNA mass ratios due 
to the increased charge density introduced by the ethylamino substitutions. 
In conclusion, the results presented in this chapter confirmed EAGC as a chitosan 
derivative with improved characteristics to overcome the low transfection efficiencies 
described previously for chitosan. EAGC was as biocompatible as chitosan, and 
showed superior cell biocompatibility when compared with PEI. EAGC polymers with a 
low molecular weight (17 and 27 kDa) demonstrated transfection ability at physiological 
pH at small polymer, DNA mass ratios. Furthermore, transfection efficiencies were 
higher than the positive control lipofectamine, for EAGC17, EAGC21 and EAGC30. 
The results showed that the polymers may have sufficient buffer capacity to allow the 
release of the nanoparticles from the endosome, resulting in high gene expression. 
This expression is dependent on the EAGC, DNA mass ratios and degree of 
substitution of the polymer. 
  
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 156 
5. Biological studies with siRNA 
5.1 Introduction 
In 1998, Mello et al. discovered the RNA interference mechanism in the nematode 
Caenorhabditis elegans [18]. Gene expression silencing can be described as follows 
(Figure 79): after the introduction of a double stranded RNA in the cell this is cleaved 
by the enzyme Dicer (cytoplasmic ribonuclease III) into small fragments (21-23 
nucleotides long) called short interfering RNA. siRNAs are relatively small 
macromolecules (approximately 13 kDa) comprising two strands: the sense and 
antisense [20]. When in the cytoplasm, siRNA is integrated into a protein complex 
called RNA induced silencing complex (RISC). Argonaut 2 (the protein part of the RISC 
complex) unwinds the double strands of siRNA and these are separated. The activated 
RISC, containing the antisense strand, pairs with a complementary sequence of 
messenger RNA and degrades it thereby preventing its translation into a protein 
(posttranscriptional gene silencing) [204]. This complementarity determines the target 
selectivity of siRNA. The same activated RISC can cleave further complementary 
mRNA strands allowing a prolonged therapeutic effect of siRNA for 3-7 days in dividing 
cells. siRNA can be synthetically produced and directly introduced in the cell at the 
level of RISC circumventing the Dicer mechanism [19-21]. The RNAi pathway is 
fundamental in eukaryotic cells for post-transcriptional protein expression regulation 
[19, 20]. 
The therapeutic use of siRNA depends on its delivery to the intracellular space. siRNA 
is an anionic and hydrophilic molecule with enhanced susceptibility to hydrolysis by 
systemic ribonucleases. It presents a short biological life (rapid elimination from 
circulation) and fast renal clearance. siRNA lacks cell/tissue targeting, being unlikely to 
interact with the negatively charged cell membrane, leading to a poor cellular uptake 
[205, 206]. In the therapeutic use of siRNA, effective design of the sequence can avoid 
off target effects, and ensure specific regions within the target mRNA are reached 
[207]. Chemical modifications of siRNA can increase its stability as well as decrease its 
inherent toxicity. However, for therapeutic applications, a delivery system is required 
not only to protect the siRNA from enzymatic degradation but also to enhance siRNA 
delivery to the target organ, cellular uptake and finally to release the siRNA in the cell 
cytoplasm in order to be incorporated in the RNAi machinery [142]. 
 
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 157 
 
Figure 79 - Schematic representation of RNAi mechanism. Adapted from Guzman-Villanueva et al. [208]. 
 
Cationic polymers are good candidates to improve the pharmacokinetics, 
pharmacodynamics, biodistribution and toxicology of siRNA [19]. These are efficient 
transfection agents due to their ability to bind and condense the nucleic acids into 
stabilized nanoparticles [19]. They have also demonstrated cellular uptake through 
nonspecific endocytosis and endosomal escape [19]. Due to the similar 
physicochemical properties of DNA and siRNA, cationic systems developed for the 
delivery of plasmid DNA have also been applied to siRNA. Nevertheless, it should be 
stated that siRNA is a much smaller molecule than plasmid DNA, resulting in a higher 
compaction of the nucleic acid and therefore smaller polyplexes [157]. Also, siRNA 
molecules need only to reach the cytosol (the site of RNAi mechanism), while plasmid 
DNA needs to be transported to the nucleus [157]. The electrostatic stabilization of 
siRNA polyplexes is weaker when compared with plasmid DNA, and this results in poor 
stability of the siRNA complexes when in the presence of biological challenges [190]. In 
fact, results presented in Chapter 3 concur with the previous. In the presence of 
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heparin, siRNA polyplexes showed release of siRNA for smaller EAGC30, siRNA mass 
ratios when compared with EAGC30-DNA complexes.  
Different cationic polymers like PEI and chitosan have been studied to improve the 
intracellular delivery of siRNA [209]. The cationic charge of these polymers interacts 
with the anionic phosphates in the siRNA backbone, allowing complexation and the 
formation of positively-charged nanoparticles (when the polymer is in excess). This 
facilitates interaction with the negatively-charged cell membrane and internalization of 
the complexes [210]. PEI has shown high transfection efficiency of siRNA in in vitro 
conditions [211]. However, the polymer’s toxicity remains a major hurdle in its further 
progress to the clinic. Therefore, research is now focused on PEI derivatives with low 
molecular weight [211]. 
Chitosan has also been used for siRNA delivery. Chitosan presents a cationic structure 
at acidic pH (due to the protonation of the amines, pKa = 6.5) that enables 
complexation with the anionic phosphates in the siRNA backbone. It is also 
biodegradable and biocompatible, desirable characteristics in an ideal vector for siRNA 
delivery [142, 159]. Previous studies revealed that siRNA transfection with chitosan is 
dependent on the molecular weight, degree of deacetylation and the N:P ratios.  
Chitosans with molecular weights lower than 20 kDa showed poor results [125, 212], 
as did chitosans with very high molecular weight (200 kDa) [129] indicating that there 
is an optimum range for chitosan molecular weight in order to achieve complete gene 
silencing (20-200 kDa).  
Howard et al. showed siRNA delivery with chitosan (114 kDa, 84% degree of 
deacetylation) in vitro and in vivo. Western blotting results demonstrated approximately 
90% knockdown of BCR/ABL-1 protein in K562 cells at an N:P ratio of 57. Significant 
knockdown of EGFP was reported in human lung carcinoma cells 48h post-
transfection. The transfection levels achieved (77.9%) were comparable to the positive 
control (78%, TransIT-TKO) [20]. 
Jogersen et al evaluated two chitosans, with molecular weights of 75.7 and 150 kDa, 
as siRNA carriers targeting the gene S100A4. A silencing effect of 60% was obtained 
with 75.5 kDa chitosan, the better of the two polymers in RMS melanoma cell line and 
SKBR3 breast cancer cell line. A higher knockdown effect was obtained in OHS cell 
line (95%) [128].  
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Techaarpornkul et al. concluded that both the molecular weight of chitosan and the 
chitosan, siRNA mass ratios of the nanoparticles influence the final gene knockdown 
results more than the nature of the salt forms. EGFP silencing (around 50%) was 
achieved with chitosan molecular weight of 20 kDa at a chitosan, siRNA mass ratio of 
32, while gene knockdown of chitosans with molecular weights of 200 and 460 kDa 
was rather poor (below 20%).  
Regarding the degree of deacetylation, it is the consensus that more deacetylated 
chitosan performs better at siRNA delivery, since these chitosans have a higher charge 
density. Deacetylated chitosan was more efficient in EGFP downregulation than 
N-acetylated chitosan in a study by Malmo et al. [212].  
The N:P ratios used in the different studies vary, but it was possible to observe that low 
molecular weight chitosans need higher N:P ratios (N:P 30-60) to obtain gene silencing 
as shown by Techaarpornkul et al.. Gene silencing results were lower for low polymer, 
siRNA mass ratios (mass ratio 4 had a gene silencing of 20%) when compared with 
higher polymer, siRNA mass ratios of 16 and 32 for a chitosan with 20 kDa [129]. 
Lower N:P ratios (N:P 2-20) have been used with chitosans of higher molecular weight 
[213].  Malmo et al. concluded that the uptake of siRNA increased with the increase of 
the N:P ratios from 10 to 60 for chitosans with a molecular weight of 16, 35, 55 and 75 
kDa. For chitosans with molecular weights of between 50 and 140 kDa the gene 
knockdown happened at N:P ratios of 10, 30 and 60, while for chitosans with a lower 
molecular weight, an N:P of 60 was required to obtain comparable results [212].  
Different derivatives of chitosan have been synthesized to address some of the issues 
that impair the transfection efficiency of chitosan, such as buffer capacity and poor 
solubility at physiological pH.  
Tripathi et al. showed improved transfection efficiency of a chitosan-PEI derivative 
when compared with chitosan. Chitosan-PEI-siRNA nanoparticles resulted in a 77% 
gene knockdown when compared with only 49% of the positive control (lipofectamine) 
[138]. Also, chitosan-PEI resulted in a 55% EGFP silencing in A549 cells, whereas PEI 
25 kDa was only capable of 19% silencing [139].  
Trimethyl chitosans are another group of chitosan derivatives that have been studied 
for siRNA delivery. Different chitosans and trimethyl chitosans were tested for their 
ability to downregulate EGFP. Formulations with trimethyl chitosan performed better 
when compared with chitosan. EGFP expression decreased between 3.9 and 12.3% 
for chitosan polyplexes and 24.3-37.1% with trimethyl chitosans. The gene expression 
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decrease obtained by trimethyl chitosan with a molecular weight of 50 kDa and 27% 
quaternization was significantly (p < 0.05) higher when compared to all of the chitosans 
used in the study [214].  
Although chitosan-siRNA polyplexes have demonstrated good transfection efficiencies 
in vitro, use of chitosan in vivo is restricted by the same issues previously discussed: 
poor solubility at physiological pH, poor buffer capacity, and instability in the presence 
of endogenous blood components [143].  
In vivo administration of most compounds – including nucleic acids – to the central 
nervous system is prevented by the blood brain barrier (BBB). Only small (molecular 
weight < 500 Da), lipophilic molecules are able to cross the BBB via transcellular 
passive diffusion, with a small number of other compounds able to cross using 
selective receptors [146, 147]. 
siRNA is a hydrophilic molecule with a molecular weight of 13 kDa that does not cross 
the BBB passively. Intranasal administration is a non-invasive method of bypassing the 
BBB. This route is the most direct, non-invasive entry into the brain, avoiding the 
adverse effects of systemic delivery. Nose to brain delivery is mainly mediated by the 
olfactory and trigeminal nerve pathways that connect the brain with the nasal cavity 
[146-148]. However, this kind of delivery presents some limitations such as a restricted 
compound molecular weight, variability in the concentration achieved in different 
regions of the brain and rapid elimination of the substances from the nasal cavity due 
to mucocilliary clearance [149, 150]. 
The delivery of siRNA to the brain through the nasal cavity has been tried by different 
groups [151, 152]. Different delivery systems have been tested to protect the siRNA 
from enzymatic degradation and to enhance its delivery, cellular uptake and release in 
the cell cytoplasm in order to be incorporated in the RNAi machinery [153-155].  
Kim et al. examined the efficiency of intranasal delivery of naked siRNA to normal rat 
brains. In vivo target gene knockdown by the intranasal delivery of B-crystallin siRNA 
was examined in the olfactory bulb, amygdala and hypothalamus. After 3 hours of 
delivery there was no change in B-crystallin immunoreactivity in any of the brain areas 
studied. However, after 12 hours of siRNA delivery, B-crystallin levels were 
significantly reduced in all three regions. These results indicated that the intranasal 
siRNA delivery enhanced the access to the central nervous system by the olfactory 
nerve pathway, allowing gene silencing in specific regions of the brain [151]. 
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The work of Renner et al. confirmed the role of the olfactory nerve pathway in the 
delivery of siRNA to the central nervous system. Thirty minutes after administration of 
fluorescently-labelled naked siRNA, it was possible to observe siRNA in the olfactory 
epithelia, olfactory bulbs and along the length of the olfactory nerve pathway. 
Furthermore, intact siRNA was extracted from the olfactory bulbs of the mice [152]. 
Intranasal delivery of fluorescently-labelled siRNA with a biodegradable PAMAM 
dendrimer was reported [153]. The efficiency of intranasal siRNA delivery was studied 
in normal rat brains by FITC-labelled control siRNA, cell-type specific immunostaining, 
and DAPI staining. One hour after intranasal delivery, fluorescently-labelled cells were 
observed in the frontal cortex, olfactory bulb, amygdala and hypothalamus. The same 
was observed after 3 and 12 hours. Expression levels of HMGB1 were studied after 
delivery of HMGB1 siRNA or nonspecific siRNA with a PAMAM dendrimer. The 
immunoreactivity of HMGB1 decreased in the olfactory bulb, amygdala and 
hypothalamus after 3 hours of siRNA intranasal delivery. In contrast, no decrease of 
HMGB1 expression was found for nonspecific siRNA. These results indicated that 
access to the central nervous system through the olfactory pathway was possible after 
intranasal administration [153].  
Intranasal delivery of siRNA with micellar copolymers prepared from methoxy 
poly(ethylene glycol) (MPEG) and polycaprolactone (PCL), conjugated with a cell-
penetrating peptide, Tat (MPEG-PCL-Tat). The brain distribution of fluorescently-
labelled siRNA was significantly higher after intranasal administration when compared 
with intravenous administration. Levels in the olfactory bulb after intranasal delivery of 
siRNA with MPEG-PCL-Tat were higher when compared with naked siRNA, suggesting 
the delivery of siRNA to the brain is through the olfactory bulb pathway. Similar results 
were obtained in the trigeminal nerve, suggesting that it is also a possible way to reach 
the brain [154].   
The intranasal delivery of siRNA with the previous micellar system was studied in an 
intracranial C6 glioma model, evaluating the association of siRNA with an anti-cancer 
drug (CPT). Untreated rats had a mean survival period of 16.6 days, compared with 
18.4 days for rats treated with naked siRNA solution. Significant differences were 
observed when the previous results were compared with the mean survival period of 
rats treated with MPEG-PCL-Tat/siRaf-1 (20.4 days), CPT-loaded MPEG-PCL-
Tat/siRNA Control (20.6 days), and CPT-loaded MPEG-PCL-Tat/siRaf-1 (28.4 days) 
[155].  
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Until now, chitosan has only been used for siRNA delivery from nose to the brain as an 
adjuvant in a dendrimer-siRNA formulation. [32P]-siRNA, complexed with PAMAM G7 
dendrimers, was administered intranasally within an in situ-forming mucoadhesive gel. 
Brain radioactivity was higher after intranasal delivery of dendriplexes both in the gel 
and in the buffer when compared with the intravenous route. After two doses of siRNA 
gel delivery the brain radioactivity increased by two-fold when compared with siRNA 
buffer delivery, and by eight-fold when compared with naked siRNA. Radioactivity was 
higher in the olfactory bulb and hypothalamus after siRNA intranasal gel administration 
than after intravenous or intranasal in buffer administration [156]. 
The previous data of this study has suggested the striking ability of the Ethylamino 
Glycol Chitosan polymer to perform as a plasmid DNA carrier. Therefore, the use of 
Ethylamino Glycol Chitosan as a siRNA carrier was analyzed. This chapter presents 
the results for in vitro and in vivo biological studies with siRNA and EAGC30 as delivery 
system. The polymer delivery efficiency, in vitro, was studied by Western Blotting. A 
small in vivo pilot study was performed to demonstrate the capacity of the polymer to 
deliver siRNA to the brain after intranasal administration. 
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5.2 Methods 
5.2.1 In vitro transfection  
Briefly, 6-well plates were seeded with 500000 cells (A431) per well and incubated 
overnight. The complexes were prepared to a final ITCH siRNA/scrambled siRNA 
(Eurofins mwg/operon, London, UK) concentration of 533nM. Polymer stock solution 
(EAGC30) was prepared in sterile dextrose (5% (w/v) filtered with a 0.22 μm Millex 
filter) to which was added equal volumes of the ITCH siRNA/scrambled siRNA stock 
solution (insiMAX universal buffer) to give EAGC30, siRNA mass ratios of 1 to 60. The 
complexes were allowed to incubate at room temperature for 1 hour, after which the 
EAGC30-ITCH siRNA/-scrambled siRNA complexes were added to the cells (750μL, 
533nM ITCH siRNA/scrambled siRNA per well) and incubated for 6h in medium (MEM, 
Life Technologies, Paisley, UK) serum free. The complexes were replaced with fresh 
MEM and the cells were then incubated for a further 48 hours. The transfection 
efficiency was determined by Western blotting.  
Lipofectamine 2000 (Invitrogen, Paisley, UK)-siRNA complexes were prepared 
according to the manufacturer’s specifications and were used as a positive control. 
Cells were incubated for six hours with lipofectamine-siRNA complexes (66.7nM 
siRNA/well), in serum-free medium and then replenished with complete media. 
 
5.2.2 Western Blotting 
Western blotting is a protein analysis technique that identifies with specific antibodies 
proteins that are on the surface of a membrane. Firstly, the proteins are separated 
according with their size by gel electrophoresis. These are then transferred to a 
membrane that is blocked to prevent non-specific binding of the antibodies. The 
proteins in the membrane are detected by specific antibodies and are revealed through 
different detection methods, such as chemiluminescence. Western blotting is a 
qualitative and semiquantitative method where the intensity of the signal should 
correlate with the abundance of protein in the membrane [215, 216].  
Forty-eight hours after siRNA delivery, protein extracts were obtained from A431 cells 
using lysis buffer containing protease inhibitors (Radio-Immunoprecipitation Assay 
(RIPA) buffer Sigma Aldrich, Dorset, UK). Protein content was determined with the 
Bicinchoninic Acid (BCA) Assay using Bovine Serum Albumin standards. 20 μg of total 
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protein was resuspended in NuPAGE® lithium dodecyl sulfate sample buffer (Life 
Technologies, Paisley, UK) and dithiothreitol sample buffer (Life Technologies, Paisley, 
UK), incubated for 15 min at 95ºC, and loaded onto a 4-12% polyacrylamide gel. After 
electrophoresis the proteins were blotted onto a nitrocellulose membrane. After 
blocking in 5% non-fat milk, overnight at 4 degrees, the membrane was incubated with 
an anti-ITCH (1:500) (BD Bioscience, San Jose, USA) and anti-actin antibody (1:2500) 
(Abcam, Cambridge, UK) for 2h at room temperature, and with horseradish peroxidase 
(HRP) secondary antibody (1:1000) (Invitrogen, Paisley, UK) for 1h at room 
temperature. Between the incubation periods the blots were washed several times with 
10% PBS and 1% Tween 20 in PBS. The membrane was incubated with SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, USA) for 5 min at 
room temperature and then submitted to detection with ChemiDoc™ XRS+ System 
(Bio Rad, Hemel, UK). For each membrane, the analysis of band intensity was 
performed using the Image Lab software (BioRad, Hemel, UK). 
 
5.2.3 In vivo administration 
Animals 
Sprague Dawley rats (200-250 g) were housed four per cage in an air conditioned unit 
maintained at 20-22°C and 50-60 % humidity, and were allowed free access to 
standard rodent chow and water. Lighting was controlled on a twelve-hour cycle, lights 
on at 07.00 hr. Animals were habituated for 7 days prior to experimentation and 
acclimatised to the procedure room for 1h prior to testing at 8.00 hr. All protocols were 
conducted under a UK Home office licence and approved by a local ethical committee. 
Formulations 
Rats (2 for each study group) were intranasally administered with siRNA alone (15 μg, 
80 μL, BLOCK-iT™ Alexa Fluor® Red Fluorescent Control, Life Technologies, Paisley, 
UK) and EAGC30-siRNA polyplex formulation at a EAGC30, siRNA mass ratio of 60 
(80μL. 15 μg of siRNA, BLOCK-iT™ Alexa Fluor® Red Fluorescent Control). Animals 
were briefly anesthetised with isoflurane and intranasally administered the formulation 
using an insulin syringe attached to PE10 tubing (15 mm). The tubing was inserted into 
one of the nares [217]. The brains were harvested after 5min. These brains were fixed 
in formalin and 0.5mm thick coronal sections were prepared for microscopy. 
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5.2.4 CARS Microscopy 
Coherent anti-stokes Raman scattering (CARS) is a four-wave mixing process in which 
a pump beam at frequency ωp and a Stokes beam at frequency ωs interact within a 
sample. When the beam frequency (ωp - ωs) matches the frequency of a Raman active 
vibrational mode, molecules are coherently driven with the excitation fields, generating 
a strong anti-stokes signal (ωas = 2ωp - ωs) [218, 219]. CARS microscopy has allowed 
visualization of DNA (phosphate stretch vibration), protein (amide I vibration) and lipids 
(CH group of stretching vibrations). CARS microscopy presents several advantages 
over conventional imaging: up to several hundred micron depth penetration into 
biological tissue, intrinsic optical sectioning and high spatial resolution, and label-free 
chemical-specific contrast [220, 221]. 
Two Photon Fluorescence (TPF) microscopy is used in thick specimens allowing 
imaging depths of ≈ 500mm and reduced phototoxicity. Two low energy photons cause 
a higher energy electronic transition in a fluorescent molecule. Local heating generated 
by the optical absorption is detected [222].  
CARS and TPF images were detected using a photomultiplier tube (R3896, 
Hamamatsu) in the epi-direction using a 750 nm long pass dichroic (750dcxr 229 
Chroma) and two filters centred at 660 nm (Ealing Inc.) to separate the signal from the 
laser fundamental, using a 60× 1.0NA water immersion objective lens (LUMFI, 210 
Olympus) to direct the laser light to the sample from the olfactory bulb region of sample 
(5 minutes after nasal dosing).  
Red contrast comes from the CARS signal, with the pump and Stokes beams tuned to 
excite the CH2 stretch at 2845 cm-1 (characteristic of lipid-rich structures such as myelin 
sheaths and lipid droplets etc.) 
The green contrast is derived from epi-detected two-photon fluorescence, excited by a 
single picosecond 1064 nm beam (532 nm absorption). The naturally occurring 
background fluorescence from the brain was separated from the particle fluorescence 
by adjusting the brightness and contrast of the images: the 16-bit data sets (i.e. a 
possible pixel intensity range of 0 – 65536) exhibited a maximum intensity value of 270 
for the control samples, and 4079 for the samples exposed to the particles. The 
combined laser power was kept below 40 mW at the sample. This power was 
sufficiently low enough to prevent photodamage from occurring. 
This experiment was performed by Dr. Natalie Garrett at the University of Exeter. 
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5.3 Results 
5.3.1 In vitro results – Western Blotting 
The transfection efficiency of siRNA by EAGC30 was evaluated in vitro by the delivery 
of anti-ITCH siRNA into A431 cells. ITCH is an ubiquitin ligase that is involved in 
controlling cell growth, differentiation and apoptotic process. Its targets are transcription 
factors and growth factor receptors that act as gene expression regulators [223]. The 
polyplexes were prepared at increasing polymer, siRNA mass ratios (1 - 60). The 
positive control was lipofectamine with anti-ITCH siRNA, a well-described in vitro 
transfection agent, and the negative controls were naked anti-ITCH siRNA, polymer 
alone, non-transfected cells and scrambled siRNA. Scrambled siRNA presents a 
sequence that does not target any particular gene. It was used as a negative control to 
distinguish non-specific effects from specific gene knockdown effect [224]. β-Actin is a 
housekeeping gene that was chosen as the “internal” control. Housekeeping genes 
encode proteins that are essential for maintenance of cell function. β-Actin allowed the 
control of cell toxicity and death, and was also used for normalization of the final results 
[225]. The transfection efficiency was determined by Western blotting analysis.  
Different parameters that might influence the transfection efficiency of siRNA were 
studied in order to optimize the transfection protocol. Variables such as siRNA dose, 




Figure 80 - Western blotting analysis of ITCH knockdown in A431 cells. Study of different EAGC, siRNA 
mass ratios with 133nM of siRNA after 6 hours incubation with the polyplexes.  - Actin was used as 
internal control. 5 mL of cell medium without serum to 50 μL complexes solution. A – Molecular weight 
marker, B – Untreated Cells, C – Polymer alone, D – Naked ITCH siRNA E – Lipofectamine + ITCH siRNA 
(133 nM siRNA), F – EAGC30, Scrambled siRNA (10:1), G – EAGC30, ITCH siRNA (10:1), H – EAGC30, 
ITCH siRNA (30:1).  
 
Two different EAGC30, siRNA mass ratios were investigated: 10 and 30. It is possible 
to observe in Figure 80 that there was no ITCH silencing for either of the EAGC30, 
siRNA mass ratios used. This may have happened due to the concentration of siRNA. 
The dose of siRNA used in in vitro studies for gene down regulation is not standard in 
  Nucleic Acid Delivery – Biocompatible Yet Efficient Platforms  
 167 
the literature. Howard et al. registered no difference in the gene silencing levels when 
increasing the siRNA dose from 100 and 200nM [20]. However, concentrations as low 
as 15nM have been used with the maximum gene knockdown achieved at 45nM [212]. 
Other studies have used concentrations between 100 and 200nM [127, 226]. The 
siRNA dose used in this experiment was 133 nM, the same as that of the positive 
control – lipofectamine. Alternatively, the EAGC30, siRNA mass ratios studied may not 
be stable enough in presence of cell medium to transfect effectively. Agarose gels 
(Chapter 3) showed that in presence of 150mM of NaCl there was dissociation of the 
complexes between EAGC30 and siRNA at EAGC30, siRNA mass ratio 10. Scrambled 
siRNA did not show any down-regulation. The positive control, lipofectamine, 
completely silenced ITCH while all the negative controls showed no gene silencing. 
The internal control in the treatments, β-Actin, did not show any decrease when 
compared with untreated cells, indicating cell viability.  
 
 
Figure 81 - Western Blotting analysis of ITCH knockdown in A431 cells. Study of different EAGC, siRNA 
mass ratios with 267nM and 533nM of siRNA after 6 hours incubation with polyplexes.  - Actin was used 
as internal control. 5 mL cell medium without serum to 100 or 200 μL complexes solution. A – Molecular 
weight marker, B – Untreated Cells, C – Polymer alone, D – Naked ITCH siRNA E – Lipofectamine + ITCH 
siRNA (133 nM siRNA), F – EAGC30, Scrambled siRNA (30:1, 267nM siRNA), G – EAGC30, ITCH siRNA 
(60:1, 267nM siRNA), H – EAGC30, ITCH siRNA (30:1, 533nM siRNA), I – EAGC30, ITCH siRNA (60:1, 
533nM siRNA).  
 
In a subsequent experiment, the dose of siRNA transfected was increased. Figure 81 
shows the results for 267nM (lanes F and G) and 533nM (lanes H and I) of siRNA. Two 
EAGC30, siRNA mass ratios were chosen: 30 and 60. The EAGC30, siRNA mass ratio 
30 allowed direct comparison with the results in Figure 80 while EAGC, siRNA mass 
ratio 60 enables us to understand if higher EAGC30, siRNA mass ratios increase gene 
silencing.  
There was no reduction of protein expression with any of the polymer treatments, 
meaning that increasing the amount of siRNA or the EAGC, siRNA mass ratios had no 
influence in decreasing the final protein expression. Negative controls showed similar 
results. The lipofectamine was the only formulation that showed gene silencing. The 
change of the dose of siRNA and the EAGC30, siRNA mass ratios did not improve the 
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silencing results. Other factors that might influence the transfection efficiency of 
EAGC30 were therefore analyzed.  
Previously, it was observed that large polyplexes have a faster sedimentation leading 
to increased transfection results due to easier contact with the cells surface. In this 
way, small complexes benefited from a reduction of the transfection volume in order to 
facilitate contact with the cells and enhance transfection of nucleic acids [179]. In this 
study (Chapter 3), TEM and size results showed that complexes formed between 
EAGC30 and siRNA presented a small size, between 50 and 200nm (for all EAGC30, 
siRNA mass ratios higher than 1). The previous transfection experiments were 
performed with 5 mL of cell medium to a maximum volume of complex solution of 
200μL. To analyze the effect of the transfection volume on protein expression, different 
volumes of cell medium and complex solutions were used. Figure 82 presents the 
results for two different doses of siRNA (267 and 533nM) and two different EAGC30, 
siRNA mass ratios, 60 and 80. The cell medium volume was reduced from 5 mL to 
2 mL and 100 and 200μL of complex solution was used. 
 
 
Figure 82 - Western Blotting analysis of ITCH knockdown in A431 cells. Study of different EAGC, siRNA 
mass ratios with 267 and 533 nM of siRNA after 6 hours incubation with polyplexes.  - Actin was used as 
internal control. 2 mL cell medium without serum to 100 or 200 μL complexes solution. A – Molecular 
weight marker, B – Untreated Cells, C – Polymer alone, D – Naked ITCH siRNA E – Lipofectamine + ITCH 
siRNA (133nM siRNA), F – EAGC30, ITCH siRNA (60:1, 267nM siRNA), G – EAGC30, ITCH siRNA (80:1, 
267nM siRNA), H – EAGC30, ITCH siRNA (60:1, 533nM siRNA), I – EAGC30, ITCH siRNA (80:1, 533nM 
siRNA).  
 
It was possible to observe a slight decrease in protein expression for EAGC30, siRNA 
mass ratios 60 and 80 with 533nM (lane H and I) of siRNA when compared with 
EAGC30, siRNA mass ratios 60 and 80 with 267nM (lane F and G). This indicates that 
a higher dose of siRNA was necessary for down-regulation of ITCH gene. The 
comparison between lane H of Figure 82 with lane I of Figure 81  (EAGC30, siRNA 
mass ratio 60, 533 nM of siRNA) allowed to conclude that the transfection volume is an 
important factor, affecting the final protein expression. 
 




Figure 83 - Western Blotting analysis of ITCH knockdown in A431 cells. Study of different EAGC, siRNA 
mass ratios with 533nM of siRNA after 6 hours incubation with polyplexes.  - Actin was used as internal 
control. 750μL cell medium without serum to 750μL complexes solution. A – Molecular weight marker, B – 
Untreated Cells, C – Polymer alone, D – Naked ITCH siRNA E – Lipofectamine + ITCH siRNA (133nM 
siRNA), F – EAGC30, ITCH siRNA (10:1), G – EAGC30, Scrambled siRNA (10:1), H – EAGC30, ITCH 
siRNA (30:1), I – EAGC30, Scrambled siRNA (30:1), J – EAGC30, Scrambled siRNA (60:1), K – EAGC30, 
ITCH siRNA (60:1). 
 
Figure 83 shows the results for gene silencing after transfecting the cells with 750 μL of 
complexes in dextrose (5%) with 750 μL of cell medium per well. The most pronounced 
downregulation was achieved after delivery of anti-ITCH siRNA by EAGC30 prepared 
at EAGC30, siRNA mass ratio 60 (lane K). The cellular levels of ITCH protein were 
also reduced for EAGC30, siRNA mass ratio 30 (lane H). To confirm the sequence 
specificity of siRNA anti-ITCH and the absence of off-target effects, the cells were also 
incubated with scrambled siRNA. Gene silencing was found to be specific, since no 
ITCH knockdown was observed with scrambled siRNA (lanes G, I and J). The levels of 
β-actin were constant for all tested formulations, and showed no cell toxicity. The 
increase of the transfection volume increased the delivery of siRNA resulting in high 
levels of gene silencing. 
 
 
Figure 84 - Western Blotting analysis of ITCH knockdown in A431 cells. Study of different EAGC, siRNA 
mass ratios with 533nM of siRNA after 6 hours incubation with polyplexes.  - Actin was used as internal 
control. 750μL cell medium without serum to 750μL complexes solution. A – Molecular weight marker, B – 
Untreated Cells, C – Polymer alone, D – Naked ITCH siRNA E – Naked Scrambled siRNA F – 
Lipofectamine + ITCH siRNA (133nM siRNA), G – EAGC30, ITCH siRNA (1:10), H – EAGC30, Scrambled 
siRNA (10:1), I – EAGC30, ITCH siRNA (30:1), J – EAGC30, Scrambled siRNA (30:1), K – EAGC30, ITCH 
siRNA (60:1), L – EAGC30:Scrambled siRNA (60:1). 
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Figure 84 shows a repetition of the transfection with increasing EAGC30, siRNA mass 
ratios. In this experiment a new negative control was included, naked scrambled siRNA 
(lane E), that did not show any knock-down effect on the target proteins. Likewise, 
none of the other negative controls produced any down-regulation effect. The results 
were comparable with Figure 83, indicating reproducibility of gene silencing with 
EAGC30, siRNA mass ratio 30 and 60.  
Table 27 summarises the different features that were studied to optimize the 
transfection protocol and obtain gene silencing with EAGC30. EAGC30, siRNA 
complexes were able to achieve down-regulation with a small dose of siRNA at an 
EAGC30, siRNA mass ratio of 30. From this study it is also possible to conclude that 
the transfection volume is an important factor with impact in the final results.  


















80 133 10 and 30 50 5000 X 
81 267 and 533 30 and 60 100 or 200 5000 X 
82 267 and 533 30 and 60 100 or 200 2000 X 
83 533 30 and 60 750 750  
84 533 30 and 60 750 750  
 
5.3.2 In vivo results – CARS Microscopy 
To understand the behaviour of the EAGC30, siRNA nanoparticles in vivo, a small pilot 
study was designed. The main objectives were the evaluation of nasal delivery to the 
brain with EAGC30 nanoparticles, and the polymer’s capacity to protect siRNA from 
degradation in vivo. Therefore, three animals groups were studied: untreated, treated 
with naked siRNA (Alexa Fluor® Fluorescent) and treated with EAGC30, siRNA 
nanoparticles at an EAGC30, siRNA mass ratio of 60. The brain tissue was harvested 
5 min after nasal administration of the treatments. CARS images of the olfactory bulb 
were taken to evaluate the delivery of fluorescently labelled siRNA.  Figure 85 shows 
the results for the untreated samples. The red contrast comes from CARS signal, with 
the beams tuned to excite the CH2 stretch characteristic of lipid-rich structures such as 
myelin sheaths.  




Figure 85 - Orthogonal view reconstructions of depth-stack images of an olfactory bulb sample (untreated 
group) using CARS with the pump and Stokes beams tuned to excite the CH2 stretch at 2845 cm-1 (red – 
brain tissue).  
 
 
Figure 86 - Orthogonal view reconstructions of depth-stack images of an olfactory bulb sample, harvested 
5 min after nasal administration of EAGC30, siRNA nanoparticles with an EAGC30, siRNA mass ratio of 
60 using contrast from TPF (green – siRNA Alexa Fluor® Fluorescent) and CARS with the pump and 
Stokes beams tuned to excite the CH2 stretch at 2845 cm-1 (red – brain tissue).   
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Figure 86 shows the results for the group treated with EAGC30, siRNA nanoparticles at 
an EAGC30, siRNA mass ratio of 60. It is possible to observe the red contrast from 
CARS signal of the brain tissues and the presence of the green fluorescence signal 
from the EAGC30, siRNA nanoparticles. These images demonstrate that nasal delivery 
to the brain (olfactory bulb) was possible with EAGC30 nanoparticles. The results from 
the analysis of the samples treated with naked siRNA have not yet been obtained. 
These results will allow the study of the polymer’s ability to protect the siRNA from 
degradation in the in vivo environment.  
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5.4 Discussion 
A literature review regarding siRNA in vitro delivery with chitosan showed good gene 
silencing results [20, 125, 212]. However, chitosan’s low solubility at physiological pH 
and poor buffer capacity are still a major drawback for its use in vivo, resulting in 
instability and insufficient intracellular siRNA release [142]. The previous data in this 
thesis has suggested the striking ability of the Ethylamino Glycol Chitosan polymer to 
perform as a plasmid DNA carrier. It is able to condense the gene, offers it protection 
from nuclease digestion and enables intracellular delivery. Therefore, the use of 
Ethylamino Glycol Chitosan as a siRNA carrier was studied. 
The transfection efficiency of EAGC30 in vitro was analysed by Western blotting. 
Western blotting is a qualitative and semiquantitative method that allows identification 
of specific proteins and evaluation of their abundance in the cells [216]. Different 
parameters that might influence the transfection efficiency of siRNA were studied, such 
as siRNA dose, volume of transfected solutions and EAGC30, siRNA mass ratios.  
 
Three different doses of siRNA were studied: 133, 267 and 533 nM (Table 27). The 
highest dose was revealed to be necessary for ITCH down-regulation. Different doses 
of siRNA had been reported in the literature. Howard et al. registered no difference in 
the gene silencing levels when increasing the siRNA dose from 100 and 200nM [20]. In 
another study, concentrations as low as 15nM were used, with the maximum gene 
knockdown achieved at 45nM [212]. Other studies have used concentrations between 
100 and 200nM [127, 226]. When comparing the different doses of siRNA between 
studies it is important to consider the number of cells transfected with each dose, 
otherwise direct comparison is not possible. Considering the concentration of siRNA 
per 1000 cells seeded, the values range from 0.5nM per 1000 cells in Howard et al. 
study [20] up to 25nM per 1000 cells [226]. The dose used in this study, which 
delivered the best results, was 1nM per 1000 cells. This falls in the lower range of the 
doses in the published literature. This direct comparison confirms the good transfection 
capacity of EAGC30 and its potential as delivery system, since the dose used to 
produce complete gene silencing is low compared with other studies.  
Increasing EAGC30, siRNA mass ratios (1-60) were tested for gene silencing. 
EAGC30, siRNA mass ratios 30 and 60 achieved down-regulation of ITCH in vitro. 
Lower EAGC30, siRNA mass ratios were not capable of gene silencing since they were 
quite unstable in the presence of biological challenges such as heparin and salt 
(Chapter 3).  These results are in line with the literature, where it has been reported 
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that low molecular weight polymers need higher polymer, siRNA mass ratios to cause 
gene down regulation.  
For a 20 kDa chitosan the optimal gene silencing was obtained at a polymer, siRNA 
mass ratio of 32, with lower gene silencing reported for polymer, siRNA mass ratios of 
4 and 8 [129]. Malmo et al. have found that fully deacetylated chitosans of low 
molecular weights (10 kDa) required N:P ratios up to 60 for efficient silencing while at 
higher molecular weights, all 3 tested ratios (10, 30, 60) performed equally with about 
an 80% silencing achieved at pH 7.2 [212]. This need for high N:P ratios is partially 
explained by the ionic interactions between siRNA and chitosan. Previous studies 
showed that the binding capacity of siRNA to chitosan is weaker when compared with 
the binding capacity of plasmid DNA with chitosan [127]. 
Finally, the volume of transfected complexes was also studied (Table 27). It was 
observed that large polyplexes have a fast sedimentation, which increased transfection 
results due to facilitated contact with the cell surface. In this way, small complexes 
benefited from a reduction of the transfection volume in order to facilitate contact with 
the cells and enhance transfection of nucleic acids [179]. Different cell medium- 
complex solution volume ratios were analyzed. Throughout the study, the cell medium 
volume was decreased and the complex medium volume was increased until a final 
ratio of 1:1 was achieved. This was found to be the optimal ratio to deliver the best 
gene silencing results.  
In summary, in vitro siRNA delivery with EAGC30 was achieved with high levels of 
gene silencing. The polymer showed similar results to previous studies with chitosan, 
where low molecular weight chitosans performed better at higher N:P ratios. However, 
the dose of siRNA necessary to achieve complete down-regulation of proteins was low, 
confirming the high transfection capacity of EAGC30. Furthermore, the polymer is 
soluble at physiological pH, and does not need to be applied in a low pH buffer; this 
overcomes one of the principal disadvantages of the use of chitosan in vivo.  
In vivo administration of nucleic acids to the central nervous system is restrained by the 
blood brain barrier. The intranasal route of administration is a non-invasive method of 
bypassing it. The delivery of siRNA to the brain through the nasal cavity has been tried 
by different groups. Different delivery systems have been tested to protect the siRNA 
from enzymatic degradation and to enhance its in vivo delivery [151, 152, 155, 156]. 
Encouraging results were obtained in the small pilot in vivo study performed of siRNA 
delivery with EAGC30 to the brain. The olfactory bulb tissue was analyzed for the 
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presence of fluorescent siRNA after nasal administration of EAGC-siRNA fluorescent 
nanoparticles at an EAGC30, siRNA mass ratio of 60. The results showed that 
EAGC30-siRNA nanoparticles were able to reach the brain when compared to a non-
treated sample. Despite the good initial results obtained further experiments are 
needed, including treatment of the brain with naked siRNA, in order to confirm the 
polymer’s capacity to protect siRNA from enzymatic degradation in vivo. 
Furthermore, the nanoparticles distribution through the different tissues of the brain as 
well as the system’s capacity for specific protein down-regulation in vivo should be 
evaluated. However, the preliminary results of this study introduce EAGC30 as a good 
candidate for in vivo siRNA delivery to the brain.  
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6. Conclusion and Future Work 
Despite the efforts to develop chitosan-based vectors, the therapeutic effectiveness of 
chitosan-based gene therapy still needs to be improved in order to achieve clinical 
significance. To date there are no reports of clinical trials for the delivery of DNA or 
siRNA using chitosan as the delivery system [54]. This work introduces a new chitosan 
based polymer: N-(2-ethylamino)-6-O-glycol chitosan (Ethylamino Glycol Chitosan, 
EAGC). EAGC was synthesized with four important considerations in mind: (i) the 
resulting polymer should be soluble at physiological pH; (ii) it should efficiently complex 
with the nucleic acids to provide stable polyplexes; (iii) it should have improved 
buffering capacity to be able to release the nucleic acids inside the cell; and (iv) it 
should retain the biocompatibility and low cell toxicity of chitosan.  
During the synthesis of EAGC, two main characteristics of the polymer were 
considered: molecular weight and charge density. An appropriate polymer molecular 
weight was needed to confer enough stability to the complexes for nucleic acid 
protection, without inhibiting intracellular release of DNA or siRNA [159]. Nucleic acid 
release is required to obtain high levels of transfection. The molecular weight of the 
three different polymers was confirmed by GPC. Two molecular weight (17 and 
27 kDa) variants of EAGC were chosen. Low molecular weight polymers were 
preferred to avoid the previously discussed drawbacks presented by high molecular 
weight polymers, such as low solubility and low biocompatibility. The initial glycol 
chitosan was substituted with ethylamino groups in order to increase the charge 
density of the polymer. Furthermore, the ethylamino group introduced in glycol chitosan 
had the additional objectives of increasing the solubility of the polymer at physiological 
pH and increasing the buffer capacity of the polymer. 
The chemical structure and degree of substitution of EAGC were confirmed by NMR. 
The 1H-NMR spectra of EAGC17, EAGC20 and EAGC30 revealed that increasing the 
molar ratio of GC:BrCH2CH2NH2 increased the overall substitution of the polymers. The 
substitution of the primary amines of chitosan with one or two ethylamino groups 
provided the new polymers with primary, secondary and tertiary amines that are 
required for good buffering, proper binding and release of nucleic acids [138, 178]. 
The buffer capacity of EAGC polymers was determined from acid–base titration curves. 
All the EAGC polymers showed an increased buffer capacity compared with GC. Also, 
it was possible to observe that the buffer capacity of EAGC increased with the 
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increasing degree of substitution. It has been previously described that tertiary amines, 
with a pKa similar to the pH of the endosome, contribute to the increase of the buffer 
capacity of cationic polymers [138, 178]. The calculation of the percentage of the 
different amino groups in each synthesized EAGC polymer revealed that the most 
substituted polymer presented the highest percentage of tertiary amines. This is likely 
to have been responsible for the trend in increasing buffer capacity across the EAGC 
polymers with increasing degrees of substitution. 
The final degree of substitution of the different batches of EAGC was controlled by the 
molar ratio of GC:BrCH2CH2NHBoc. However, it was not possible to control the number 
of double or single substitutions during synthesis. Further work is necessary to 
completely understand the mechanism of the reaction and enable full control of the 
number of primary, secondary and tertiary amines present in the final polymer.  
 
The capacity of cationic polymers, like EAGC, to compact the structure of nucleic acids 
relies on electrostatic interactions between the positively charged polymer and 
negatively charged DNA or siRNA. The agarose gel retardation assay revealed that 
GC28 and GC17 were not able to completely condense with DNA at any polymer, DNA 
mass ratio. EAGC14, with the lowest amount of amines introduced on the GC 
backbone, revealed condensation results as poor as GC17. However, when the 
number of amines was increased, through the introduction of the ethylamino double 
substitution, EAGC13 and EAGC17 showed improved retention capacity of the DNA 
after 1h of incubation. EAGC30 presented the strongest DNA binding ability, as the 
DNA mobility was fully retarded at polymer, DNA mass ratios as low as 5 after 30min of 
incubation.  
All EAGC polymers contain primary amines displaying high pKa values, between 9 and 
10. This makes them fully protonated at physiological pH, and the resulting positive 
charge readily enables condensation with the negatively charged nucleic acids. This is 
in particular contrast to chitosan, where the pKa of the amine groups, as previously 
discussed, does not allow them to be protonated at physiological pH [114]. 
EAGC30 was the polymer chosen to condense siRNA due to the particular 
characteristics of the nucleic acid. Previously, some authors had demonstrated that to 
achieve stable nanoparticles, siRNA requires polymers with higher molecular weight, 
charge density and N:P ratio [125, 190]. Agarose gel results for EAGC30 with siRNA 
showed that this polymer was able to retain the nucleic acid for EAGC30, siRNA mass 
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ratios as low as 5, and after just 30 minutes of incubation, despite its relatively low 
molecular weight (molecular weight of 27 kDa).  
Morphological characterization of the polyplexes formed between EAGC and 
DNA/siRNA was made by TEM. The complexes were spherical or toroid for all 
EAGC-DNA and EAGC30-siRNA nanoparticles. Particle size was determined by 
nanoparticle tracking analysis for the three polymers EAGC17, EAGC21 and EAGC30 
complexed with plasmid DNA. EAGC nanoparticles with plasmid DNA showed a 
maximum diameter of 450 nm for all three polymers studied. The particles formed 
between EAGC30 and siRNA between 150 and 500nm in size. The polyplexes formed 
between EAGC17, EAGC21 and EAGC30 and DNA presented a positive charge of 
around +40mV for all EACG, DNA mass ratios above 5. Similar results were obtained 
for siRNA nanoparticles with EAGC30. These results confirmed the high protonation of 
EAGC polymers, even at physiological pH. 
The extra- and intracellular environment has a strong impact on the stability of 
nanoparticles formed with cationic polymers. Anionic proteins, salt and nucleases are 
among the major hurdles that polyplexes need to overcome even before reaching the 
cell surface [179]. Increasing the substitution of the polymer, leading to higher charge 
density, improved the capacity of the polymers to retain the DNA in the presence of 
heparin, with EAGC30 retaining the DNA for a polymer, DNA mass ratio as low as 10. 
For siRNA nanoparticles, EAGC30 was only able to completely retain the siRNA for an 
EAGC30, siRNA mass ratio of 30. EAGC complexes showed good stability in the 
presence of NaCl (150nM). EAGC17 presented the most unstable particles, while 
EAGC30 did not release the plasmid DNA at any polymer, DNA mass ratios. 
EAGC30-siRNA particles were unstable in the presence of NaCl for small EAGC30, 
siRNA mass ratios, 5 and 10. Finally, the complexes were tested against the presence 
of nucleases. All polymers were able to protect the DNA from degradation at all 
polymer, DNA mass ratios, and EAGC30 also was able to protect siRNA for all 
EAGC30, siRNA mass ratios. It was clear that an increase in molecular weight and 
charge density of EAGC resulted in a greater stability to biological challenges. 
In summary, EAGC30, siRNA nanoparticles were less stable in the presence of the 
different biological challenges when compared with DNA, EAGC30 nanoparticles. This 
increased instability has been described before and it is attributed to the smaller size of 
siRNA and its lower charge density compared with DNA [125, 190]. 
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The toxicity of chitosan is intimately related with its molecular weight and charge 
density. Chitosans of high molecular weight (100 kDa) and degree of deacetylation 
[95] were less biocompatible than low molecular weight polymers (10 kDa) [105]. The 
toxicity of EAGC polymers increased with the charge density. EAGC17 presented the 
lowest toxicity (IC50 = 1.826 ± 0.09 mg mL-1), since it had the lowest molecular weight 
and charge density of the three polymers. EAGC30 was the least biocompatible 
polymer (IC50 = 0.522 ± 0.17 mg mL-1). All EAGC polymers were more biocompatible 
than PEI [101] and the introduction of the extra positive charge did not decrease the 
polymer’s biocompatibility when compared with chitosan [86].  
Different parameters that might influence the transfection efficiency of plasmid DNA, 
such as incubation time of the complexes with cells, were studied in order to optimize 
the transfection protocol. The optimal time should balance detectable expression with 
limited toxicity. After 6 hours the transfection values were three times higher when 
compared with 4 hours of incubation. Also, for 6h of incubation, the results of the 
polymer-DNA treatments were significantly better when compared with lipofectamine 
(###p0.001). The presence of proteins can impair the transfection of the plasmid DNA 
due to non-specific interactions between the nanoparticles and the serum components 
[120]. The presence of 10% of FBS in cell medium did not interfere with the 
transfection ability of the EAGC21 nanoparticles. Similar transfection results were 
obtained in the presence or absence of proteins.  
The results for EAGC17, EAGC21 and EAGC30 showed that transfection ability is 
dependent on the degree of substitution of the polymers and EAGC, DNA mass ratios. 
The transfection ability increased with the number of amines in the polymer backbone. 
The increased number of primary amines, with pKa of 9-10, allowed EAGC to be 
protonated at physiological pH. Thus, transfection was achieved without the use of 
acidic buffers. The additional secondary and tertiary amines introduced by the 
ethylamino substitution increased the buffer capacity; buffer capacity was higher for 
polymers with a higher degrees of substitution. This may have enhanced the ability of 
the EAGC-DNA complexes to cause endosomal rupture. All polymers studied in this 
project were superior transfection agents than the positive control, lipofectamine, 
especially at high polymer, DNA mass ratios. 
For the three polymers, an increase of polymer, DNA mass ratio led to an increase in 
transfection, with EAGC30 reaching a plateau at EAGC30, DNA mass ratio of 30. The 
increased charge density at low molecular weights displayed by EAGC also allowed 
good transfection even at polymer, DNA mass ratios as low as 5. 
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The in vitro transfection efficiency of siRNA by EAGC30 was analysed by Western 
blotting. Different parameters that might influence the transfection efficiency of siRNA 
were studied, including siRNA dose, volume of transfected solutions and EAGC30, 
siRNA mass ratios. Three different doses of siRNA were studied: 133, 267 and 
533 nM. The highest dose was revealed to be necessary for ITCH down-regulation. 
This falls in the lower range of the doses in the published literature [127, 212, 226] 
confirming the high transfection capacity of the new polymer, EAGC30, and its potential 
as a gene delivery system.  
Increasing EAGC30, siRNA mass ratios (1-60) were tested for gene silencing. 
EAGC30, siRNA mass ratios 30 and 60 achieved high levels of down-regulation of 
ITCH in vitro. These results are in line with the literature, where it has been reported 
that low molecular weight polymers need higher polymer, siRNA mass ratios to obtain 
down-regulation [129, 212]. Also, the EAGC30-siRNA nanoparticles had shown higher 
stability in the presence of heparin and salt for EAGC30, siRNA mass ratios 30 and 60 
than at lower EAGC30, siRNA mass ratios. This need for high N:P ratios is partially 
explained by the weak ionic interactions between siRNA and chitosan [127]. Finally, the 
volume of transfected complexes was also studied. Different cell medium, complex 
solution volume ratios were analyzed until an optimal ratio of 1:1 was reached; this 
delivered the best gene silencing results.  
In vivo administration of nucleic acids to the central nervous system is restrained by the 
blood brain barrier. The intranasal route of administration is a non-invasive method of 
bypassing it. Different delivery systems have previously been tested to protect the 
siRNA from enzymatic degradation and to enhance its in vivo delivery [151, 152, 155, 
156]. Encouraging results were obtained in the small pilot in vivo study of siRNA 
delivery to the brain using EAGC30. The olfactory bulb tissue was analyzed for the 
presence of fluorescent siRNA after nasal administration of siRNA fluorescent 
nanoparticles at EAGC30, siRNA mass ratio 60. The results showed that 
EAGC30-siRNA nanoparticles were able to reach the brain, and could be visualized by 
CARS microscopy. Despite the good results obtained further experiments are needed, 
including treatment of the brain with naked siRNA, in order to confirm the polymer’s 
ability to protect the siRNA from enzymatic degradation in vivo. Furthermore, the 
nanoparticles distribution through the different tissues of the brain, as well as the 
system’s capacity for specific protein down-regulation in vivo, should be fully evaluated.  
In conclusion, a new chitosan-based polymer for gene delivery, Ethylamino Glycol 
Chitosan, was synthesized and characterized. Three different polymers (EAGC17, 
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EAGC21 and EAGC30), with increased degree of ethylamine substitution, were 
studied. The nanoparticles obtained between the different polymers and DNA/siRNA 
were characterized regarding size, zeta potential, morphology, and behaviour when in 
the presence of biological challenges. Ethylamino Glycol Chitosan demonstrated good 
biocompatibility when compared with PEI and chitosan. In vitro transfection efficiency 
with DNA was carried out in A431 cells, and all three polymers were shown to be better 
transfection agents than lipofectamine, particularly at high polymer, DNA mass ratios. 
EAGC30 was capable of in vitro gene silencing, and the preliminary in vivo results of 
this study introduced EAGC30 as a good candidate for in vivo siRNA delivery to the 
brain.  
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Figure A.2 - dn/dc curve of Glycol Chitosan (4h). 




Figure A.3 - GPC-MALLS Chromatogram of EAGC17 (5mg mL-1). 
 
Figure A.4 - dn/dc curve of Ethylamino Glycol Chitosan (EAGC17). 
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Figure A.5 - GPC-MALLS Chromatogram of EAGC30 (5mg mL-1). 
 
Figure A.6 - dn/dc curve of Ethylamino Glycol Chitosan (EAGC30). 
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Figure A.7 - Chemical structure of 2-(Boc-amino) ethyl bromide. 
 
 
Figure A.8 - 1H NMR of 2-(Boc-amino) ethyl bromide. 
 
Table A.1 - Protons assignments and chemical shifts for 2-(Boc-amino) ethyl bromide. 




Corresponding proton on 
the structure 
a 1.5 ppm (CH3)3 (Boc Group) 
b 3.5ppm CH2 (ethyl amino group) 
c 5ppm NH 









Figure A.9 – Nanosight particle tracking analysis results for the particle size distribution of EAGC30-DNA 
particles at polymer, DNA mass ratio 1. EAGC30 was incubated with DNA in dextrose 5% for 1h. DNA 




Figure A.10 – Nanosight particle tracking analysis results for the particle size distribution of EAGC17-DNA 
particles at polymer, DNA mass ratio 5. EAGC17 was incubated with DNA in dextrose 5% for 1h. DNA 
concentration 0.1 mg mL-1. The data was expressed as mean values (± standard error) of three 
experiments. 
 
